
<html lang="en"     class="pb-page"  data-request-id="ecafc1c1-ba1b-42e5-bd61-f6cea77c6f53"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2013.56.issue-6;website:website:acspubs;article:article:10.1021/jm301619u;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met" /></meta><meta name="dc.Creator" content="Alan B.  Northrup" /></meta><meta name="dc.Creator" content="Matthew H.  Katcher" /></meta><meta name="dc.Creator" content="Michael D.  Altman" /></meta><meta name="dc.Creator" content="Melissa  Chenard" /></meta><meta name="dc.Creator" content="Matthew H.  Daniels" /></meta><meta name="dc.Creator" content="Sujal V.  Deshmukh" /></meta><meta name="dc.Creator" content="Danielle  Falcone" /></meta><meta name="dc.Creator" content="David J.  Guerin" /></meta><meta name="dc.Creator" content="Harold  Hatch" /></meta><meta name="dc.Creator" content="Chaomin  Li" /></meta><meta name="dc.Creator" content="Wei  Lu" /></meta><meta name="dc.Creator" content="Bart  Lutterbach" /></meta><meta name="dc.Creator" content="Timothy J.  Allison" /></meta><meta name="dc.Creator" content="Sangita B.  Patel" /></meta><meta name="dc.Creator" content="John F.  Reilly" /></meta><meta name="dc.Creator" content="Michael  Reutershan" /></meta><meta name="dc.Creator" content="Keith W.  Rickert" /></meta><meta name="dc.Creator" content="Craig  Rosenstein" /></meta><meta name="dc.Creator" content="Stephen M.  Soisson" /></meta><meta name="dc.Creator" content="Alexander A.  Szewczak" /></meta><meta name="dc.Creator" content="Deborah  Walker" /></meta><meta name="dc.Creator" content="Kevin  Wilson" /></meta><meta name="dc.Creator" content="Jonathan R.  Young" /></meta><meta name="dc.Creator" content="Bo-Sheng  Pan" /></meta><meta name="dc.Creator" content="Christopher J.  Dinsmore" /></meta><meta name="dc.Description" content="This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (M..." /></meta><meta name="Description" content="This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (M..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 18, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301619u" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301619u" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301619u" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301619u" /></link>
        
    
    

<title>Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301619u" /></meta><meta property="og:title" content="Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0016.jpeg" /></meta><meta property="og:description" content="This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under investigation as a treatment for cancer. The design of 11r was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access 11r and analogues. We provide a rationale for the observed selectivity based on X-ray crystallographic evidence and discuss selectivity trends with additional examples. Importantly, 11r provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase conformation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301619u"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301619u">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301619u&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301619u&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301619u&amp;href=/doi/10.1021/jm301619u" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2294-2310</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm301590z" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm301632e" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 1-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan+B.++Northrup">Alan B. Northrup</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+H.++Katcher">Matthew H. Katcher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Altman">Michael D. Altman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melissa++Chenard">Melissa Chenard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+H.++Daniels">Matthew H. Daniels</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sujal+V.++Deshmukh">Sujal V. Deshmukh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danielle++Falcone">Danielle Falcone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+J.++Guerin">David J. Guerin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Harold++Hatch">Harold Hatch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chaomin++Li">Chaomin Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Lu">Wei Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bart++Lutterbach">Bart Lutterbach</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+J.++Allison">Timothy J. Allison</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sangita+B.++Patel">Sangita B. Patel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+F.++Reilly">John F. Reilly</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Reutershan">Michael Reutershan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keith+W.++Rickert">Keith W. Rickert</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Craig++Rosenstein">Craig Rosenstein</a></span><span class="author-xref-symbol author-aff-symbol"><sup>¶</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+M.++Soisson">Stephen M. Soisson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+A.++Szewczak">Alexander A. Szewczak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>¶</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deborah++Walker">Deborah Walker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>×</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Wilson">Kevin Wilson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+R.++Young">Jonathan R. Young</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bo-Sheng++Pan">Bo-Sheng Pan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Dinsmore">Christopher J. Dinsmore</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Department of Chemistry, <sup>‡</sup>Department of Chemistry Modeling and Informatics, <sup>§</sup>Department of in Vivo Pharmacology, <sup>∥</sup>Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism, <sup>⊥</sup>Department of Oncology, <sup>#</sup>Department of Structural Chemistry, <sup>¶</sup>Department of in Vitro Pharmacology, <sup>×</sup>Department of Basic Pharmaceutical Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 617-992-2061. Fax: 617-992-2407. E-mail: <a href="/cdn-cgi/l/email-protection#77161b161928191805031f050207371a1205141c5914181a"><span class="__cf_email__" data-cfemail="16777a777849787964627e646366567b7364757d3875797b">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301619u&amp;href=/doi/10.1021%2Fjm301619u" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2294–2310</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 4, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 November 2012</li><li><span class="item_label"><b>Published</b> online</span>18 March 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 March 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301619u" title="DOI URL">https://doi.org/10.1021/jm301619u</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2294%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAlan%2BB.%2BNorthrup%252C%2BMatthew%2BH.%2BKatcher%252C%2BMichael%2BD.%2BAltman%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D6%26contentID%3Djm301619u%26title%3DDiscovery%2Bof%2B1-%255B3-%25281-Methyl-1H-pyrazol-4-yl%2529-5-oxo-5H-benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-7-yl%255D-N-%2528pyridin-2-ylmethyl%2529methanesulfonamide%2B%2528MK-8033%2529%253A%2BA%2BSpecific%2Bc-Met%252FRon%2BDual%2BKinase%2BInhibitor%2Bwith%2BPreferential%2BAffinity%2Bfor%2Bthe%2BActivated%2BState%2Bof%2Bc-Met%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2310%26publicationDate%3DMarch%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301619u"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3275</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">24</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301619u" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;B. Northrup&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;H. Katcher&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Altman&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;Chenard&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;H. Daniels&quot;},{&quot;first_name&quot;:&quot;Sujal&quot;,&quot;last_name&quot;:&quot;V. Deshmukh&quot;},{&quot;first_name&quot;:&quot;Danielle&quot;,&quot;last_name&quot;:&quot;Falcone&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;J. Guerin&quot;},{&quot;first_name&quot;:&quot;Harold&quot;,&quot;last_name&quot;:&quot;Hatch&quot;},{&quot;first_name&quot;:&quot;Chaomin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Bart&quot;,&quot;last_name&quot;:&quot;Lutterbach&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;J. Allison&quot;},{&quot;first_name&quot;:&quot;Sangita&quot;,&quot;last_name&quot;:&quot;B. Patel&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;F. Reilly&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Reutershan&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;W. Rickert&quot;},{&quot;first_name&quot;:&quot;Craig&quot;,&quot;last_name&quot;:&quot;Rosenstein&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;M. Soisson&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;A. Szewczak&quot;},{&quot;first_name&quot;:&quot;Deborah&quot;,&quot;last_name&quot;:&quot;Walker&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Wilson&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;R. Young&quot;},{&quot;first_name&quot;:&quot;Bo-Sheng&quot;,&quot;last_name&quot;:&quot;Pan&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Dinsmore&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;2294-2310&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301619u&quot;},&quot;abstract&quot;:&quot;This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under investigation as a treatment for cancer. The design of 11r was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access 11r and analogues. We provide a rationale for the observed selectivity based on X-ray crystallographic evidence and discuss selectivity trends with additional examples. Importantly, 11r provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase con&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301619u&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301619u" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301619u&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301619u" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301619u&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301619u" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301619u&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301619u&amp;href=/doi/10.1021/jm301619u" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301619u" /></input><a href="/doi/pdf/10.1021/jm301619u" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301619u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301619u%26sid%3Dliteratum%253Aachs%26pmid%3D23379595%26genre%3Darticle%26aulast%3DNorthrup%26date%3D2013%26atitle%3DDiscovery%2Bof%2B1-%255B3-%25281-Methyl-1H-pyrazol-4-yl%2529-5-oxo-5H-benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-7-yl%255D-N-%2528pyridin-2-ylmethyl%2529methanesulfonamide%2B%2528MK-8033%2529%253A%2BA%2BSpecific%2Bc-Met%252FRon%2BDual%2BKinase%2BInhibitor%2Bwith%2BPreferential%2BAffinity%2Bfor%2Bthe%2BActivated%2BState%2Bof%2Bc-Met%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D6%26spage%3D2294%26epage%3D2310%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290716" title="Sulfones">Sulfones</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jmcmar.2013.56.issue-6/production/jmcmar.2013.56.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one <b>11r</b> (MK-8033), a dual c-Met/Ron inhibitor under investigation as a treatment for cancer. The design of <b>11r</b> was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access <b>11r</b> and analogues. We provide a rationale for the observed selectivity based on X-ray crystallographic evidence and discuss selectivity trends with additional examples. Importantly, <b>11r</b> provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase conformation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35317" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35317" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery and development of protein kinase inhibitors has comprised a substantial proportion of pharmaceutical research over the past decade resulting in several FDA approved drugs. Increasingly, kinase inhibitor discovery efforts have focused on specific inhibitors for a target due to the hypothesis that specificity will result in an improved safety profile versus multikinase inhibitors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Protein kinases can adopt conformations corresponding to different states of phosphorylation and activity. Accordingly, there have been attempts to correlate specificity with compound binding preferences to either active-like or inactive-like protein conformations. To that end, the discovery of type II inhibitors (i.e., those binding to the inactive “DFG-out” conformation first observed with Imatinib in complex with Abl) has fueled a dogma in the field that targeting the inactive conformation with type II inhibitors will demonstrate superior specificity when compared to inhibitors of the activated kinase because the allosteric binding pocket afforded by the DFG-out conformation provides unique opportunities for specificity.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Activating mutations of kinases are commononly observed in cancer and can also be induced by treatment with type II inhibitors,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> leading to an acute need for agents that target activating muations in cancer (e.g., Nilotinib for the treatment of Imatinib-resistant chronic myelogenous leukemia).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">c-Met and Ron are receptor tyrosine kinase members of the c-Met proto-oncogene family and are closely related in structure and function.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> c-Met is the receptor for hepatocyte growth factor (also known as scatter factor), and Ron is the receptor for macrophage stimulating protein. Abberent expression of c-Met and Ron has been correlated with poor prognosis, and activating c-Met mutations have been observed in human tumors.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Signaling cross-talk has been observed between the c-Met and Ron receptors;<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> therefore, it may be desirable to inhibit signaling through both receptors for optimal therapeutic benefit. Indeed, concomitant overexpression of both c-Met and Ron are negative prognostic factors in breast<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and bladder cancers.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Because of its status as a proto-oncogene, c-Met has attracted significant attention as an anticancer target with several agents in clinical development including one marketed agent, the ALK/c-Met inhibitor Crizotinib.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Notably, the type I and type II inhibitors in clinical development are multikinase inhibitors with c-Met inhibition as one of a number of activities (e.g., Crizotinib and GSK-1363089/XL-880,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> respectively). The specific c-Met inhibitors JNJ-38877605<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (Phase III), EMD-1214063<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and PF-04217903<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (both in phase I clinical studies), respectively, as well as a series of triazolopyridinone inhibitors,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> are all believed to bind the inactive form of the receptor preferentially although likely not through a classical DFG-out type II binding mode. Interestingly, it has been shown that inactive form binders to c-Met can induce activating resistance mutations in c-Met in cell culture.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Additionally, ARQ-197 is reported to be a c-Met inhibitor that was, until recently, in late-stage clinical studies.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Our laboratories have previously described the discovery of <b>18</b> (MK-2461),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> a multitargeted c-Met inhibitor that was shown through binding studies and in vitro biochemistry experiments to preferentially bind the activated conformation of c-Met. The current manuscript documents the discovery of <b>11r</b> (MK-8033), a specific dual c-Met/Ron inhibitor, demonstrating that both high kinase specificity and also activity against clinically activating mutations can be achieved through targeting the activated kinase conformation.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0017.gif" alt="" id="fx1" /></img></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of acetamide derivatives is outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> from the versatile tricyclic dihalide intermediate <b>1</b>. Amides <b>5a</b>–<b>g</b> were prepared via arylation of diethylmalonate,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> followed by decarboxylation, Suzuki–Miyaura coupling and amide formation. Functionalization of the benzylic position was also possible by trapping the corresponding enolate of intermediate <b>4</b> with electrophiles to provide esters <b>6a</b> and <b>6b</b> that were then converted to the corresponding primary amides <b>7a</b> and <b>7b</b>.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Acetamide Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Pd<sub>2</sub>(dba)<sub>3</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF<sub>4</sub>, dimethylmalonate, K<sub>3</sub>PO<sub>4</sub>, toluene, 70 °C; (b) 6N HCl, AcOH, 110 °C; (c) SOCl<sub>2</sub>, MeOH, relux; (d) Pd<sub>2</sub>(dba)<sub>3</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF4, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, KF, DMF, 130 °C; (e) 1N NaOH, THF, rt; (f) Et<sub>3</sub>N, HATU, amine, CH<sub>2</sub>Cl<sub>2</sub>, rt; (g) LDA, MeI, THF, −78 °C; (h) LDA, <i>rac</i>-(10)-(camphorylsulfonyl)oxaziridine, THF, −78 °C.</p></p></figure><div class="NLM_p">The preparation of benzylic sulfonamide derivatives <b>11a</b>–<b>y</b> is outlined in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and required the invention of two new chemical reactions for these structure–activity studies: a palladium-catalyzed coupling of β-sulfamylacetates to afford intermediates <b>9a</b> and <b>9b</b> and an amine exchange reaction to provide access to a diverse range of products <b>11a</b>–<b>v</b> at the final step of the synthesis.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> It was found that exchange reactions of amines with dimethylsulfonamide <b>10a</b> required harsh conditions and afforded products <b>11</b> in low yield. Replacement of <b>10a</b> with intermediate <b>10b</b> in amine exchange reactions permitted the use of lower reaction temperatures and provided improved yields of products <b>11a</b>–<b>w</b>. The increased reactivity of <b>10b</b> is presumably due to the lower p<i>K</i><sub>a</sub> of the <i>N</i>-methylaniline leaving group as compared to dimethylamine from <b>10a</b>. The use of an exchangeable sulfonamide permitted bidirectional SAR studies that installed either the left-hand aryl or right-hand sulfonamide moiety first in the synthetic operation. For example, compounds <b>11r</b> and <b>16</b> were prepared via sulfonamide exchange with 2-pyridylmethylamine followed by Suzuki–Miyaura coupling.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benzylic Sulfonamide Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) for <b>8a</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, PPh<sub>3</sub>, NaH, dioxane 70 °C; for <b>8b</b>, Pd(OAc)<sub>2</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF<sub>4</sub>, NaO<i>t</i>-Bu, dioxane, 90 °C. (b) 1N NaOH, 50 °C. (c) Pd<sub>2</sub>(dba)<sub>3</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF<sub>4</sub>, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, KF, DMF, 130 °C. (d) for <b>9a</b>, Cs<sub>2</sub>CO<sub>3</sub>, amine, dioxane, 180 °C; for <b>9b</b>, amine, NMP, 190 °C. (e) 2-aminomethylpyridine, NMP, 130–135 °C. (f) for <b>11r</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, PCy<sub>3</sub>, lithium 2-hydroxy-4,4,5,5-tetramethyl-2-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,3,2-dioxaborolan-2-uide hydrate, DMF, 100 °C; for <b>16</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF<sub>4</sub>, KF, <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl]piperidine-1-carboxylate, DMF, 130 °C, then HCl, dioxane.</p></p></figure><div class="NLM_p">Sulfone <b>13</b> was prepared as outlined in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Installation of a methanol unit to <b>1</b> via cross-coupling and alcohol deprotection was followed by mesylation, displacement with 2-pyridin-2-ylethanethiol, and oxidation to the corresponding sulfone. Suzuki–Miyaura coupling completed the synthesis of <b>13</b>.</div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Sulfone <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Potassium (2-(trimethylsilyl)ethoxy)methyltrifluoroborate Pd(OAc)<sub>2</sub>, RuPhos, Cs<sub>2</sub>CO<sub>3,</sub> 10:1 dioxane/water, 100 °C; (b) BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (c) MsCl, Et<sub>3</sub>N, dioxane, 0 °C; (d) NaH, 2-pyridin-2-ylethanethiol, DMF; (e) MCPBA, CH<sub>2</sub>Cl<sub>2</sub>; (f) Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, lithium 2-hydroxy-4,4,5,5-tetramethyl-2-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,3,2-dioxaborolan-2-uide hydrate, DMF, 150 °C.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Prior studies leading to compound <b>18</b> established that the tricyclic core binds deeply in the ATP site, adopting a slightly bent geometry, with the pyridine nitrogen making a hydrogen bond interaction with the hinge backbone (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>E). Only substitution at the 3 and 7 positions of the tricyclic core were compatible with achieving the desired potency, as these unburied positions extend toward solvent and the catalytic residues, respectively.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> To improve on <b>18</b>, we focused on the simpler <i>N</i>,<i>N</i>-dimethlysulfamide analogue <b>12</b>, which was an intriguing lead for further optimization based on its desirable properties (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). While <b>12</b> displayed favorable potency (enzymatic and cellular), pharmacokinetic parameters, and lacked appreciable inhibition of the hERG ion channel, dimethylsulfamide <b>12</b> was found to be a potent time-dependent inhibitor of CYP3A4 (TDI) and also inhibited various kinase off-targets beyond c-Met and Ron (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). It is well-known that reversible or time-dependent CYP inhibitors can inhibit the metabolism of common anticancer agents, resulting in increased clinical AUCs and potentially toxicity given the narrow therapeutic index displayed by many oncology drugs.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> As the standard of care for most oncology patients involves combinatorial therapy, it is desirable for new agents not to perpetrate drug–drug interactions; therefore, minimizing TDI was a major consideration for molecular design.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Properties of Compound <b>12</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">CYP3A4 enzyme and inhibitor are preincubated for 30 min at the indicated concentration and the enzyme activity is compared to a zero minute incubation control with the same inhibitor to calculate the percentage of lost activity via preincubation. See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div></div><div></div></div><div class="NLM_p">While metabolite ID experiments were unable to pinpoint the site of oxidation on the tricyclic core structure of <b>12</b>, it was hypothesized the electron-rich aniline substructure present in <b>12</b> may be responsible for the observed TDI given the well-known propensity for bioactivation of anilines.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> While the initial intent was to prepare sulfonamide <b>11c</b> as a direct comparator to sulfamide <b>12</b>, initial attempts at the synthesis of <b>11c</b> were unsuccessful and a series of C-7 substituted tricyclic acetamides were evaluated to test the hypothesis that sulfamide replacements would alleviate the TDI issue (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Unfortunately, a >100-fold loss in potency was observed for dimethylamide <b>5c</b> vs dimethylsulfamide <b>12</b> as well as for the direct analogues of <b>18</b> and <b>11r</b>: <b>5f</b> and <b>5g</b>, respectively. A partial recovery of the lost potency was noted with the introduction of primary amides <b>5a</b>, <b>7a</b>, and <b>7b</b> but not amides <b>5b</b>, <b>5c</b>, and <b>5e</b>. While encouraging results in cellular biochemical potency were achieved for compound <b>7b</b>, attempts at further potency optimization were not successful. As the primary hypothesis for preparing compounds <b>5</b> and <b>7</b> was to understand whether C-7 carbon analogues of <b>12</b> would remove the TDI liability, compounds <b>5a</b> and <b>5g</b> were selected for further evalulation.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency of C-7 Acetamides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0010.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">To monitor the risk of TDI of CYP3A4, a screening assay was employed that measures the activity of CYP3A4 to metabolize testosterone with either 0 or 30 min of preincubation of CYP3A4 with the test article. The percentage of CYP3A4 activity lost due to preincubation was then calculated and reported as the primary end point for the assay.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> On the basis of kinetic considerations, assay variability and internal experience translating the screening results to more definitive kinetic experiments, results with <30% CYP3A4 activity lost in this screening assay are considered to have a low risk of demonstrating significant TDI of CYP3A4, whereas compounds showing >50% lost are likely to demonstrate TDI of CYP3A4. Gratifyingly, both <b>5a</b> and <b>5g</b> demonstrated <10% CYP3A4 activity lost, providing support for the hypothesis that C-7 carbon-substituted analogues of <b>12</b> may reduce the potential for TDI of CYP3A4.</div><div class="NLM_p">With the aim of maintaining a favorable CYP inhibition profile while improving potency relative to the acetamides <b>5</b> and <b>7</b>, a series of benzylic sulfonamides were investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) following the invention of two new chemical reactions: the palladium-catalyzed coupling of β-sulfamylacetates and an amine exchange reaction. Similar to the acetamides above, benzylic sulfonamides <b>11a</b>–<b>v</b> were typically not time-dependent inhibitors of CYP3A4, except for aniline derivative <b>11h</b>. With the exception of isothiazole <b>11o</b> and 4-aminomethylpyridine <b>11q</b>, the benzylic sulfonamides displayed <50% reversible inhibition of CYP3A4 at 10 μM. The benzylic sulfonamides, in contrast to acetamides <b>5</b> and <b>7</b>, tolerated a broad range of amine substituents while maintaining favorable potency. Simple primary and secondary alkyl sulfonamides were moderately potent (e.g., <b>11a</b>, <b>11b</b>, <b>11d</b> c-Met IC<sub>50</sub> = 42–163 nM), whereas tertiary sulfonamides <b>11c</b> and <b>11s</b> were substantially less potent (c-Met IC<sub>50</sub> = 2294, 4950 nM, respectively), similar to modestly improved potency observed with the introduction of either polar (e.g., <b>11e</b> c-Met IC<sub>50</sub> = 45 nM) or cyclic alkyl substituents (e.g., <b>11f</b>, <b>11g</b> c-Met IC<sub>50</sub> = 53, 14 nM, respectively). Significant increases in potency, in constrast, were observed with benzylamines (e.g., <b>11i</b>,<b>k</b>,<b>l</b> c-Met IC<sub>50</sub> = 5–11 nM) and, in particular, heterocyclic methylamine analogues (e.g., <b>11m</b>–<b>r</b> c-Met IC<sub>50</sub> = 1–8 nM). Aminoethylbenzene derivative <b>11j</b> demonstrated substitution α to the sulfonamide nitrogen affords diminished potency (c-Met IC<sub>50</sub> = 52 nM). Sulfonamide <i>N</i>-alkylation provided >1000× loss in potency, supporting a critical role for a C-7 hydrogen-bond donor for maintaining c-Met potency (cf. <b>11r</b> and <b>11s</b>). The overall profile of 2-aminomethylpyridine derivative <b>11r</b> warranted further exploration of the SAR. While pyridine N-oxidation provides equivalent potency (<b>11t</b> c-Met IC<sub>50</sub> = 2 nM), saturated or homologated analogues are less potent (<b>11u</b>, <b>11v</b> c-Met IC<sub>50</sub> = 67, 55 nM, respectively) but still retain the favorable CYP inhibition profile of <b>11r</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Potency and CYP Inhibition of Diverse C-7 Benzylic Sulfonamides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0011.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0012.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_p">On the basis of a superior in vivo PK profile vs other analogues with favorable potency and minimal CYP inhibition (e.g., <b>11m</b>, <b>11n</b>, <b>11t</b>), aminomethylpyridine derivative <b>11r</b> was selected for further profiling (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Evaluation of CYP3A4 inhibition kinetics confirmed the screening data in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> that <b>11r</b> is not a time-dependent inhibitor of CYP3A4 up to a test concentration of 100 μM. Compound <b>11r</b> is a weak inhibitor of cytochrome P450s at high μM concentrations (IC<sub>50</sub>s > 11 μM). Taken together, those data indicate <b>11r</b> has a low risk of perpetrating CYP-mediated drug–drug interactions. Additionally, <b>11r</b> exhibits low to moderate clearance in rats and dogs and also favorable bioavailability in both species. <b>11r</b> potently inhibited c-Met/HGF-dependent cellular phenotypes in vitro. These include phosphorylation of Y1349 of c-Met in the c-Met-dependent gastric cancer cell line GTL-16 (IC<sub>50</sub> = 0.03 μM) and proliferation of the same cell line (IC<sub>50</sub> = 0.58 μM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Properties of <b>11r</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0013.gif" alt="" id="fx7" /></img><div></div></div><div class="NLM_p">On the basis of the structural homology of <b>11r</b> to <b>18</b>, we reasoned that <b>11r</b> may also preferentially bind to and inhibit the catalytic activity of activated c-Met kinase. Such a mode of action is further supported by a BIAcore-based direct binding assay showing that <b>11r</b> binds 3-fold more tightly to phosphorylated c-Met kinase domain (<i>K</i><sub>d</sub> = 3.2 nM) than to its unphosphorylated counterpart (<i>K</i><sub>d</sub> = 10.4 nM). Significantly, <b>11r</b> potently inhibits kinase activity of three oncogenic c-Met activation loop mutants, Y1230C, Y1230H, and Y1235D (IC<sub>50</sub>s ranging from 0.6 to 1 nM at 50 μM ATP, Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) in addition to other c-Met activating mutants N1100Y and M1250T.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Inhibitory Effect of <b>11r</b> on Wild Type and Mutant c-Met Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center" char=".">mean IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT c-Met</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met(N1100Y)</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met(Y1230C)</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met(Y1230H)</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met(Y1235D)</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met(M1250T)</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td></tr></tbody></table></div></div><div class="NLM_p">To our surprise, <b>11r</b> is a highly specific c-Met/Ron dual inhibitor. Compound <b>11r</b> was tested at 1 μM using a panel of 221 kinases. Only two kinases, c-Met and Ron, were inhibited by more than 90% and merely four other kinases (Fes, FGFR3, Flt4, and Mer) were inhibited by more than 50%, with the inhibition ranging from 60 to 70%. Follow-up titration experiments demonstrated <b>11r</b> is >100-fold selective relative to Ron and c-Met inhibition versus the measured kinome (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_p">Because of the exquisite dual c-Met/Ron specificity of <b>11r</b> unlike the structurally related <b>18</b>, several analogues were assessed in broad kinase panels to help understand the basis for kinase selectivity (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Surprisingly, minor modifications to the structure of <b>11r</b> led to dramatic loss of either potency or selectivity. For example, replacement of the <b>11r</b> sulfonamide with a sulfone, sulfamide, or amide in compounds <b>13</b>, <b>14</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and <b>5g</b> lost 10- to >100-fold potency and engendered similar off-targets as <b>18</b>. Removal of the aminomethylpyridine moiety to afford compound <b>11a</b> also resulted in lost potency and selectivity. Homologation of acetamide <b>5g</b> to propionamide <b>15</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> however, was successful in both improving the potency 10-fold and also achieving a c-Met specific profile, albeit with ∼80-fold reduced potency relative to <b>11r</b>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Potency and Selectivity of <b>11r</b> and Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0014.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0015.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for complete selectivity profiles.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">10 μM test concentration.</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last">0.1 μM test concentration.</p></div></div><div></div></div><div class="NLM_p">It was hoped that an X-ray cocrystal structure of <b>11r</b> with c-Met could provide valuable insights into explaining the origin of kinase selectivity for <b>11r</b>. While attempts to crystallize <b>11r</b> with c-Met failed, the X-ray crystal structure of <b>16</b> bound to the doubly phosphorylated form of c-Met (activation loop sites pY1234 and pY1235) was determined to 1.99 Å resolution (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S9">Supporting Information Table S9</a>). Compound <b>16</b> has comparable kinase selectivity to <b>11r</b> and differs from compound <b>11r</b> only due to the nature of the pyrazole substituent, which is solvent directed. Similar to what our laboratories have reported for sulfamide <b>17</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and amide <b>15</b><a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> bound to activated c-Met (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), sulfonamide <b>16</b> binds deeply in the ATP-site, adopting a slightly bent geometry while making a key hydrogen bonding interaction to the hinge region (Met-1160) via the pyridyl nitrogen of the tricyclic ring system (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A,B,E). However, unlike <b>17</b>, compound <b>16</b> does not make a key hydrogen bond to the carboxylate side chain of Asp-1222, a residue involved in catalysis that is conserved throughout the kinome (Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B,E). On the basis of the SAR around <b>18</b>, this interaction is likely responsible for a significant portion of its potency.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> This suggests that the interactions made by the sulfonamide region of <b>11r</b> and <b>16</b> likely provide a comparable enhancement of potency but in a c-Met/Ron selective manner. The sulfonamide NH of <b>16</b> makes a hydrogen bond to the side chain carbonyl of Asn-1209, a conserved residue among <b>18</b> off-targets, which in turn directs the pyridine ring into a small pocket formed by the backbone of the glycine-rich loop (residues 1086–1088) and the side chains of His-1088 and Arg-1208 (Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B,C). The pyridine ring forms an edge–face interaction with His-1088 and a face–face π-stacking interaction with Arg-1208, which is recruited by the inhibitor. To form this pocket, the glycine-rich loop closes down on <b>16</b> as compared to the structure of c-Met bound to <b>17</b>, such that His-1088 makes an apparent salt bridge with Asp-1204 in the C-terminal lobe (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C). It is interesting to note that His-1088 is a unique residue to c-Met and Ron as compared within the off-target kinases of <b>18</b>. To probe whether the direct aryl–ayl interactions between inhibitors and His-1088/Arg-1208 were important for selectivity, saturated derivates such as <b>11e</b>, <b>11u</b>, and <b>11w</b> were prepared. Although some of these compounds exhibited reduced potency against c-Met, their selectivity profiles remained c-Met/Ron selective (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). This led us to the alternative hypothesis that perhaps filling the pocket created by a more closed glycine-rich loop conformation (potentially mediated by His-1088) was important for selectivity. This hypothesis was partially challenged by the discovery of selective c-Met/Ron compounds such as <b>15</b>. In the previously reported structure of <b>15</b> bound to c-Met,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> the pyridyl amide region does not enter this pocket but is instead directed toward solvent (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>D). However, the c-Met glycine-rich loop does adopt the same closed conformation as observed with <b>16</b> even though <b>15</b> does not occupy this region. Therefore, the induction of this conformation, potentially mediated by His-1088, could be a structural mechanism for c-Met/Ron selectivity although these results highlight the difficulty in generally ascribing the selectivity trends in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> to specific structural features.</div><figure id="fig1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. c-Met ligands <b>15</b> and <b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Ribbon cartoon image of the X-ray crystal structure of <b>16</b> (green) bound to activated c-Met kinase domain (gray). Phosphotyrosines pY1234 and pY1235 (magenta) part of the activation loop are also highlighted. (B) Binding pose of <b>16</b> in the ATP binding pocket. (C) Close-up view of the interactions of <b>16</b> with c-Met. (D) Overlay of the structures of <b>15</b> (cyan)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and <b>16</b> (green) bound to activated c-Met. The yellow arrow highlights the different disposition of the pyridymethylamine fragment between the two structures. (E) Overlay of the structures of <b>17</b> (magenta)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and <b>16</b> (green) bound to activated c-Met.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The c-Met amplified cell line GTL-16 expresses a highly activated c-Met kinase and is sensitive to c-Met small molecule inhibitors.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><b>11r</b> potently inhibited GTL-16 proliferation with an IC<sub>50</sub> of 582 ± 30 nM. By contrast, the HCT116 cell line, which does not harbor basal c-Met activation, was not inhibited by <b>11r</b> (IC<sub>50</sub> > 10000 nM). Further analysis of larger cell panels confirmed that <b>11r</b> selectively inhibited growth in c-Met amplified cell lines.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">To determine plasma levels required to inhibit Met phosphorylation, <b>11r</b> was orally dosed in GTL-16 tumor xenograft bearing mice. Mice were euthanized 1 h after dosing and tested for p-Met(Y1349) in tumors and <b>11r</b> concentrations in plasma. At 100 mg/kg, essentially complete inhibition of p-Met (Y1349) was achieved. An in vivo IC<sub>50</sub> of 1.3 μM was deduced from the relationship between plasma <b>11r</b> level and Met pY1349 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B). This IC<sub>50</sub> is a 45-fold shift from the in vitro IC<sub>50</sub> (<12 nM) in 10% fetal bovine serum, most likely due to compound binding to plasma proteins in vivo. An IC<sub>50</sub> of 1.7 μM was also obtained when samples were collected after an 8 h time point (data not shown).</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. GTL-16 tumor xenograft PK/PD and efficacy of <b>11r</b>. (A) Inhibition by <b>11r</b> of c-Met (Y1349) phosphorylation in GTL-16 tumors. The tumor bearing mice were given a single oral dose of 10, 30, 100, or 400 mg/kg of <b>11r</b> and euthanized 1 h after dosing. The extent of c-Met (Y1349) phosphorylation in the tumors was determined by quantitative Western blotting. Shown are representative images of phospho-c-Met (Y1349) and total c-Met blots. (B) The relationship between the phospho-c-Met (Y1349) levels of all individual tumors and the corresponding host plasma total <b>11r</b> concentrations. (C) The effects of orally administered <b>11r</b> on the growth of GTL-16 tumor. Asterisks indicate statistically significant difference from vehicle-treated group based on two way repeated measures ANOVA (* <i>P</i> < 0.05, ** P = 0.011, *** <i>P</i> < 0.01).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Antitumor activity of <b>11r</b> was evaluated in human GTL-16 c-Met amplified gastric tumor xenografts in CD1-nude mice. Treatment with escalating doses of <b>11r</b> (bid, po) for 21 days led to antitumor efficacies in a dose-dependent manner. Dosing at 3, 10, 30, and 100 mg/kg resulted in 22, 18, 57, and 86% tumor growth inhibition, respectively, relative to tumors from vehicle-treated mice (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S10">Supporting Information Table S10</a>). We also observed significant tumor inhibition with 100 mg/kg <b>11r</b> with once daily dosing. Efficacy at 100 mg/kg bid <b>11r</b> was comparable to that of the previously described multitargeted c-Met inhibitor <b>18</b> also dosed at 100 mg/kg/bid. Finally, treatment with <b>11r</b> had no effect on body weight or animal body weight relative to control animals. Analysis of the time course of exposure in the GTL-16 xenograft efficacy experiment (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) relative to the ex vivo determined p-Met(Y1349) IC<sub>50</sub> is supportive of the notion that plasma concentrations exceeding IC<sub>50</sub> for 16 h per day is required for maximal efficacy.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Replacement of the sulfamide substructure on the 5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-ones scaffold present in <b>12</b> with a range of sulfonamides provided compounds with reduced potential to perpetrate drug–drug interactions via TDI of CYP3A4 while retaining preferential binding to the activated kinase conformation. <b>11r</b> is the first example of a specific kinase inhibitor with preferential binding to the activated kinase conformation; however, the structural basis of its specificity is not fully established as close analogues such as <b>14</b> do not retain the high degree of specificity. <b>11r</b> is also unique among clinical c-Met inhibitors as it also inhibits Ron with similar potency to c-Met. Importantly, <b>11r</b> provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to results reported with c-Met inhibitors lacking preferential binding to the active kinase conformation.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68212" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68212" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">Commercial reagents were obtained from reputable suppliers and used as received. All solvents were purchased in septum-sealed bottles stored under an inert atmosphere. All reactions were sealed with septa through which an argon atmosphere was introduced unless otherwise noted. Liquid reagents and solvents were transferred under a positive pressure of nitrogen via syringe. Reactions were conducted in microwave vials or round-bottomed flasks containing Teflon-coated magnetic stir bars. Microwave reactions were performed with a Biotage Initiator series microwave (fixed hold time setting; reaction temperatures monitored by the internal infrared sensor).</div><div class="NLM_p">Reactions were monitored by thin layer chromatography (TLC) on precoated TLC glass plates (silica gel 60 F254, 250 μm thickness) or by LC-MS (30 mm × 2 mm 2 μm column + guard; 2 mL injection; 3–98% MeCN/water + 0.05% TFA gradient over 2.3 min; 0.9 mL/min flow; APCI; positive ion mode; UV detection at 254 nM). Visualization of the developed TLC chromatogram was performed by fluorescence quenching. Flash chromatography was performed on an automated purification system using prepacked silica gel columns. <sup>1</sup>H and <sup>13</sup>C NMR were recorded on a 500 MHz Varian spectrometer; chemical shifts (δ) are reported relative to residual protio solvent signals. Data for NMR spectra are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet), coupling constant (Hz), integration.</div><div class="NLM_p last">All compounds reported are of at least 95% purity, as judged by LCAP (150 mm × 4.6 mm ID, 5 μm column; 5 μL injection; 10–100% MeCN/H<sub>2</sub>O + 0.05% TFA gradient over 6.75 min; 1 mL/min flow; ESI; positive ion mode; UV detection at 254 nM).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Diethyl (3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)propanedioate (<b>2</b>)</h3><div class="NLM_p last">A flask was charged with tricyclic dihalide <b>1</b> (500 mg, 1.56 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (57 mg, 0.062 mmol), tri-<i>tert</i>-butylphosphine HBF<sub>4</sub> salt (36 mg, 0.13 mmol), diethyl malonate (0.30 mL, 2.0 mmol), and potassium phosphate (1010 mg, 4.77 mmol), placed under an inert atmosphere, and then toluene (7.8 mL) was added. The reaction mixture was heated to 70 °C with stirring overnight, then cooled to room temperature and filtered through a plug of silica gel, washing with dichloromethane. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography on silica gel eluting with EtOAc/hexanes to afford the title compound (369 mg, 0.924 mmol, 59% yield) as an orange oil that slowly began to crystallize upon standing. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (d, <i>J</i> = 2.0 Hz, 1H), 8.46 (d, <i>J</i> = 2.0 Hz, 1H), 8.18 (d, <i>J</i> = 1.5 Hz, 1H), 7.82 (m, 2H), 7.47 (d, <i>J</i> = 10.5 Hz, 1H), 7.32 (d, <i>J</i> = 10.0 Hz, 1H), 5.28 (s, 1H), 4.15 (m, 4H), 1.16 (m, 6H). MS (APCI) calcd for C<sub>21</sub>H<sub>19</sub>ClNO<sub>5</sub> [M + H]<sup>+</sup>, 400.1; found, 400.1.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Ethyl [3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetate (<b>4</b>)</h3><div class="NLM_p">Step 1: Diethyl (3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)propanedioate (4.12 g, 10.3 mmol) was dissolved in 6N HCl (25.0 mL, 150 mmol) and AcOH (25.0 mL) and then heated to 110 °C. After 2 h., the reaction mixture was concentrated under reduced pressure. The residual yellow solid (3.09 g, 10.3 mmol) was suspended in ethanol (51.6 mL), and then SOCl<sub>2</sub> (1.88 mL, 25.8 mmol) was added dropwise with stirring. The resulting solution was then heated to reflux for 2 h and then cooled to room temperature. Aqueous sodium hydrogen carbonate (saturated, 500 mL) was cautiously added, and the resulting mixture was extracted with ethyl acetate (3 × 150 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with EtOAc/hexanes to afford ethyl (3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)acetate (2.03g, 6.19 mmol, 60% yield) as a white solid. MS (APCI) calcd for C<sub>18</sub>H<sub>15</sub>ClNO<sub>3</sub> [M + H]<sup>+</sup>, 328.1; found, 328.0.</div><div class="NLM_p last">Step 2: Ethyl (3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)acetate (2.03 g, 6.19 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (1.55 g, 7.43 mmol), tri-<i>tert</i>-butylphosphonium tetrafluoroborate (162 mg, 0.557 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (227 mg, 0.248 mmol), and potassium fluoride (1.19 g, 20.4 mmol) were combined in a vial and then placed under a nitrogen atmosphere. DMF (61.9 mL) was added, and the resulting suspension was heated to 130 °C and left to stir for 1 h. The reaction mixture was then poured into aqueous sodium hydrogen carbonate (500 mL) and extracted with dichloromethane (5 × 100 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with EtOAc/hexanes to ethyl acatate + 10% methanol to afford the title compound (1.95 g, 5.23 mmol, 84% yield) as an orange solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (d, <i>J</i> = 2.0 Hz, 1H), 8.53 (d, <i>J</i> = 1.5 Hz, 1H), 8.46 (s, 1H), 8.13 (s, 1H), 8.04 (d, 1.5 Hz, 1H), 7.75 (d, <i>J</i> = 7.0 Hz, 1H), 7.69 (dd, <i>J</i> = 7.0, 1.5 Hz, 1H), 7.38 (d, <i>J</i> = 10.5 Hz, 1H), 7.29 (d, <i>J</i> = 10.0 Hz, 1H), 4.08 (q, <i>J</i> = 6.0 Hz, 2H), 3.88 (s, 3H), 3.87 (s, 2H), 1.17 (t, <i>J</i> = 6 Hz, 3H). MS (APCI) calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 374.1; found, 374.2.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> [3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetic Acid</h3><div class="NLM_p last">Ethyl [3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetate (1.00 g, 2.68 mmol) was suspended in THF (10.7 mL) and 1N NaOH (5.36 mL, 5.36 mmol) with stirring. After 90 min, the reaction was neutralized with 1N HCl (5.36 mL) to form a yellow solution that was poured into brine (50 mL). A yellow precipitated was formed, collected via filtration, and dried under reduced pressure. The filtrate was extracting with ethyl acetate, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was combined with the dried filter cake to afford the title compound (867 mg, 2.51 mmol, 94% yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.5 (br s, 1H), 9.20 (d, <i>J</i> = 2.0 Hz, 1H), 8.53 (d, <i>J</i> = 2.0 Hz, 1H), 8.46 (s, 1H), 8.13 (s, 1H), 8.03 (d, 1.5 Hz, 1H), 7.74 (d, <i>J</i> = 6.5 Hz, 1H), 7.69 (dd, <i>J</i> = 7.0, 2.0 Hz, 1H), 7.38 (d, <i>J</i> = 10.0 Hz, 1H), 7.29 (d, <i>J</i> = 10.5 Hz, 1H), 3.88 (s, 3H), 3.78 (s, 2H). MS (APCI) calcd for C<sub>20</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 346.1; found, 346.1.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 2-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetamide (<b>5a</b>)</h3><div class="NLM_p last">Triethylamine (101 μL, 0.724 mmol) and HATU (55 mg, 0.15 mmol) were added, followed by 2 M ammonia in isopropyl alcohol (145 μL, 0.290 mmol) to a suspension of [3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetic acid (50 mg, 0.145 mmol) in dichloromethane (1.5 mL). After 3 h, the reaction was concentrated under reduced pressure and then the residue was purified by preparative HPLC (reverse phase (C-18), eluting with acetonitrile/water + 0.1% TFA) to afford the title compound (34 mg, 0.098 mmol, 68% yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (d, <i>J</i> = 1.5 Hz, 1H), 8.52 (d, <i>J</i> = 1.5 Hz, 1H), 8.45 (s, 1H), 8.12 (s, 1H), 8.03 (d, 1.0 Hz, 1H), 7.72 (d, <i>J</i> = 6.5 Hz, 1H), 7.68 (dd, <i>J</i> = 6.5, 1.5 Hz, 1H), 7.58 (s, 1H), 7.37 (d, <i>J</i> = 10.0 Hz, 1H), 7.28 (d, <i>J</i> = 10.0 Hz, 1H), 6.97 (s, 1H), 3.88 (s, 3H), 3.55 (s, 2H). MS (APCI) calcd for C<sub>20</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 345.1; found, 345.2. <b>5b</b>–<b>g</b> were prepared according to the protocol employed for the synthesis of <b>5a</b>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Ethyl 2-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]propanoate (<b>6a</b>)</h3><div class="NLM_p last">Ethyl [3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetate (250 mg, 0.670 mmol) was dissolved in THF (6.7 mL) and then cooled to −78 °C. LDA (0.670 mL, 1.34 mmol) was added dropwise, and the resulting solution was stirred at −78 °C for 30 min. Then, methyl iodide (0.084 mL, 1.4 mmol) was added dropwise. After 15 min, the reaction mixture was neutralized with 1 M HCl (1.5 mL) and partitioned between saturated aqueous sodium hydrogen carbonate (100 mL) and dichloromethane (50 mL), and the aqueous layer was further extracted with dichloromethane (3 × 50 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc + 10% MeOH/hexanes) to afford the title compound contaminated with ethyl [3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetate (109 mg, 0.203 mmol, 72% purity, 30% yield) as a yellow oil. MS (APCI) calcd for C<sub>23</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 388.2; found, 388.1.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Ethyl Hydroxy[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetate (<b>6b</b>)</h3><div class="NLM_p last">Ethyl [3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetate (250 mg, 0.670 mmol) was dissolved in THF (6.7 mL) and then cooled to −78 °C. LDA (0.670 mL, 1.34 mmol) was added dropwise, and the resulting solution was then stirred at −78 °C for 30 min. Then, racemic (10)-(camphorylsulfonyl)oxaziridine (384 mg, 1.67 mmol) was added dropwise as a solution in tetrahydrofuran (2.0 mL). After 15 min, the reaction mixture was neutralized with 1.5 mL of 1 M HCl and then partitioned between saturated aqueous sodium hydrogen carbonate (100 mL) and dichloromethane (50 mL), and the aqueous layer was further extracted with dichloromethane (3 × 50 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC reverse phase (C-18), eluting with acetonitrile/water + 0.1% TFA, to afford the title compound (62.6 mg, 0.161 mmol, 24% yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (d, <i>J</i> = 2.0 Hz, 1H), 8.54 (d, <i>J</i> = 2.0 Hz, 1H), 8.46 (s, 1H), 8.20 (d, <i>J</i> = 1 Hz, 1H), 8.13 (s, 1H), 7.80 (m, 2H), 7.38 (d, <i>J</i> = 10.5 Hz, 1H), 7.29 (d, <i>J</i> = 10.5 Hz, 1H), 6.33 (d, <i>J</i> = 4.5 Hz, 1H), 5.33 (d, <i>J</i> = 4.5 Hz, 1H), 4.09 (m, 2H), 3.88 (s, 3H), 1.12 (t, <i>J</i> = 6.0 Hz, 3H). MS (APCI) calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 390.1; found, 390.1.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 2-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]propanamide (<b>7a</b>)</h3><div class="NLM_p">Step 1: Ethyl 2-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]propanoate contaminated with ethyl [3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetate (109 mg, 0.281 mmol, 72% purity) was dissolved in THF (1125 μL). NaOH (1.0N, 563 μL, 0.563 mmol) was added, and the resulting suspension was stirred at room temperature for 30 min before heating to reflux. Then, the reaction was cooled to room temperature, neutralized with HCl (1.0N, 563 μL, 0.563 mmol), concentrated under reduced pressure, filtered, and dried under reduced pressure to afford 2-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]propanoic acid contaminated with [3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetic acid (101 mg, 72% purity) as a yellow powder. MS (APCI) calcd for C<sub>21</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 360.1; found, 360.1.</div><div class="NLM_p last">Step 2: 2-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]propanoic acid (101 mg, 0.281 mmol) was suspended in dichloromethane (2.81 mL) at room temperature. Then, triethylamine (0.196 mL, 1.41 mmol) was added followed by HATU (214 mg, 0.562 mmol) and finally ammonia in isopropyl alcohol (2.0 M, 0.562 mL, 1.12 mmol). The mixture was allowed to stir at room temperature for 1 h and then concentrated under reduced pressure. The residue was purified by preparative HPLC reverse phase (C-18), eluting with acetonitrile/water + 0.1% TFA, to afford the title compound (40 mg, 0.11 mmol, 40% yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (d, <i>J</i> = 2.0 Hz, 1H), 8.52 (d, <i>J</i> = 1.5 Hz, 1H), 8.45 (s, 1H), 8.13 (s, 1H), 8.08 (s, 1H), 7.74 (s, 2H), 7.51 (s, 1H), 7.37 (d, <i>J</i> = 10.5 Hz, 1H), 7.27 (d, <i>J</i> = 10.0 Hz, 1H), 6.92 (s, 1H), 3.88 (s, 3H), 3.75 (q, <i>J</i> = 5.5 Hz, 1H), 1.36 (d, <i>J</i> = 6.0 Hz). MS (APCI) calcd for C<sub>21</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 359.1; found, 359.1.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-Hydroxy-2-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetamide (<b>7b</b>)</h3><div class="NLM_p">Step 1: Ethyl hydroxy[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetate (63 mg, 0.16 mmol) was suspended in NaOH (1.0N, 322 μL, 0.322 mmol) and THF (643 μL) with stirring at room temperature. After 90 min, the mixture was neutralized with 1N HCl (322 mL) to form a yellow solution and then concentrated under reduced pressure to afford hydroxy[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetic acid as a yellow solid that was used directly in the next step. MS (APCI) calcd for C<sub>20</sub>H<sub>16</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 362.1; found, 362.1.</div><div class="NLM_p last">Step 2: Triethylamine (55.9 μL, 0.401 mmol), HATU (31 mg, 0.080 mmol), and then ammonia in isopropyl alcohol (2.0 M, 80 μL, 0.161 mmol) were added to a stirring suspension of hydroxy[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]acetic acid (29 mg, 0.080 mmol) in dichloromethane (803 μL) at room temperature. The reaction was stirred overnight and then concentrated under reduced pressure. The residue was taken up in dichloromethane (803 μL) and to this was added triethylamine (55.9 μL, 0.401 mmol), HATU (31 mg, 0.080 mmol), and then ammonia in isopropyl alcohol (2.0 M, 80 μL, 0.16 mmol). After stirring for a further 24 h, the reaction was concentrated under reduced pressure. The residue was purified by preparative HPLC reverse phase (C-18), eluting with acetonitrile/water + 0.1% TFA, to afford the title compound (5 mg, 0.01 mmol, 17% yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (d, <i>J</i> = 2.0 Hz, 1H), 8.53 (d, <i>J</i> = 2.0 Hz, 1H), 8.46 (s, 1H), 8.21 (d, <i>J</i> = 1.0 Hz, 1H), 8.13 (s, 1H), 7.84 (dd, <i>J</i> = 6.5, 1.5 Hz, 1H), 7.75 (d, <i>J</i> = 7.0 Hz), 7.51 (d, <i>J</i> = 1.5 Hz, 1H), 7.38 (d, <i>J</i> = 10.5 Hz, 1H), 7.29 (d, <i>J</i> = 10.0 Hz, 1H), 7.27 (d, <i>J</i> = 1.0 Hz, 1H), 6.30 (d, <i>J</i> = 4.0 Hz, 1H), 5.03 (d, <i>J</i> = 4.0 Hz, 1H). MS (APCI) calcd for C<sub>20</sub>H<sub>17</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 361.1; found, 361.1.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Methyl [(Dimethylamino)sulfonyl]acetate (<b>8a</b>)</h3><div class="NLM_p last">Dimethylamine in THF (57.9 mL, 116 mmol) was dissolved in dichloromethane (29.0 mL) and cooled to 0 °C. Then, methyl (chlorosulfonyl)acetate (prepared according to ref <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">27</a>) (10.0 g, 57.9 mmol) was added dropwise as a solution in dichloromethane (29.0 mL) while maintaining the temperature below 5 °C. The resulting solution was allowed to warm to room temperature over the course of 2 h. Then, brine (200 mL) was added and the aqueous phase was extracted with dichloromethane (3 × 100 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexanes gradient) to afford the title compound (5.98 g, 33.0 mmol, 57% yield) as a yellow liquid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.25 (s, 2H), 3.68 (s, 3H), 2.78 (s, 6H). MS (APCI) calcd for C<sub>5</sub>H<sub>12</sub>NO<sub>4</sub>S [M + H]<sup>+</sup>, 182.0; found, 182.0.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Methyl {[Methyl(phenyl)amino]sulfonyl}acetate (<b>8b</b>)</h3><div class="NLM_p last">Chlorine gas was passed through a suspension of ice (230 g), CH<sub>2</sub>Cl<sub>2</sub> (457 mL), and methyl thioglycolate (86.0 mL, 942 mmol), with external cooling with an ice/water bath to maintain an internal temperature below 30 °C. After approximately 6 h, the yellow/green color of the dissolved chlorine persisted for 30 min after gas flow was stopped and passing additional chlorine gas was no longer exothermic. The cooling bath was then removed, and the biphasic mixture was allowed to stir at ambient temperature for 1 h before being sparged with nitrogen for 20 min. The layers were then separated, and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide the intermediate methyl (chlorosulfonyl)acetate (160 g, 927 mmol) as a yellow oil. A portion of the intermediate methyl (chlorosulfonyl)acetate (100 g, 579 mmol) was added dropwise as a solution in CH<sub>2</sub>Cl<sub>2</sub> (290 mL) to a stirring −15 °C solution of <i>N</i>-methylaniline (124 g, 1159 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (290 mL). The rate of addition was adjusted to maintain the internal temperature below 5 °C. After the addition was complete, the reaction mixture was allowed to warm to room temperature over the course of 2 h, and 1 M HCl (1000 mL) was added and the aqueous phase was extracted with dichloromethane (2 × 500 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting oil was seed crystallized to afford a brown solid. Recrystallization from hot ethanol (320 mL) provided the title compound (110 g, 152 mmol, 78% yield) as an off-white solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.40 (m, 4H), 7.31 (m, 1H), 4.30 (s, 2H), 3.65 (s, 3H), 3.26 (s, 3H). MS (APCI) calcd for C<sub>25</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 244.1; found, 244.0.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 1-(3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)-<i>N</i>,<i>N</i>-dimethylmethanesulfonamide (<b>9a</b>)</h3><div class="NLM_p">Step 1: A 200 mL round-bottom flask was charged with methyl [(dimethylamino)sulfonyl]acetate (5.26 g, 29.0 mmol) and dioxane (77 mL), cooled to 0 °C, and then sodium hydride (2.32 g, 58.0 mmol) was added in one portion. After 15 min, the mixture was warmed to room temperature and 7-bromo-3-chloro-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (6.20g, 19.34 mmol) was added followed by Pd<sub>2</sub>(dba)<sub>3</sub> (0.71 g, 0.77 mmol) and triphenylphosphine (1.22 g, 4.64 mmol). The resulting suspension was degassed by sparging with nitrogen for 30 min. Then, the mixture was heated to 70 °C and left to stir overnight. The reaction was then cooled to room temperature, poured into brine (500 mL), and extracted with dichloromethane (3 × 150 mL). The combined organics were then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexanes gradient) to afford methyl (3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)[(dimethylamino)sulfonyl]acetate (2.04 g, 4.85 mmol, 25% yield) as a yellow oil that solidified to a yellow solid upon standing. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.00 (d, 1H), 8.49 (d, 1H), 8.47 (d, 1H), 8.07 (dd, 1H), 7.88 (d, 1H), 7.48 (d, 1H), 7.34 (d, 1H), 6.05 (s, 1H), 3.75 (s, 3H), 2.68 (s, 6H). MS (APCI) calcd for C<sub>19</sub>H<sub>18</sub>ClN<sub>2</sub>O<sub>5</sub>S [M + H]<sup>+</sup>, 421.1; found, 421.0.</div><div class="NLM_p last">Step 2: Methyl (3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)[(dimethylamino)sulfonyl]acetate (2.04 g, 4.85 mmol) was dissolved in a mixture of AcOH (24.2 mL) and 6N HCl (24.24 mL) and heated to 100 °C for 3 h. The solution was then cooled to room temperature, basified with saturated aqueous sodium hydrogen carbonate, and extracted with dichloromethane (3 × 50 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexanes gradient) to afford the title compound (1.44 g, 3.97 mmol, 82% yield) as a yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (d, 1H), 8.48 (d, 1H), 8.21 (s, 1H), 7.84 (m, 2H), 7.49 (d, 1H), 7.33 (d, 1H), 4.63 (s, 2H), 2.74 (s, 6H). MS (APCI) calcd for C<sub>17</sub>H<sub>16</sub>ClN<sub>2</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 363.1; found, 363.1.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Methyl (3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)[methyl(phenyl)sulfamoyl]acetate</h3><div class="NLM_p last">Sodium <i>tert</i>-butoxide (8.99 g, 94 mmol) was added in one portion to a 250 mL flask containing methyl {[methyl(phenyl)amino]sulfonyl}acetate (7.59 g, 31.2 mmol) and dioxane (125 mL) at room temperature. After 15 min, 7-bromo-3-chloro-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (10.00 g, 31.2 mmol) was added, followed by palladium(II) acetate (0.35 g, 1.6 mmol) and tri-<i>tert</i>-butylphosphonium tetrafluoroborate (1.36 g, 4.68 mmol). The resulting suspension was degassed by sparging with nitrogen for 30 min. Then the mixture was heated to 90 °C in a prewarmed bath and left to stir for 1 h. Then the reaction mixture was cooled to room temperature, acidified with 1N HCl (100 mL), basified with saturated aqueous sodium hydrogen carbonate (400 mL), and extracted with dichloromethane (3 × 250 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexanes gradient) to afford the ttile compound (11.8 g, 24.4 mmol, 78% yield) as a yellow foam. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (d, 1H), 8.46 (d, 1H), 8.42 (d, 1H), 8.03 (dd, 1H), 7.81 (d, 1H), 7.44 (d, 1H), 7.33 (d, 1H), 7.22 (m, 2H), 7.17 (m, 2H), 7.11 (m, 1H), 6.10 (s, 1H), 3.71 (s, 3H), 3.20 (s, 3H). MS (APCI) calcd for C<sub>24</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>5</sub>S [M + H]<sup>+</sup>, 483.1; found, 483.0.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 1-(3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)-<i>N</i>-methyl-<i>N</i>-phenylmethanesulfonamide (<b>9b</b>)</h3><div class="NLM_p last">Sodium <i>tert</i>-butoxide (47.4 g, 493 mmol) was added in one portion to a 1 L flask containing methyl {[methyl(phenyl)amino]sulfonyl}acetate (40.0 g, 164 mmol) and dissolved in dioxane (658 mL) at 0 °C. After 15 min, 7-bromo-3-chloro-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (52.7 g, 164 mmol) was added, followed by palladium(II) acetate (1.85 g, 8.22 mmol) and tri-<i>tert</i>-butylphosphonium tetrafluoroborate (7.16 g, 24.7 mmol). The resulting suspension was degassed by sparging with nitrogen for 30 min. Then the mixture was heated to 90 °C in a prewarmed bath and left to stir for 1 h. Then the reaction flask was cooled to 50 °C, 1N NaOH (500 mL) was added, and the solution was stirred for 1h. Then the solution was diluted with saturated aqueous sodium hydrogen carbonate (800 mL) and extracted with dichloromethane (3 × 500 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc/hexanes gradient) to afford the title compound (51.65 g, 122.0 mmol, 74% yield) as a pale-yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (d, 1H), 8.47 (m, 1H), 8.17 (s, 1H), 7.81 (s, 2H), 7.47 (d, 1H), 7.32 (m, 5H), 7.21 (m, 1H), 4.75 (s, 2H), 3.24 (s, 3H). MS (APCI) calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>2</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 425.1; found, 425.0.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>,<i>N</i>-Dimethyl-1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]methanesulfonamide (<b>10a</b>)</h3><div class="NLM_p last">1-(3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)-<i>N</i>,<i>N</i>-dimethylmethanesulfonamide (1.44 g, 3.97 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i> pyrazole (1.24 g, 5.95 mmol), tri-<i>tert</i>-butylphosphonium tetrafluoroborate (104 mg, 0.357 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (145 mg, 0.159 mmol), and potassium fluoride (761 mg, 13.1 mmol) were combined as solids and then placed under a nitrogen atmosphere. DMF (39.7 mL) was added, and the resulting suspension was heated to 130 °C and left to stir for 1 h. Then the reaction was cooled to room temperature and partitioned between saturated aqueous sodium hydrogen carbonate (250 mL) and dichloromethane (250 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica (EtOAc + 10% MeOH/hexanes gradient) to afford the title compound (1.33 g, 3.25 mmol, 82% yield) as a yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.21 (d, 1H), 8.54 (d, 1H), 8.47 (s, 1H), 8.19 (s, 1H), 8.14 (s, 1H), 7.81 (m, 2H), 7.40 (d, 1H), 7.32 (d, 1H), 4.63 (s, 2H), 3.88 (s, 3H), 2.74 (s, 6H). MS (APCI) calcd for C<sub>21</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 409.1; found, 409.1.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-Methyl-1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-phenylmethanesulfonamide (<b>10b</b>)</h3><div class="NLM_p last">1-(3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)-<i>N</i>-methyl-<i>N</i>-phenylmethanesulfonamide (4.40 g, 10.4 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i> pyrazole (2.59 g, 12.4 mmol), potassium fluoride (1.99 g, 34.2 mmol), tri-<i>tert</i>-butylphosphonium tetrafluoroborate (0.27 g, 0.93 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub> (379 mg, 0.414 mmol) were combined as solids and placed under a nitrogen atmosphere. DMF (104 mL) was added, the mixture was degassed, and then the reaction was heated to 130 °C with stirring for 2 h. After cooling to room temperature, the mixture was poured into aqueous sodium hydrogen carbonate (saturated, 250 mL) and extracted with dichloromethane (4 × 250 mL). The organic extracts were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was then dissolved in hot dioxane (500 mL). Hexanes were added until a precipitate formed. After standing at room temperature overnight, the precipitate was collected to afford the title compound (2.30 g, 4.90 mmol, 47% yield) as a gray solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (d, 1H), 8.53 (d, 1H), 8.47 (s, 1H), 8.15 (s, 1H), 8.14 (d, 1H), 7.78 (m, 2H), 7.39 (d, 1H), 7.32 (m, 5H), 7.20 (m, 1H), 4.75 (s, 2H), 3.88 (s, 3H), 3.23 (s, 3H). MS (APCI) calcd for C<sub>21</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 409.1; found, 409.1.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 1-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-phenylmethanesulfonamide (<b>11h</b>)</h3><div class="NLM_p last">Cesium carbonate (80 mg, 0.25 mmol) was added to a solution of <i>N</i>,<i>N</i>-dimethyl-1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]methanesulfonamide (50 mg, 0.12 mmol) and aniline (559 μL, 6.12 mmol) in dioxane (1113 μL) and water (111 μL) in a sealed pressure vessel. The vial was then sealed, and the mixture was heated to 180 °C for 3 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC reverse phase (C-18), eluting with acetonitrile/water + 0.1% TFA, to afford the title compound (7.3 mg, 0.016 mmol, 13% yield) as a yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.84 (br s, 1H), 9.22 (d, 1H), 8.51 (d, 1H), 8.48 (s, 1H), 8.15 (s, 1H), 8.04 (d, 1H), 7.76 (d, 1H), 7.63 (dd, 1H), 7.38 (d, 1H), 7.32 (d, 1H), 7.27 (m, 2H), 7.16 (dd, 2H), 7.00 (m, 1H), 4.68 (s, 2H), 3.89 (s, 3H). MS (APCI) calcd for C<sub>25</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 457.1; found, 457.1. <b>11a</b>–<b>e</b>, <b>11i</b>–<b>k</b>, and <b>11p</b>–<b>q</b> were prepared by the same method as <b>11h</b> in library format.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-[<i>trans</i>-2-Aminocyclohexyl]-1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]methanesulfonamide (<b>11g</b>)</h3><div class="NLM_p last"><i>N</i>-methyl-1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-phenylmethanesulfonamide (100 mg, 0.213 mmol) and (1<i>R</i>,2<i>R</i>)-(−)-1,2-diaminocyclohexane (109 mg, 0.956 mmol) were dissolved in <i>N</i>-methyl-2-pyrrolidinone (2.0 mL) in a 5 mL sealed pressure vessel. The vial was capped and heated to 190 °C for 0.5 h. The mixture was diluted with MeOH and purified by preparative HPLC reverse phase (C-18), eluting with acetonitrile/water + 0.05% TFA to afford the title compound (80 mg, 0.17 mmol, 79% yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.02 (s, 1H), 8.55 (s, 1H), 8.33 (s, 1H), 7.92 (s, 1H), 7.82 (s, 2H), 7.61 (d, <i>J</i> = 7.9, 1H), 7.37 (d, <i>J</i> = 12.4, 1H), 7.22 (d, <i>J</i> = 12.5, 1H), 4.55 (d, <i>J</i> = 13.5, 1H), 4.43 (d, <i>J</i> = 13.7, 1H), 3.99 (s, 3H), 2.97 (s, 1H), 2.37 (t, <i>J</i> = 10.3, 1H), 2.23 (s, 1H), 2.01 (s, 2H), 1.96 (d, <i>J</i> = 12.7, 1H), 1.72 (s, 2H), 1.23 (m, 5H). MS (APCI) calcd for C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 478.2; found, 477.8. <b>11f</b>, <b>11l</b>, <b>11m</b>, <b>11o</b>, <b>11s</b>, <b>11u</b>, and <b>11v</b> were prepared in library format in analogy to <b>11g</b>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 1-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-[(2-methylpyrimidin-4-yl)methyl]methanesulfonamide (<b>11n</b>)</h3><div class="NLM_p">Step 1: <i>N</i>-Methyl-1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-phenylmethanesulfonamide (1.30 g 2.76 mmol), methanesulfonic acid (3.7 mL), and water (7.4 mL) were placed in a sealed pressure vessel. The mixture was heated at 110 °C for 43 h. The reaction mixture was cooled to ambient temperature, and solids were collected by filtration, washed with water (20 mL) and EtOAc (20 mL), and dried to afford 1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-phenylmethanesulfonic acid (850 mg, 2.23 mmol, 81% yield) of as off-white solid that was used without further purification. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (d, 1H), 8.68 (d, 1H), 8.49 (s, 1H), 8.16 (s, 1H), 8.07 (s, 1H), 7.73 (dd, 1H), 7.68 (d, 1H), 7.43 (d, 1H), 7.22 (d, 1H), 3.90 (s, 2H), 3.87 (s, 3H). MS (APCI) calcd for C<sub>19</sub>H<sub>16</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 382.1; found, 382.1.</div><div class="NLM_p last">Step 2: In a 10 mL round-bottom flask charged with 1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-phenylmethanesulfonic acid (50 mg, 0.13 mmol) in dichloromethane (1.3 mL) was added DMF (12 uL, 0.16 mmol), followed by oxalyl chloride ((2 M in dichloromethane, 328 uL, 0.65 mmol). The resulting mixture was stirred for 1.5 h, and then volatiles were removed in vacuo. The crude reside was taken up in dichloromethane (1.3 mL), and 1-(2-methylpyrimidin-4-yl)methanamine dihydrochloride (103 mg, 0.524 mmol) was added. The mixture was stirred for 5 min, followed by addition of triethylamine (146 uL, 1.05 mmol), and stirred for 30 min. The crude reaction mixture was directly subjected to silica gel column chromatography (25 g, 0–100% 10:1:0.5 EtOAc/MeOH/Et<sub>3</sub>N in hexanes) to afford 1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-[(2-methylpyrimidin-4-yl)methyl]methanesulfonamide (20 mg, 0.041 mmol, 31% yield). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.95 (d, 1H), 8.50 (d, 1H), 8.42 (d, 1H), 8.18 (d, 1H), 7.88 (s, 1H), 7.79 (s, 1H), 7.73 (dd, 1H), 7.52 (d, 1H), 7.25 (d, 1H), 7.11 (d, 1H), 7.03 (d, 1H), 4.45 (s, 2H), 4.25 (s, 2H), 3.97 (s, 3H), 2.63 (s, 3H). MS (APCI) calcd for C<sub>25</sub>H<sub>23</sub>N<sub>6</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 487.1; found, 487.1.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (<b>11r</b>)</h3><div class="NLM_p">Step 1: 2-Aminomethylpyridine (55.9 mL, 546 mmol) was added to a solution of 1-(3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)-<i>N</i>-methyl-<i>N</i>-phenylmethanesulfonamide (51.6 g, 121 mmol) in <i>N</i>-methyl-2-pyrrolidinone (1214 mL) at room temperature. The solution was then heated to 130–135 °C for 2 h in a prewarmed oil bath. The solution was then cooled to room temperature and poured into aqueous sodium hydrogen carbonate (saturated, 3.0 L) and ice–water (500 mL) and extracted with ethyl acetate (3 × 500 mL). The combined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexanes gradient) to afford 1-(3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (37.2 g, 87.0 mmol, 72% yield) as a yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (d, 1H), 8.47 (d, 1H), 8.46 (m, 1H), 8.16 (d, 1H), 7.81 (m, 3H), 7.76 (m, 1H), 7.49 (d, 1H), 7.38 (d, 1H), 7.32 (d, 1H), 7.25 (m, 1H), 4.63 (s, 2H), 4.22 (d, 2H). MS (APCI) calcd for C<sub>21</sub>H<sub>17</sub>ClN<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 426.1; found, 426.0.</div><div class="NLM_p last">Step 2: 1-(3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (22.04 g, 51.80 mmol), lithium 2-hydroxy-4,4,5,5-tetramethyl-2-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,3,2-dioxaborolan-2-uide hydrate (25.3 g, 88.0 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (2.37 g, 2.59 mmol), and tricyclohexylphosphine (1.81 g, 6.47 mmol) were placed in a flask under an atmosphere of argon. DMF (518 mL) was added, and argon was bubbled through the solution for several minutes. The solution was then heated at 100 °C for 4 h. The mixture was cooled to room temperature, poured into aqueous sodium hydrogen carbonate (saturated, 70 mL), and extracted with ethyl acetate (2 × 75 mL). The coimbined organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with EtOAc + 10% MeOH + 1% Et<sub>3</sub>N/hexanes gradient to afford the title compound (17.3 g, 36.7 mmol, 71% yield) as a pale-yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.21 (d, 1H), 8.53 (d, 1H), 8.47 (m, 1H), 8.46 (m, 1H), 8.15 (d, 1H), 8.14 (s, 1H), 7.78 (m, 4H), 7.39 (m, 2H), 7.32 (d, 1H), 7.24 (m, 1H), 4.63 (s, 2H), 4.22 (d, 1H), 3.88 (s, 3H). MS (APCI) calcd for C<sub>25</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 472.1; found, 472.1.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 1-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-[(1-oxidopyridin-2-yl)methyl]methanesulfonamide (<b>11t</b>)</h3><div class="NLM_p last">3-Chloroperoxybenzoic acid (26 mg, 0.11 mmol) was added to a solution of 1-[3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (50 mg, 0.11 mmol) in dichloromethane (1.06 mL) at 0 °C. After 15 min, the reaction was allowed to warm to room temperature and stirring was continued for 6 h. Then, aqueous sodium hydrogen carbonate (saturated, 50 mL) was added, and the mixture was extracted with dichloromethane (3 × 50 mL). The combined organic extracts were washed with aqueous sodium hydrogen carbonate (saturated, 2 × 75 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative HPLC reverse phase (C-18), eluting with acetonitrile/water + 0.05% TFA, to afford the title compound as a yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.21 (d, 1 H), 8.53 (d, 1H), 8.47 (s, 1H), 8.25 (d, 1H), 8.17 (s, 1H), 8.14 (s, 1H), 7.80 (m, 3H), 7.46 (d, 1H), 7.40 (d, 1H), 7.34 (m, 3H), 4.71 (s, 2H), 4.27 (d, 2H), 3.88 (s, 3H). MS (APCI) calcd for C<sub>25</sub>H<sub>21</sub>N<sub>5</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 488.1; found, 488.1.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 3-Chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one</h3><div class="NLM_p last">7-Bromo-3-chloro-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (5.00 g, 15.6 mmol), potassium (2-(trimethylsilyl)ethoxy)methyltrifluoroborate (4.46 g, 18.7 mmol), palladium(II) acetate (175 mg, 0.780 mmol), RuPhos (728 mg, 1.56 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (15.25 g, 46.80 mmol) were taken up in 1,4-dioxane (55 mL)/water (5.5 mL). The flask was evacuated and backfilled with N<sub>2</sub> three times before stirring at 100 °C for 18 h. Additional palladium(II) acetate (88 mg, 0.39 mmol) and RuPhos (364 mg, 0.780 mmol) were added, the flask was evacuated and backfilled with N<sub>2</sub> three times before stirring at 100 °C for an additional 24 h. The reaction mixture was cooled to room temperature, saturated NH<sub>4</sub>Cl was added, and the products extracted into dichloromethane. The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Purification of the residue by flash chromatography (2–20% EtOAc/hexanes) gave 3-chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (3.22 g, 8.66 mmol, 56% yield) as a yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (d, <i>J</i> = 2.4 Hz, 1 H), 8.42 (d, <i>J</i> = 2.4 Hz, 1 H), 8.07 (s, 1 H), 7.77 (d, <i>J</i> = 7.8 Hz, 1 H), 7.72 (dd, <i>J</i> = 7.8 and 1.8 Hz, 1 H), 7.44 (d, <i>J</i> = 12.0 Hz, 1 H), 7.25 (d, <i>J</i> = 12.0 Hz, 1 H), 4.56 (s, 2 H), 3.56 (t, <i>J</i> = 7.8 Hz, 2 H), 0.92 (t, <i>J</i> = 7.8 Hz, 2 H), −0.03, (s, 9 H). MS (APCI) calcd for C<sub>20</sub>H<sub>23</sub>ClNO<sub>2</sub>Si [M + H]<sup>+</sup>, 372.1; found, 372.1.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 3-Chloro-7-(hydroxymethyl)-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one</h3><div class="NLM_p last">3-Chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (2.32 g, 6.24 mmol) was taken up in dichloromethane (12 mL) and cooled to 0 °C. Boron trifluoride etherate (3.95 mL, 31.2 mmol) was added before slowly warming to room temperature and stirring for 18 h. Saturated NaHCO<sub>3</sub> was added, and the resulting precipitate collected by filtration, washing with water and dichloromethane. The crude solid was recrystallized from dichloromethane to give 3-chloro-7-(hydroxymethyl)-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (367 mg, 1.35 mmol, 22% yield) as a yellow solid (1st crop). The mother liquor was concentrated in vacuo while loading onto silica and purification by flash chromatography (12–100% EtOAc/hexanes) gave 3-chloro-7-(hydroxymethyl)-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (415 mg, 1.53 mmol, 25% yield) as a yellow solid (2nd crop). The dichloromethane filtrate was concentrated in vacuo while loading onto MgSO<sub>4</sub> and purification by flash chromatography (12–100% EtOAc/hexanes) gave 3-chloro-7-(hydroxymethyl)-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (0.37 g, 1.4 mmol, 22% yield) as a yellow solid (3rd crop). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (d, <i>J</i> = 2.4 Hz, 1 H), 8.45 (d, <i>J</i> = 2.4 Hz, 1 H), 8.11 (s, 1 H), 7.77–7.73 (m, 2 H), 7.45 (d, <i>J</i> = 12.6 Hz, 1 H), 7.26 (d, <i>J</i> = 12.6 Hz, 1 H), 5.46 (t, <i>J</i> = 5.4 Hz, 1 H), 4.63 (d, <i>J</i> = 5.4 Hz, 2 H). MS (APCI) calcd for C<sub>15</sub>H<sub>11</sub>ClNO<sub>2</sub> [M + H]<sup>+</sup>, 272.0; found, 272.0.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)methylmethanesulfonate</h3><div class="NLM_p last">3-Chloro-7-(hydroxymethyl)-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (0.32 g, 1.2 mmol) and Et<sub>3</sub>N (0.230 mL, 1.65 mmol) were taken up in 1,4-dioxane (6 mL) and cooled to 0 °C. Methanesulfonyl chloride (0.11 mL, 1.4 mmol) was added before warming to room temperature and stirring for 2 h. Water was added and the products extracted into EtOAc. The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was recrystallized from EtOAc/hexanes to give (3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)methylmethanesulfonate (0.32 g, 0.92 mmol, 78% yield) as yellow needles. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.97 (d, <i>J</i> = 2.4 Hz, 1 H), 8.44 (d, <i>J</i> = 2.4 Hz, 1 H), 8.18 (s, 1 H), 7.86 (s, 2 H), 7.48 (d, <i>J</i> = 12.6 Hz, 1 H), 7.31 (d, <i>J</i> = 12.6 Hz, 1 H), 5.42 (s, 2 H), 3.26 (s, 3 H). MS (APCI) calcd for C<sub>16</sub>H<sub>13</sub>ClNO<sub>4</sub>S [M + H]<sup>+</sup>, 350.0; found, 349.9.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3-Chloro-7-{[(2-pyridin-2-ylethyl)thio]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one</h3><div class="NLM_p last">Sodium hydride (60 wt %, 9 mg, 0.2 mmol) was suspended in DMF (0.5 mL), and a solution of 2-pyridin-2-ylethanethiol (31 mg, 0.22 mmol) in DMF (0.2 mL) was added, forming a yellow solution. To this mixture was added a warm solution of (3-chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)methylmethanesulfonate (60 mg, 0.17 mmol) in DMF (1 mL). The resulting mixture was stirred at room temperature for 30 min. Water was added and the products extracted into EtOAc. The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Purification of the residue by flash chromatography (12–100% EtOAc/hexanes) gave 3-chloro-7-{[(2-pyridin-2-ylethyl)thio]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (24 mg, 0.061 mmol, 36% yield) as a yellow gum. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.79 (d, <i>J</i> = 2.4 Hz, 1 H), 8.50–8.49 (m, 2 H), 8.15 (m, 1 H), 7.68 (dd, <i>J</i> = 7.8 and 1.8 Hz, 1 H), 7.58–7.54 (m, 2 H), 7.30 (d, <i>J</i> = 12.6 Hz, 1 H), 7.24 (d, <i>J</i> = 12.6 Hz, 1 H), 7.13–7.09 (m, 2 H), 3.80 (s, 2 H), 3.02 (t, <i>J</i> = 7.5 Hz, 2 H), 2.83 (t, <i>J</i> = 7.5 Hz, 2 H). MS (APCI) calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>2</sub>OS [M + H]<sup>+</sup>, 393.1; found, 393.0.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-Chloro-7-{[(2-pyridin-2-ylethyl)sulfonyl]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one</h3><div class="NLM_p last">3-Chloro-7-{[(2-pyridin-2-ylethyl)thio]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (23 mg, 0.059 mmol) and MCPBA (77 wt %, 26 mg, 0.12 mmol) were stirred in dichloromethane (2 mL) at room temperature for 18 h. The reaction mixture was purified directly by flash chromatography (12–100% EtOAc/hexanes) to afford 3-chloro-7-{[(2-pyridin-2-ylethyl)sulfonyl]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (11 mg, 0.026 mmol, 44% yield) as an off-white solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (d, <i>J</i> = 2.4 Hz, 1 H), 8.46–8.44 (m, 2 H), 8.02 (s, 1 H), 7.86–7.82 (m, 2 H), 7.71–7.68 (m, 1 H), 7.47 (d, <i>J</i> = 12.0 Hz, 1 H), 7.33–7.30 (m, 2 H), 7.23–7.20 (m, 1 H), 4.77 (s, 2 H), 3.52–3.48 (m, 2 H), 3.18–3.14 (m, 2 H). MS (APCI) calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>2</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 425.1; found, 425.0.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-7-{[(2-pyridin-2-ylethyl)sulfonyl]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (<b>13</b>)</h3><div class="NLM_p last">1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, lithium ate salt (10 mg, 0.042 mmol), Pd<sub>2</sub>dba<sub>3</sub> (1 mg, 1 μmol), and X-Phos (1 mg, 2 μmol) were added to a 2 mL sealed pressure vessel. The vial was evacuated and backfilled with N<sub>2</sub> three times before adding a solution of 3-chloro-7-{[(2-pyridin-2-ylethyl)sulfonyl]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (9 mg, 0.02 mmol) in DMF (1 mL). The resulting dark solution was heated to 150 °C for 20 min under microwave irradiation. Saturated NH<sub>4</sub>Cl was added and the products extracted into EtOAc (twice). The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Purification of the residue by flash chromatography (0–10% MeOH/EtOAc) afforded 3-(1-methyl-1<i>H</i>-pyrazol-4-yl)-7-{[(2-pyridin-2-ylethyl)sulfonyl]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (6 mg, 0.01 mmol, 60% yield) as a yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (d, <i>J</i> = 1.8 Hz, 1 H), 8.52 (d, <i>J</i> = 1.8 Hz, 1 H), 8.47–8.44 (m, 2 H), 8.18 (s, 1 H), 8.13 (s, 1 H), 7.83–7.79 (m, 2 H), 7.70–7.67 (m, 1 H), 7.39 (d, <i>J</i> = 12.6 Hz, 1 H), 7.34–7.31 (m, 2 H), 7.22–7.19 (m, 1 H), 4.77 (s, 2 H), 3.87 (s, 3 H), 3.52–3.48 (m, 2 H), 3.18–3.14 (m, 2 H). MS (APCI) calcd for C<sub>26</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 471.1; found, 471.1.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>tert</i>-Butyl 4-[(Methylsulfonyl)oxy]piperidine-1-carboxylate</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate (2.0 g, 9.9 mmol) and triethylamine (2.70 mL, 19.9 mmol) in dichloromethane (20 mL) at 0 °C was added methanesulfonyl chloride (1.15 mL, 14.9 mmol). The reaction mixture was allowed to warm to RT and stirred overnight. The reaction mixture was filtered, and the filtrate was diluted with dichloromethane and washed with 1N HCl and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dryloaded onto silica gel, and the crude residue was purified by flash chromatography (5–40% EtOAc/hexane) to provide <i>tert</i>-butyl 4-[(methylsulfonyl)oxy]piperidine-1-carboxylate (2.3 g, 8.2 mmol, 84% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 4.87 (m, 1H), 3.69 (m, 2H), 3.30 (m, 2H), 3.03 (s, 3H), 1.95 (m, 2H), 1.80 (m, 2H), 1.45 (s, 9H).</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>tert</i>-Butyl 4-(4-Iodo-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-[(methylsulfonyl)oxy]piperidine-1-carboxylate (1.0 g, 3.6 mmol) and 4-iodopyrazole (0.70 g, 3.6 mmol) in DMF (10 mL) was added NaH (60% mineral oil, 215 mg, 5.40 mmol). The reaction mixture was stirred under nitrogen until release of hydrogen gas ceased. The reaction was then placed in a microwave reactor and heated to 110 °C for 30 min. The reaction mixture was diluted with EtOAc and washed with brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dryloaded onto silica gel, and the crude residue was purified by flash chromatography (5–40% EtOAc/hexane) to give <i>tert</i>-butyl 4-(4-iodo-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (740 mg, 1.96 mmol, 55% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.98 (s, 1H), 7.51 (s, 1H), 4.34 (m, 1H), 4.01 (m, 2H), 2.86 (m, 2H), 1.94 (m, 2H), 1.72 (qd, 2H), 1.39 (s, 9H).</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>tert</i>-Butyl 4-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl]piperidine-1-carboxylate</h3><div class="NLM_p last"><i>tert</i>-Butyl 4-(4-iodo-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (1.6 g, 4.3 mmol), bis(pinacolato)diboron (1.5 g, 6.1 mmol), potassium acetate (1.70 g, 17.4 mmol), and 1,1′ bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.2 g, 0.2 mmol) were combined in a vial and dissolved in DMSO (17 mL). The mixture was sparged with argon for 10 min and then heated to 80 °C for 3 h. The reaction mixture was diluted with EtOAc and filtered over Celite, and the filtrate was washed with brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and filtered, and the crude residue was purified by flash chromatography (7–60% EtOAc/hexane) to give <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl]piperidine-1-carboxylate (1.2 g, 3.2 mmol, 73% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.79 (s, 1H), 7.73 (s, 1H), 4.60 (m, 1H), 4.25 (m, 2H), 2.88 (m, 2H), 2.12 (m, 2H), 1.90 (m, 2H), 1.46 (s, 9H), 1.31 (s, 6H), 1.24 (s, 6H). MS (ESI) calcd for C<sub>19</sub>H<sub>32</sub>BN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 378.3; found, 378.2.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>tert</i>-Butyl 4-[4-(5-Oxo-7-{[(pyridin-2-ylmethyl)sulfamoyl]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl]piperidine-1-carboxylate</h3><div class="NLM_p last">1-(3-Chloro-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl)-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (84 mg, 0.20 mmol), <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl]piperidine-1-carboxylate (112 mg, 0.297 mmol), potassium fluoride (38 mg, 0.65 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (9 mg, 0.01 mmol), and tri-<i>t</i>-butylphosphonium tetrafluoroborate (6 mg, 0.02 mmol) were combined in a vial and dissolved in DMF (1.0 mL). The mixture was sparged with argon for 10 min and then heated to 130 °C overnight. The reaction mixture was diluted with EtOAc and washed with NH<sub>4</sub>Cl and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dryloaded onto silica gel, and the crude residue was purified by flash chromatography (12–100% EtOAc/hexane, followed by 0–10% dichloromethane-MeOH) to give <i>tert</i>-butyl 4-[4-(5-oxo-7-{[(pyridin-2-ylmethyl)sulfamoyl]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl]piperidine-1-carboxylate (26 mg, 0.040 mmol, 20% yield) as an orange solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.24 (d, 1H), 8.65 (s, 1H), 8.58 (d, 1H), 8.48 (m, 1H), 8.19 (s, 1H), 8.15 (d, 1H), 7.80 (m, 4H), 7.40 (m, 2H), 7.34 (d, 1H), 7.25 (m, 1H), 4.64 (s, 2H), 4.44 (m, 1H), 4.23 (d, 1H), 4.02 (m, 2H), 3.15 (m, 2H), 2.05 (m, 2H), 1.82 (m, 2H), 1.40 (s, 9H). MS (ESI) calcd for C<sub>33</sub>H<sub>35</sub>N<sub>7</sub>O<sub>5</sub>S [M + H]<sup>+</sup>, 641.2; found, 641.3.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 1-{5-Oxo-3-[1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl]-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl}-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (<b>16</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-[4-(5-oxo-7-{[(pyridin-2-ylmethyl)sulfamoyl]methyl}-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-3-yl)-1<i>H</i>-pyrazol-1-yl]piperidine-1-carboxylate (26 mg, 0.040 mmol) in dichloromethane (0.3 mL) was added HCl (4 M in dioxane, 0.5 mL). The reaction mixture stirred at RT for 1 h. The solution was concentrated in vacuo and diluted with DMSO (1.0 mL) and DMF (1.0 mL). The residue was purified by preparative HPLC reverse phase (C-18), eluting with acetonitrile/water + 0.05% TFA. Fractions containing pure compound were collected, and the free base was liberated using PL-HCO<sub>3</sub> cartridges (Stratospheres, 0.9 mmol) and lyophillized to afford 1-{5-oxo-3-[1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl]-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl}-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (5 mg, 0.008 mmol, 21% yield) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.27 (d, 1H), 8.61 (s, 1H), 8.59 (d, 1H), 8.47 (m, 1H), 8.23 (s, 1H), 8.15 (d, 1H), 7.80 (m, 4H), 7.41 (m, 2H), 7.34 (d, 1H), 7.26 (m, 1H), 4.64 (s, 2H), 4.42 (m, 1H), 4.23 (d, 1H), 3.28 (m, 2H), 2.93 (m, 2H), 2.18 (m, 2H), 2.03 (m, 2H). MS (ESI) calcd for C<sub>28</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 541.2; found, 541.2.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> In Vitro Kinase Assays</h3><div class="NLM_p last">As described in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">24</a>, c-Met-catalyzed phosphorylation of <i>N</i>-biotinylated peptide (EQEDEPEGDYFEWLE-CONH<sub>2</sub>) was measured using a time-resolved fluorescence resonance energy transfer assay. To evaluate kinase selectivity, a single concentration (1 μmol/L) of <b>11r</b> and <b>12</b> was tested using 221 kinases by Upstate Biotechnology, Inc. (Millipore), which also determined the <b>11r</b> IC<sub>50</sub> for the kinases for which IC<sub>50</sub> values are reported. The <b>11r</b> IC<sub>50</sub> for Ron, Mer, Flt1, Flt3, Flt4, KDR, PDGFRβ, FGFR1, FGFR2, FGFR3, TrkA, and TrkB were determined using time-resolved fluorescence resonance energy transfer assays similar to the c-Met kinase assay. For compounds <b>11a</b>, <b>11u</b>, <b>11w</b>, and <b>13</b>–<b>16</b>, kinase assays were performed using commercially available ProfilerPro kinase selectivity assay kits from Caliper Life Sciences, Inc. at test concentrations of 0.1 and 1 μM. Compound <b>5g</b> was evaluated by InVitrogen, Inc. using a Z′-LYTE kinase assay format or Adapta Universal Kinase Assay at test concentrations of 0.1, 1, and 10 μM. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for tabulated results.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Cellular Assays</h3><div class="NLM_p last">As described in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">24</a>, proliferation and viability of tumor cells was measured using the ViaLight PLUS kit (Cambrex). Analysis of phosphorylation status of c-Met, in cells: Tumor cells were treated for 2 h with <b>11r</b> or vehicle in RPMI 1640 supplemented with 10% fetal bovine serum and 10 mmol/L HEPES. When called for, the cells were stimulated with HGF during the last 10 min of the 2 h incubation. The cells were lysed with a denaturing or nondenaturing buffer containing phosphatase and protease inhibitors and subjected to Western blot or immunoprecipitation–Western blot analysis.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Tumor Xenograft Model</h3><div class="NLM_p last">As described in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">24</a>, GTL-16 cells were inoculated sc into the flank of female nude CD-1 nu/nu mice. When mean tumor size reached a predetermined range, the mice were randomized and given vehicle or <b>11r</b> by po gavage once or twice daily. Tumor volumes were determined using calipers. The percentage increase in the volume of a xenograft tumor on day <i>n</i> versus day 0 (the day when dosing of <b>11r</b> began) was calculated as (tumor volume on day <i>n</i> – tumor volume on day 0/tumor volume on day 0) × 100. The mean percentage of tumor growth inhibition in each <b>11r</b>-treated group relative to the vehicle-treated group was calculated as (1 – mean percent increase of tumor volume in the <b>11r</b>-treated group/mean percent increase of the tumor volume in the vehicle-treated group) × 100.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Measurement of c-Met (Y1349) Phosphorylation in Xenograft Tumors</h3><div class="NLM_p last">As described in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">24</a>, mice bearing GTL-16 tumors were euthanized 1 h after po administration of <b>11r</b>. The tumors were excised, snap-frozen, and dispersed using a Qiagen Tissue-Lyser in a nondenaturing lysis buffer containing protease and phosphatase inhibitors. The homogenate was lysed at 4 °C for 1 h, clarified by centrifugation, and then analyzed by quantitative Western blotting for phospho-c-Met (Y1349) and total c-Met. The pMet (Y1349) signal of each c-Met band was normalized with its total c-Met signal. To combine or compare data from several gels, the pY1349/total Met ratio for each c-Met band was further normalized to the average pY1349/total c-Met ratio of the vehicle-treated tumor samples on the same gel.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Time-Dependent Inhibition of CYP3A4</h3><div class="NLM_p">The time-dependent inhibition assay for CYP3A4 was performed in two steps, a preincubation step where the test compound was incubated with human liver microsomes and the secondary incubation period where CYP3A4 substrate, testosterone, was added to the preincubate to measure residual CYP3A4 activity. Wells contained human liver microsomes (42.5 μL, 2.35 mg/mL) which were diluted from a stock (20 mg/mL) in potassium phosphate buffer (50 mM, pH 7.4) such that the final concentration in the 50 μL preincubation was 2 mg/mL. The wells also contained test compound (2.5 μL at 20 times the incubation concentration) in a solvent mixture of DMSO:water:methanol (10:50:40), and the same solvent in the absence of the test compound was used as the control. The final concentrations of the test compound in the preincubations were 1.56, 3.13, 6.25, 12.5, 25, 50, and 100 μM. The preincubation times used were 0, 5, 10, 15, and 20 min. Separate preincubations were used for each preincubation time point. The rack containing the wells was prewarmed for 30 min at 37 °C in an incubator that was gently shaken, and the temperature was maintained at 37 °C for the duration of the incubations. The preincubation period was initiated by the addition of NADPH (5 μL, 10 mM) that had been prewarmed to 37 °C for 10 min. Following the preincubation step, the secondary incubations were initiated by performing a 10-fold dilution of the preincubate using 450 μL of a prewarmed (37 °C) solution of NADPH (1 mM) and testosterone (222 μM) in potassium phosphate (50 mM, pH 7.4) The final concentration of NADPH and testosterone in the 500 μL incubation was 1 mM and 200 μM, respectively. After a 10 min incubation period, each well was quenched with 1 mL of acetonitrile containing the internal standard, cortisone (0.6 μg/mL), and placed on ice. The rack was centrifuged at 3202<i>g</i> for 10 min, and 200 μL of the supernatant was diluted with 100 μL of water, mixed well, and analyzed by LC-MS-MS.</div><div class="NLM_p">Samples (10 μL) were injected onto a C<sub>18</sub> column (2.0 mm × 30 mm, 3 μm particle size) and eluted using water containing 0.1% formic acid as the aqueous mobile phase (A), and acetonitrile containing 0.1% formic acid as the organic phase (B), according to the following gradient table (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>):</div><div class="NLM_table-wrap" id="tbl7">Table 7<div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">time (min)</th><th class="colsep0 rowsep0" align="center" char=".">flow rate (mL/min)</th><th class="colsep0 rowsep0" align="center" char=".">%A</th><th class="colsep0 rowsep0" align="center" char=".">%B</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">0.00</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3.02</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3.52</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3.53</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr></tbody></table></div></div><div class="NLM_p last">The eluent from the column was sent to the mass spectrometer and specific multiple reaction monitoring transitions for testosterone metabolite, 6β-OH testosterone (305 <i>m</i>/<i>z</i> > 269 <i>m</i>/<i>z</i>), and cortisone (361 <i>m</i>/<i>z</i> > 185 <i>m</i>/<i>z</i>) were used for MS/MS detection. Integrated area ratios of the analyte (6β-OH testosterone) to the internal standard (cortisone) were analyzed by nonlinear regression to calculate <i>K</i><sub>i</sub> and <i>k</i><sub>inact</sub>.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Crystallography</h3><div class="NLM_p last">Crystals of c-Met were grown essentially as previously described.<a onclick="showRef(event, 'ref18 ref25'); return false;" href="javascript:void(0);" class="ref ref18 ref25">(18, 25)</a> Crystals were obtained using 15.6 mg/mL enzyme preincubated with a 2-fold molar excess of compound <b>16</b> and mixed at a 1:1 ratio with the reservoir solution (150 mM malic acid, 20% PEG 3350, pH 7.0). Diffraction quality crystals were grown by microseeding at 20 °C in sitting drops and stabilized for data collection with reservoir solution plus 20% ethylene glycol. Data were collected at 100 K using a Rigaku FRE+ generator (Rigaku MSC) equipped with a Saturn 944 CCD detector using an X-ray wavelength of 1.54 Å. Oscillation frames of 0.5° were collected over a total rotation rotaion range of 240°. Data were integrated and reduced with HKL2000. Structures were determined by molecular replacement using the structure of the c-Met kinase domain in complex with K252a (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W">1R1W</a>) as a starting model for rigid body refinement with REFMAC as implemented in CCP4. The model was rebuilt manually with Coot and completed using iterative rounds of refinement and rebuilding. Structure alignments were performed with SSM and DALI. Figures were prepared with PyMOL.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53"><a href="/doi/suppl/10.1021/jm301619u">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55817" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55817" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Kinase selectivity profiles of compounds <b>5g</b>, <b>11a</b>, <b>11r</b>, <b>11u</b>, <b>11w</b>, <b>12</b>–<b>16</b>, X-ray statistics for <b>16</b>, time course of exposure in the GTL-16 xenograft efficacy and PK/PD experiments, and characterization data for <b>5b</b>–<b>d</b>, <b>11a</b>–<b>f</b>, <b>11i</b>–<b>m</b>, <b>11p</b>–<b>q</b>, <b>11s</b>, <b>11u</b>–<b>w</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301619u/suppl_file/jm301619u_si_001.pdf">jm301619u_si_001.pdf (600.77 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IWD">4IWD</a>.</p><div class="testing" data-doi="10.1021/jm301619u" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan B. Northrup</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#52333e333c0d3c3d20263a202722123f372031397c313d3f"><span class="__cf_email__" data-cfemail="08696469665766677a7c607a7d7848656d7a6b63266b6765">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew H. Katcher</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Altman</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa Chenard</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew H. Daniels</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sujal V. Deshmukh</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danielle Falcone</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David J. Guerin</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harold Hatch</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chaomin Li</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Lu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bart Lutterbach</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy J. Allison</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sangita B. Patel</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John F. Reilly</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Reutershan</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith W. Rickert</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Craig Rosenstein</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen M. Soisson</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander A. Szewczak</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deborah Walker</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Wilson</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan R. Young</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo-Sheng Pan</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Dinsmore</span> - <span class="hlFld-Affiliation affiliation">†Department
of Chemistry, ‡Department of Chemistry Modeling and Informatics, §Department of in Vivo Pharmacology, ∥Department of Pharmacokinetics,
Pharmacodynamics & Drug Metabolism, ⊥Department of Oncology, #Department of
Structural Chemistry, ¶Department of in Vitro Pharmacology, ×Department of Basic Pharmaceutical
Sciences, Merck & Co., Inc., 33 Avenue Louis Pasteur, BMB-3, Boston, Massachusetts 02115, United
States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i55" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i55"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i56" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i56"> Abbreviations Used</h2><tr><td class="NLM_term">APCI</td><td class="NLM_def"><p class="first last">atmospheric-pressure chemical ionization</p></td></tr><tr><td class="NLM_term">Cl<sub>p</sub></td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">MCPBA</td><td class="NLM_def"><p class="first last"><i>meta</i>-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">MS/MS</td><td class="NLM_def"><p class="first last">tandem mass spectrometry</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">RuPhos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time-dependent inhibition of CYP3A4</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>d</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">X-Phos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="note"><p class="first last">For example, see:</p></div><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mansi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiery-Vuillemin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calcagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocquain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demarchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurina, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivot, X.</span><span> </span><span class="NLM_article-title">Safety profile of new Anticancer Drugs</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1517%2F14740330903530663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=20175699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVCgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=301-317&author=L.+Mansiauthor=A.+Thiery-Vuilleminauthor=T.+Nguyenauthor=F.+Bazanauthor=F.+Calcagnoauthor=J.+Rocquainauthor=M.+Demarchiauthor=C.+Villanuevaauthor=T.+Maurinaauthor=X.+Pivot&title=Safety+profile+of+new+Anticancer+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of new anticancer drugs</span></div><div class="casAuthors">Mansi, Laura; Thiery-Vuillemin, Antoine; Nguyen, Thierry; Bazan, Fernando; Calcagno, Fabien; Rocquain, Julien; Demarchi, Martin; Villanueva, Cristian; Maurina, Tristan; Pivot, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-317</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The development of targeted anticancer therapies stems from advances in mol. biol.  New agents range from antibodies that form complexes with antigens on the surface of the cancer cell to small mols. that have been engineered to block key enzymic reactions.  The interaction of the antibody or drug with its target inhibits key pathways involved in cell proliferation or metastasis, or activates pathways leading to cell death.  Such pathways constitute ideal pharmacol. targets.  Clin. benefits from these novel therapeutic strategies are striking for patients with metastatic diseases.  Areas covered: This review analyses the main toxicities among most common targeted therapies that have been approved by the FDA or European Medicines Agency for their clin. utilization in solid tumors treatment.  What the reader will gain: Here, the main toxicity and safety data among new anticancer targeted therapies are described.  Data are organized through the pathways targeted by the drugs.  Take home message: The emergence of new targeted anticancer therapies promises more efficient and less toxic therapies.  Generally, they are well tolerated, toxicities are commonly mild to moderate and can be handled rapidly.  However, if most of these adverse events are manageable, life threatening and fatal complications can still occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiiiFyqEsHs7Vg90H21EOLACvtfcHk0lgOOP_pM6Fasw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVCgtr8%253D&md5=dc68a83909ddc594ec9359fc15123e68</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1517%2F14740330903530663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740330903530663%26sid%3Dliteratum%253Aachs%26aulast%3DMansi%26aufirst%3DL.%26aulast%3DThiery-Vuillemin%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DBazan%26aufirst%3DF.%26aulast%3DCalcagno%26aufirst%3DF.%26aulast%3DRocquain%26aufirst%3DJ.%26aulast%3DDemarchi%26aufirst%3DM.%26aulast%3DVillanueva%26aufirst%3DC.%26aulast%3DMaurina%26aufirst%3DT.%26aulast%3DPivot%26aufirst%3DX.%26atitle%3DSafety%2520profile%2520of%2520new%2520Anticancer%2520Drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2010%26volume%3D9%26spage%3D301%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mellor, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentin, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R.R A.</span><span> </span><span class="NLM_article-title">Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1093%2Ftoxsci%2Fkfq378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=21177772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1eksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2011&pages=14-32&author=H.+R.+Mellorauthor=A.+R.+Bellauthor=J.-P.+Valentinauthor=R.R+A.+Roberts&title=Cardiotoxicity+Associated+with+Targeting+Kinase+Pathways+in+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer</span></div><div class="casAuthors">Mellor, Howard R.; Bell, Alex R.; Valentin, Jean-Pierre; Roberts, Ruth R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-32</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Cardiotoxicity, also referred to as drug-induced cardiac injury, is an issue assocd. with the use of some small-mol. kinase inhibitors and antibody-based therapies targeting signaling pathways in cancer.  Although these drugs have had a major impact on cancer patient survival, data have implicated kinase-targeting agents such as sunitinib, imatinib, trastuzumab, and sorafenib in adversely affecting cardiac function in a subset of treated individuals.  In many cases, adverse cardiac events in the clinic were not anticipated based on preclin. safety evaluation of the mol.  To support the development of efficacious and safe kinase inhibitors for the treatment of cancer and other indications, new preclin. approaches and screens are required to predict clin. cardiotoxicity.  Lab. investigations into the underlying mol. mechanisms of heart toxicity induced by these mols. have identified potentially common themes including mitochondrial perturbation and modulation of adenosine monophosphate-activated protein kinase activity.  Studies characterizing cardiac-specific kinase knockout mouse models have developed our understanding of the homeostatic role of some of these signaling mediators in the heart.  Therefore, when considering kinases as potential future targets or when examg. secondary pharmacol. interactions of novel kinase inhibitors, these models may help to inform us of the potential adverse cardiac effects in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQ3BHazaLTrVg90H21EOLACvtfcHk0lgOOP_pM6Fasw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1eksL8%253D&md5=eb48e8a0b89ef96d7e48255c51ff8728</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfq378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfq378%26sid%3Dliteratum%253Aachs%26aulast%3DMellor%26aufirst%3DH.%2BR.%26aulast%3DBell%26aufirst%3DA.%2BR.%26aulast%3DValentin%26aufirst%3DJ.-P.%26aulast%3DRoberts%26aufirst%3DR.R%2BA.%26atitle%3DCardiotoxicity%2520Associated%2520with%2520Targeting%2520Kinase%2520Pathways%2520in%2520Cancer%26jtitle%3DToxicol.%2520Sci.%26date%3D2011%26volume%3D120%26spage%3D14%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Force, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaja, K. L.</span><span> </span><span class="NLM_article-title">Cardiotoxicity of Kinase Inhibitors: The Prediction and Translation of Preclinical Models to Clinical Outcomes</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=111-126&author=T.+Forceauthor=K.+L.+Kolaja&title=Cardiotoxicity+of+Kinase+Inhibitors%3A+The+Prediction+and+Translation+of+Preclinical+Models+to+Clinical+Outcomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForce%26aufirst%3DT.%26aulast%3DKolaja%26aufirst%3DK.%2BL.%26atitle%3DCardiotoxicity%2520of%2520Kinase%2520Inhibitors%253A%2520The%2520Prediction%2520and%2520Translation%2520of%2520Preclinical%2520Models%2520to%2520Clinical%2520Outcomes%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D111%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2681</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+the+%E2%80%9CGatekeeper+Door%E2%80%9D%3A+Exploiting+the+Active+Kinase+Conformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520the%2520%25E2%2580%259CGatekeeper%2520Door%25E2%2580%259D%253A%2520Exploiting%2520the%2520Active%2520Kinase%2520Conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2681%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-1509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wisserauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0lhQLZsqS_MxoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWisser%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D1509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="note"><p class="first last">For the discovery and characterization of Nilotinib, see:</p></div><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">AMN107: Tightening the Grip of Imatinib</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=117-119&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=M.+W.+N.+Deiningerauthor=B.+J.+Druker&title=AMN107%3A+Tightening+the+Grip+of+Imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAMN107%253A%2520Tightening%2520the%2520Grip%2520of%2520Imatinib%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D117%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a Selective Inhibitor of Native and Mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Brueggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+Selective+Inhibitor+of+Native+and+Mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lhQLZsqS_MxoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Native%2520and%2520Mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="note"><p class="first last">For general references on c-Met and Ron, see</p></div><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Birchmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Met, Metastasis, Motility and More</span> <span class="citation_source-journal">Nature Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1038%2Fnrm1261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=14685170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFeju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=915-925&author=C.+Birchmeierauthor=W.+Birchmeierauthor=E.+Gherardiauthor=G.+F.+Vande+Woude&title=Met%2C+Metastasis%2C+Motility+and+More"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Met, metastasis, motility and more</span></div><div class="casAuthors">Birchmeier, Carmen; Birhcmeier, Walter; Gherardi, Ermanno; Vande Woude, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-925</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatocyte growth factor. scatter factor and its receptor, the tyrosine kinase Met, arose late in evolution and are unique to vertebrates.  In spite of this, Met uses mols. such as Gab1 - homologues of which are present in Caenorhabditis elegans and Drosophila melanogaster - for downstream signalling. Pivotal roles for Met in development and cancer have been established: Met controls cell migration and growth in embryogenesis; it also controls growth, invasion and metastasis in cancer cells; and activating Met mutations predispose to human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_-6XRpZ-sLVg90H21EOLACvtfcHk0lhQLZsqS_MxoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFeju7s%253D&md5=ff5a02c73415784480c628fe65299a81</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1038%2Fnrm1261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1261%26sid%3Dliteratum%253Aachs%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DMet%252C%2520Metastasis%252C%2520Motility%2520and%2520More%26jtitle%3DNature%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D915%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Benvenuti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">The MET Receptor Tyrosine Kinase in Invasion and Metastasis</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">213</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1002%2Fjcp.21183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=17607709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=316-325&author=S.+Benvenutiauthor=P.+M.+Comoglio&title=The+MET+Receptor+Tyrosine+Kinase+in+Invasion+and+Metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">The MET receptor tyrosine kinase in invasion and metastasis</span></div><div class="casAuthors">Benvenuti, Silvia; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-325</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Various cytokines and sol. growth factors upon interaction with their membrane receptors are responsible for inducing cellular proliferation, differentiation, movement, and protection from anoikis (a planned suicide activated by normal cells in absence of attachment to neighboring cells or extracellular matrix (EMC)).  Among those sol. factors a major position is exerted by hepatocyte growth factor (HGF) together with its receptor MET and macrophage-stimulating protein (MSP) in cooperation with its receptor RON.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1QrqNHPoSM7Vg90H21EOLACvtfcHk0lirKfJN1hahSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM&md5=8994572071201c78fd2df1b504ab1a4e</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21183%26sid%3Dliteratum%253Aachs%26aulast%3DBenvenuti%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DThe%2520MET%2520Receptor%2520Tyrosine%2520Kinase%2520in%2520Invasion%2520and%2520Metastasis%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D316%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ponzetto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maina, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dalla Zonca, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panayotou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">A Multifunctional Docking Site Mediates Signaling and Transformation by the Hepatocyte Growth Factor/Scatter Factor Receptor Family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1994&pages=261-271&author=C.+Ponzettoauthor=A.+Bardelliauthor=Z.+Zhenauthor=F.+Mainaauthor=P.+dalla+Zoncaauthor=S.+Giordanoauthor=A.+Grazianiauthor=G.+Panayotouauthor=P.+M.+Comoglio&title=A+Multifunctional+Docking+Site+Mediates+Signaling+and+Transformation+by+the+Hepatocyte+Growth+Factor%2FScatter+Factor+Receptor+Family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPonzetto%26aufirst%3DC.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DZ.%26aulast%3DMaina%26aufirst%3DF.%26aulast%3Ddalla%2BZonca%26aufirst%3DP.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DGraziani%26aufirst%3DA.%26aulast%3DPanayotou%26aufirst%3DG.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DA%2520Multifunctional%2520Docking%2520Site%2520Mediates%2520Signaling%2520and%2520Transformation%2520by%2520the%2520Hepatocyte%2520Growth%2520Factor%252FScatter%2520Factor%2520Receptor%2520Family%26jtitle%3DCell%26date%3D1994%26volume%3D77%26spage%3D261%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Accornero, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavone, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratta, M.</span><span> </span><span class="NLM_article-title">The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2699</span><span class="NLM_x">–</span> <span class="NLM_lpage">2712</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.2174%2F092986710791859261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=20586722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaju7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2699-2712&author=P.+Accorneroauthor=L.+M.+Pavoneauthor=M.+Baratta&title=The+Scatter+Factor+Signaling+Pathways+as+Therapeutic+Associated+Target+in+Cancer+Treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">The scatter factor signaling pathways as therapeutic associated target in cancer treatment</span></div><div class="casAuthors">Accornero, P.; Pavone, L. M.; Baratta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2699-2712</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTKs) are key regulators of crit. cellular processes such as proliferation, differentiation, neo-vascularization, and tissue repair.  In addn. to their importance in the regulation of normal physiol., aberrant expression of certain RTKs has also been assocd. to the development and progression of many types of cancer.  C-Met and RON are two RTKs with closely related sequences, structural homol., and similar functional properties.  Both these receptors, once activated by their resp. ligands, the Hepatocyte Growth Factor/Scatter Factor (HGF/SF1) and the Macrophage Stimulating Protein/Scatter Factor 2 (MSP/SF2), can induce cell migration, invasion and proliferation.  Soon after its discovery in the mid-1980s, c-Met attracted a great interest because of its role in modulating cell motility.  Moreover, the causal role for c-Met activating mutations in human cancer propelled an intensive drug discovery effort throughout academic institutions and pharmaceutical companies.  While c-Met is now a well-accepted target for anticancer drug design, less is known about the role of RON in cancer and less has been done to target this receptor.  In this review we will discuss the biol. relevance of c-Met and RON, their deregulation in human cancers and the progress, so far, in identifying c-Met and RON signaling inhibitors.  Finally, we will focus on the development of therapeutic strategies and drug efficacy studies based on interfering the scatter factor signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Hgvw__jLh7Vg90H21EOLACvtfcHk0lirKfJN1hahSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaju7bO&md5=fa07abb77ab1a86234c9ebee9d377cf3</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.2174%2F092986710791859261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791859261%26sid%3Dliteratum%253Aachs%26aulast%3DAccornero%26aufirst%3DP.%26aulast%3DPavone%26aufirst%3DL.%2BM.%26aulast%3DBaratta%26aufirst%3DM.%26atitle%3DThe%2520Scatter%2520Factor%2520Signaling%2520Pathways%2520as%2520Therapeutic%2520Associated%2520Target%2520in%2520Cancer%2520Treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D2699%26epage%3D2712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="note"><p class="first last">For examples of Met mutations or overexpression in human cancer, see</p></div><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gonzatti-Haces, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oroszlan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Characterization of the TPR-MET Oncogene p65 and the MET Protooncogene p140 Protein–Tyrosine Kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=21-25&author=M.+Gonzatti-Hacesauthor=A.+Sethauthor=M.+Parkauthor=T.+Copelandauthor=S.+Oroszlanauthor=G.+F.+Vande+Woude&title=Characterization+of+the+TPR-MET+Oncogene+p65+and+the+MET+Protooncogene+p140+Protein%E2%80%93Tyrosine+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGonzatti-Haces%26aufirst%3DM.%26aulast%3DSeth%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DCopeland%26aufirst%3DT.%26aulast%3DOroszlan%26aufirst%3DS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DCharacterization%2520of%2520the%2520TPR-MET%2520Oncogene%2520p65%2520and%2520the%2520MET%2520Protooncogene%2520p140%2520Protein%25E2%2580%2593Tyrosine%2520Kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1988%26volume%3D85%26spage%3D21%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schmidt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duh, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choyke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubensky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allikmets, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chidambaram, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergerheim, U. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltis, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamarron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernues, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lips, C. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, L.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geil, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orcutt, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stackhouse, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slife, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brauch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niehans, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storkel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerman, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linehan, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zbar, B.</span><span> </span><span class="NLM_article-title">Germline and Somatic Mutations in the Tyrosine Kinase Domain of the MET Proto-oncogene in Papillary Renal Carcinomas</span> <span class="citation_source-journal">Nature Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1038%2Fng0597-68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=9140397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADyaK2sXivFKhsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=68-73&author=L.+Schmidtauthor=F.+M.+Duhauthor=F.+Chenauthor=T.+Kishidaauthor=G.+Glennauthor=P.+Choykeauthor=S.+W.+Schererauthor=Z.+Zhuangauthor=I.+Lubenskyauthor=M.+Deanauthor=R.+Allikmetsauthor=A.+Chidambaramauthor=U.+R.+Bergerheimauthor=J.+T.+Feltisauthor=C.+Casadevallauthor=A.+Zamarronauthor=M.+Bernuesauthor=S.+Richardauthor=C.+J.+M.+Lipsauthor=M.+M.+Waltherauthor=L.-C.+Tsuiauthor=L.+Geilauthor=M.+L.+Orcuttauthor=T.+Stackhouseauthor=J.+Lipanauthor=L.+Slifeauthor=H.+Brauchauthor=J.+Deckerauthor=G.+Niehansauthor=M.+D.+Hughsonauthor=H.+Mochauthor=S.+Storkelauthor=M.+I.+Lermanauthor=W.+M.+Linehanauthor=B.+Zbar&title=Germline+and+Somatic+Mutations+in+the+Tyrosine+Kinase+Domain+of+the+MET+Proto-oncogene+in+Papillary+Renal+Carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas</span></div><div class="casAuthors">Schmidt, Laura; Duh, Fuh-Mei; Chen, Fan; Kishida, Takeshi; Glenn, Gladys; Choyke, Peter; Scherer, Stephen W.; Zhuang, Zhenping; Lubensky, Irina; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumors.  The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance.  HPRC is histol. and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8).  Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome.  Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of both copies of the VHL gene by mutation, and/or by hypermethylation.  We found that the HPRC gene was located at chromosome 7q31.1-34 in a 27-centimorgan (cM) interval between D7S496 and D7S1837.  We identified missense mutations located in the tyrosine kinase domain of the MET gene in the germline of affected members of HPRC families and in a subset of sporadic papillary renal carcinomas.  Three mutations in the MET gene are located in codons that are homologous to those in c-kit and RET, proto-oncogenes that are targets of naturally-occurring mutations.  The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm-x_dqJPR-7Vg90H21EOLACvtfcHk0lhbdlz9Jre9eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFKhsbw%253D&md5=7209dbbaa538b418defad117830df3c9</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1038%2Fng0597-68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0597-68%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DL.%26aulast%3DDuh%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DKishida%26aufirst%3DT.%26aulast%3DGlenn%26aufirst%3DG.%26aulast%3DChoyke%26aufirst%3DP.%26aulast%3DScherer%26aufirst%3DS.%2BW.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DLubensky%26aufirst%3DI.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DChidambaram%26aufirst%3DA.%26aulast%3DBergerheim%26aufirst%3DU.%2BR.%26aulast%3DFeltis%26aufirst%3DJ.%2BT.%26aulast%3DCasadevall%26aufirst%3DC.%26aulast%3DZamarron%26aufirst%3DA.%26aulast%3DBernues%26aufirst%3DM.%26aulast%3DRichard%26aufirst%3DS.%26aulast%3DLips%26aufirst%3DC.%2BJ.%2BM.%26aulast%3DWalther%26aufirst%3DM.%2BM.%26aulast%3DTsui%26aufirst%3DL.-C.%26aulast%3DGeil%26aufirst%3DL.%26aulast%3DOrcutt%26aufirst%3DM.%2BL.%26aulast%3DStackhouse%26aufirst%3DT.%26aulast%3DLipan%26aufirst%3DJ.%26aulast%3DSlife%26aufirst%3DL.%26aulast%3DBrauch%26aufirst%3DH.%26aulast%3DDecker%26aufirst%3DJ.%26aulast%3DNiehans%26aufirst%3DG.%26aulast%3DHughson%26aufirst%3DM.%2BD.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DStorkel%26aufirst%3DS.%26aulast%3DLerman%26aufirst%3DM.%2BI.%26aulast%3DLinehan%26aufirst%3DW.%2BM.%26aulast%3DZbar%26aufirst%3DB.%26atitle%3DGermline%2520and%2520Somatic%2520Mutations%2520in%2520the%2520Tyrosine%2520Kinase%2520Domain%2520of%2520the%2520MET%2520Proto-oncogene%2520in%2520Papillary%2520Renal%2520Carcinomas%26jtitle%3DNature%2520Genet.%26date%3D1997%26volume%3D16%26spage%3D68%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jeffers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiscella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anver, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koochekpour, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">The Mutationally Activated Met Receptor Mediates Motility and Metastasis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">14422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=1441-14422&author=M.+Jeffersauthor=M.+Fiscellaauthor=C.+P.+Webbauthor=M.+Anverauthor=S.+Koochekpourauthor=G.+F.+Vande+Woude&title=The+Mutationally+Activated+Met+Receptor+Mediates+Motility+and+Metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DFiscella%26aufirst%3DM.%26aulast%3DWebb%26aufirst%3DC.%2BP.%26aulast%3DAnver%26aufirst%3DM.%26aulast%3DKoochekpour%26aufirst%3DS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DThe%2520Mutationally%2520Activated%2520Met%2520Receptor%2520Mediates%2520Motility%2520and%2520Metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D1441%26epage%3D14422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Bean, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitale, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motoi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szoke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broderick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdarl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerald, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">MET Amplification Occurs With or Without T790M Mutations in EGFR Mutant Lung Tumors with Acquired Resistance to Gefitinib or Erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">20932</span><span class="NLM_x">–</span> <span class="NLM_lpage">20937</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=20932-20937&author=J.+Beanauthor=C.+Brennanauthor=J.-Y.+Shihauthor=G.+Rielyauthor=A.+Vialeauthor=L.+Wangauthor=D.+Chitaleauthor=N.+Motoiauthor=J.+Szokeauthor=S.+Broderickauthor=M.+Balakauthor=W.-C.+Changauthor=C.-J.+Yuauthor=A.+Gazdarlauthor=H.+Passauthor=V.+Ruschauthor=W.+Geraldauthor=S.-F.+Huangauthor=P.-C.+Yangauthor=V.+Millerauthor=M.+Ladanyiauthor=C.-H.+Yangauthor=W.+Pao&title=MET+Amplification+Occurs+With+or+Without+T790M+Mutations+in+EGFR+Mutant+Lung+Tumors+with+Acquired+Resistance+to+Gefitinib+or+Erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBean%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DShih%26aufirst%3DJ.-Y.%26aulast%3DRiely%26aufirst%3DG.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChitale%26aufirst%3DD.%26aulast%3DMotoi%26aufirst%3DN.%26aulast%3DSzoke%26aufirst%3DJ.%26aulast%3DBroderick%26aufirst%3DS.%26aulast%3DBalak%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DW.-C.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DGazdarl%26aufirst%3DA.%26aulast%3DPass%26aufirst%3DH.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DGerald%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DS.-F.%26aulast%3DYang%26aufirst%3DP.-C.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DMET%2520Amplification%2520Occurs%2520With%2520or%2520Without%2520T790M%2520Mutations%2520in%2520EGFR%2520Mutant%2520Lung%2520Tumors%2520with%2520Acquired%2520Resistance%2520to%2520Gefitinib%2520or%2520Erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D20932%26epage%3D20937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For examples of Ron mutations or overexpression in human cancer, see</p></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtz, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiang, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. H.</span><span> </span><span class="NLM_article-title">Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">261</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1006%2Fexcr.2000.5012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=11082293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotVyntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=2000&pages=229-238&author=Y.+Q.+Chenauthor=Y.+Q.+Zhouauthor=D.+Angeloniauthor=A.+L.+Kurtzauthor=X.+Z.+Qiangauthor=M.+H.+Wang&title=Overexpression+and+Activation+of+the+RON+Receptor+Tyrosine+Kinase+in+a+Panel+of+Human+Colorectal+Carcinoma+Cell+Lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines</span></div><div class="casAuthors">Chen, Yi-Qing; Zhou, Yong-Qing; Angeloni, Debora; Kurtz, Avrom L.; Qiang, Xiao-Zhi; Wang, Ming-Hai</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">RON is a receptor tyrosine kinase belonging to the MET proto-oncogene family.  The purposes of this study are to det. the expression and activation of RON in a panel of human colon carcinoma cell lines.  Western blotting showed that RON is barely detectable in normal and SV-40-transformed colon epithelial cells, but highly expressed and constitutively activated in several colon carcinoma cell lines including Colo201, HT-29, HCT116, and SW837.  Moreover, a novel RON variant with a mol. mass of 160 kDa (RONΔ160) was identified from HT-29 cells.  The cDNA encoding RONΔ160 has an in-frame deletion of 109 amino acids in the extracellular domain of the RON β chain, which is caused by splicing out of two exons in the RON mRNA.  No mutations were found in the kinase domain of the RON gene in five carcinoma cell lines screened.  By expressing RON in colon epithelial cells, the authors found that RON activation increases cell motile-invasive activities and protects cells against apoptotic death.  These data suggest that RON expression and activation are deregulated in colon carcinoma cell lines.  By abnormal activation of RON, this receptor and its variant may regulate motile-invasive phenotypes of certain colon carcinoma cells in vivo.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR0_6X3BvVi7Vg90H21EOLACvtfcHk0li9k6fn0f5wkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotVyntrg%253D&md5=7d0ad2a749fb3cc647452dfafce89a03</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1006%2Fexcr.2000.5012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexcr.2000.5012%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DZhou%26aufirst%3DY.%2BQ.%26aulast%3DAngeloni%26aufirst%3DD.%26aulast%3DKurtz%26aufirst%3DA.%2BL.%26aulast%3DQiang%26aufirst%3DX.%2BZ.%26aulast%3DWang%26aufirst%3DM.%2BH.%26atitle%3DOverexpression%2520and%2520Activation%2520of%2520the%2520RON%2520Receptor%2520Tyrosine%2520Kinase%2520in%2520a%2520Panel%2520of%2520Human%2520Colorectal%2520Carcinoma%2520Cell%2520Lines%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2000%26volume%3D261%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zhou, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. H.</span><span> </span><span class="NLM_article-title">Altered Expression of the RON Receptor Tyrosine Kinase in Primary Human Colorectal Adenocarcinomas: Generation of Different Splicing RON Variants and their Oncogenic Potential</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=186-197&author=Y.+Q.+Zhouauthor=C.+Heauthor=Y.+Q.+Chenauthor=D.+Wangauthor=M.+H.+Wang&title=Altered+Expression+of+the+RON+Receptor+Tyrosine+Kinase+in+Primary+Human+Colorectal+Adenocarcinomas%3A+Generation+of+Different+Splicing+RON+Variants+and+their+Oncogenic+Potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%2BQ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DM.%2BH.%26atitle%3DAltered%2520Expression%2520of%2520the%2520RON%2520Receptor%2520Tyrosine%2520Kinase%2520in%2520Primary%2520Human%2520Colorectal%2520Adenocarcinomas%253A%2520Generation%2520of%2520Different%2520Splicing%2520RON%2520Variants%2520and%2520their%2520Oncogenic%2520Potential%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D186%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Bardella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggiora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patane, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranzani, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span> </span><span class="NLM_article-title">Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell–Cell Adhesion through E-Cadherin Transcriptional Repression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">5154</span><span class="NLM_x">–</span> <span class="NLM_lpage">5161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=5154-5161&author=C.+Bardellaauthor=B.+Costaauthor=P.+Maggioraauthor=S.+Pataneauthor=M.+Oliveroauthor=G.+N.+Ranzaniauthor=B.+M.+Deauthor=P.+M.+Comoglioauthor=M.+F.+Di+Renzo&title=Truncated+RON+Tyrosine+Kinase+Drives+Tumor+Cell+Progression+and+Abrogates+Cell%E2%80%93Cell+Adhesion+through+E-Cadherin+Transcriptional+Repression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBardella%26aufirst%3DC.%26aulast%3DCosta%26aufirst%3DB.%26aulast%3DMaggiora%26aufirst%3DP.%26aulast%3DPatane%26aufirst%3DS.%26aulast%3DOlivero%26aufirst%3DM.%26aulast%3DRanzani%26aufirst%3DG.%2BN.%26aulast%3DDe%26aufirst%3DB.%2BM.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26atitle%3DTruncated%2520RON%2520Tyrosine%2520Kinase%2520Drives%2520Tumor%2520Cell%2520Progression%2520and%2520Abrogates%2520Cell%25E2%2580%2593Cell%2520Adhesion%2520through%2520E-Cadherin%2520Transcriptional%2520Repression%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D5154%26epage%3D5161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Zinser, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toney, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathrose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kader, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peace, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, S. E.</span><span> </span><span class="NLM_article-title">Mammary-Specific Ron Receptor Overexpression Induces Highly Metastatic Mammary Tumors Associated with Beta-Catenin Activation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11967</span><span class="NLM_x">–</span> <span class="NLM_lpage">11974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11967-11974&author=G.+M.+Zinserauthor=M.+A.+Leonisauthor=K.+Toneyauthor=P.+Pathroseauthor=M.+Thobeauthor=S.+A.+Kaderauthor=B.+E.+Peaceauthor=S.+R.+Beaumanauthor=M.+H.+Collinsauthor=S.+E.+Waltz&title=Mammary-Specific+Ron+Receptor+Overexpression+Induces+Highly+Metastatic+Mammary+Tumors+Associated+with+Beta-Catenin+Activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZinser%26aufirst%3DG.%2BM.%26aulast%3DLeonis%26aufirst%3DM.%2BA.%26aulast%3DToney%26aufirst%3DK.%26aulast%3DPathrose%26aufirst%3DP.%26aulast%3DThobe%26aufirst%3DM.%26aulast%3DKader%26aufirst%3DS.%2BA.%26aulast%3DPeace%26aufirst%3DB.%2BE.%26aulast%3DBeauman%26aufirst%3DS.%2BR.%26aulast%3DCollins%26aufirst%3DM.%2BH.%26aulast%3DWaltz%26aufirst%3DS.%2BE.%26atitle%3DMammary-Specific%2520Ron%2520Receptor%2520Overexpression%2520Induces%2520Highly%2520Metastatic%2520Mammary%2520Tumors%2520Associated%2520with%2520Beta-Catenin%2520Activation%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11967%26epage%3D11974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Follenzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gual, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Cross-Talk Between the Proto-Oncogenes Met and Ron</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3049</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3041-3049&author=A.+Follenziauthor=S.+Bakovicauthor=P.+Gualauthor=M.+C.+Stellaauthor=P.+Longatiauthor=P.+M.+Comoglio&title=Cross-Talk+Between+the+Proto-Oncogenes+Met+and+Ron"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFollenzi%26aufirst%3DA.%26aulast%3DBakovic%26aufirst%3DS.%26aulast%3DGual%26aufirst%3DP.%26aulast%3DStella%26aufirst%3DM.%2BC.%26aulast%3DLongati%26aufirst%3DP.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DCross-Talk%2520Between%2520the%2520Proto-Oncogenes%2520Met%2520and%2520Ron%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D3041%26epage%3D3049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lee, W.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.-R.</span><span> </span><span class="NLM_article-title">Prognostic Significance of Co-Expression of RON and MET Receptors in Node-Negative Breast Cancer Patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2222</span><span class="NLM_x">–</span> <span class="NLM_lpage">2228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1158%2F1078-0432.CCR-04-1761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=15788670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFajurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=2222-2228&author=W.-Y.+Leeauthor=H.+H.+W.+Chenauthor=N.-H.+Chowauthor=W.-C.+Suauthor=P.-W.+Linauthor=H.-R.+Guo&title=Prognostic+Significance+of+Co-Expression+of+RON+and+MET+Receptors+in+Node-Negative+Breast+Cancer+Patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients</span></div><div class="casAuthors">Lee, Wen-Ying; Chen, Helen H. W.; Chow, Nan-Haw; Su, Wu-Chou; Lin, Pin-Wen; Guo, How-Ran</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2222-2228</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">RON and MET belong to a subfamily of tyrosine kinase receptors.  They both can induce invasive growth, including migration, cell dissocn., and matrix invasion.  Crosslinking expts. show that RON and MET form a noncovalent complex on the cell surface and cooperate in intracellular signaling.  We wanted to examine the clin. significance of RON and MET expression patterns in node-neg. breast cancer.  We studied the protein expressions of RON and MET in five breast cancer cell lines and a homogeneous cohort of 103 T1-2N0M0 breast carcinoma patients, including 52 patients with distant metastases and 51 patients with no evidence of disease after at least a 10-yr follow-up.  Both HCC1937 and MDA-MB-231 cancer cell lines co-overexpressed RON and MET.  The MCF-7 cell line did not express RON or MET.  In multiple logistic regression anal., RON expression (odds ratio, 2.6; P = 0.05) and MET expression (odds ratio, 4.7; P = 0.009) were independent predictors of distant relapse.  RON+/MET+ and RON-/MET+ tumors resulted in a large risk increase for 10-yr disease-free survival after adjusting for tumor size, histol. grade, estrogen receptor, bcl-2, HER-2/neu, and p53 status by multivariate Cox anal. (risk ratio, 5.3; P = 0.001 and risk ratio, 3.76; P = 0.005).  The 10-yr disease-free survival was 79.3% in patients with RON-/MET- tumors, was only 11.8% in patients with RON+/MET+ tumors, and was 43.9% and 55.6% in patients with RON-/MET+ and RON+/MET- tumors.  Co-expression of RON and MET seems to signify an aggressive phenotype in node-neg. breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZp05sUF36GLVg90H21EOLACvtfcHk0li9k6fn0f5wkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFajurk%253D&md5=214da143124696d658d77bcdb2a6c0af</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1761%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.-Y.%26aulast%3DChen%26aufirst%3DH.%2BH.%2BW.%26aulast%3DChow%26aufirst%3DN.-H.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DLin%26aufirst%3DP.-W.%26aulast%3DGuo%26aufirst%3DH.-R.%26atitle%3DPrognostic%2520Significance%2520of%2520Co-Expression%2520of%2520RON%2520and%2520MET%2520Receptors%2520in%2520Node-Negative%2520Breast%2520Cancer%2520Patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D2222%26epage%3D2228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cheng, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. H-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzai, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N.-H.</span><span> </span><span class="NLM_article-title">Co-Expression of RON and MET is a Prognostic Indicator for Patients with Transitional-Cell Carcinoma of the Bladder</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">1906</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1038%2Fsj.bjc.6602593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=15870710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkt1Sgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=1906-1914&author=H.-L.+Chengauthor=H.-S.+Liuauthor=Y.-J.+Linauthor=H.+H-W.+Chenauthor=P.-Y.+Hsuauthor=T.-Y.+Changauthor=C.-L.+Hoauthor=T.-S.+Tzaiauthor=N.-H.+Chow&title=Co-Expression+of+RON+and+MET+is+a+Prognostic+Indicator+for+Patients+with+Transitional-Cell+Carcinoma+of+the+Bladder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder</span></div><div class="casAuthors">Cheng, H-L.; Liu, H-S.; Lin, Y-J.; Chen, H. H-W.; Hsu, P-Y.; Chang, T-Y.; Ho, C-L.; Tzai, T-S.; Chow, N-H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1906-1914</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Recepteur d'Origine Nantais (RON) is a distinct receptor tyrosine kinase in the c-met proto-oncogene family.  We examd. the mutational and expression patterns of RON in eight human uroepithelial cell lines.  Biol. effects of RON overexpression on cancer cells were investigated in vitro, and the prognostic significance of RON and/or c-met protein (MET) expression was analyzed in a bladder cancer cohort (n=183).  There was no evidence of mutation in the kinase domain of RON.  Overexpression of RON using an inducible Tet-off system induced increased cell proliferation, motility, and antiapoptosis.  Immunohistochem. anal. showed that RON was overexpressed in 60 cases (32.8%) of primary tumors, with 14 (23.3%) showing a high level of expression.  Recepteur d'Origine Nantais expression was pos. assocd. with histol. grading, larger size, nonpapillary contour, and tumor stage (all P<0.01).  In addn., MET was overexpressed in 82 cases (44.8%).  Co-expressed RON and MET was significantly assocd. with decreased overall survival (P=0.005) or metastasis-free survival (P=0.01) in 35 cases (19.1%).  Recepteur d'Origine Nantais-assocd. signalling may play an important role in the progression of human bladder cancer.  Evaluation of RON and MET expression status may identify a subset of bladder-cancer patients who require more intensive treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy3Jc9r7lea7Vg90H21EOLACvtfcHk0lgGavaU1RCzdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkt1Sgsrs%253D&md5=2da682ab6fe899da8b0b959e6c86d0e4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602593%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.-L.%26aulast%3DLiu%26aufirst%3DH.-S.%26aulast%3DLin%26aufirst%3DY.-J.%26aulast%3DChen%26aufirst%3DH.%2BH-W.%26aulast%3DHsu%26aufirst%3DP.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DHo%26aufirst%3DC.-L.%26aulast%3DTzai%26aufirst%3DT.-S.%26aulast%3DChow%26aufirst%3DN.-H.%26atitle%3DCo-Expression%2520of%2520RON%2520and%2520MET%2520is%2520a%2520Prognostic%2520Indicator%2520for%2520Patients%2520with%2520Transitional-Cell%2520Carcinoma%2520of%2520the%2520Bladder%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D1906%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+Orally+Available+Small-Molecule+Inhibitor+of+c-Met%2C+PF-2341066%2C+Exhibits+Cytoreductive+Antitumor+Efficacy+through+Antiproliferative+and+Antiangiogenic+Mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lgGavaU1RCzdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520Orally%2520Available%2520Small-Molecule%2520Inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520Exhibits%2520Cytoreductive%2520Antitumor%2520Efficacy%2520through%2520Antiproliferative%2520and%2520Antiangiogenic%2520Mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.-A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+Tumor+Cell+Growth%2C+Invasion%2C+and+Metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+Novel+Inhibitor+of+HGF+and+VEGF+Receptor+Tyrosine+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.-A.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520Tumor%2520Cell%2520Growth%252C%2520Invasion%252C%2520and%2520Metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520Novel%2520Inhibitor%2520of%2520HGF%2520and%2520VEGF%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">See also a recent report of a more selective type II inhibitor:</p></div><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Angelo, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span> </span><span class="NLM_article-title">Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1858</span><span class="NLM_x">–</span> <span class="NLM_lpage">1867</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1858-1867&author=L.+Liuauthor=M.+H.+Normanauthor=M.+Leeauthor=N.+Xiauthor=A.+Siegmundauthor=A.+A.+Boezioauthor=S.+Bookerauthor=D.+Choquetteauthor=N.+D.+D%E2%80%99Angeloauthor=J.+Germainauthor=K.+Yangauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+F.+Bellonauthor=D.+A.+Whittingtonauthor=J.-C.+Harmangeauthor=C.+Dominguezauthor=T.-S.+Kimauthor=I.+Dussault&title=Structure-Based+Design+of+Novel+Class+II+c-Met+Inhibitors%3A+1.+Identification+of+Pyrazolone-Based+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBooker%26aufirst%3DS.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DT.-S.%26aulast%3DDussault%26aufirst%3DI.%26atitle%3DStructure-Based%2520Design%2520of%2520Novel%2520Class%2520II%2520c-Met%2520Inhibitors%253A%25201.%2520Identification%2520of%2520Pyrazolone-Based%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1858%26epage%3D1867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Lu, T.; Alexander, R.; Connors, R. W.; Cummings, M. D.; Galemmo, R. A.; Hufnagel, H. R.; Johnson, D. L.; Khalil, E.; Leonard, K. A.; Markotan, T. P.; Maroney, A. C.; Sechler, J. L.; Travins, J. M.; Tuman, R. W.</span>PCT Int. Appl. WO 2007075567,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lu%2C+T.%3B+Alexander%2C+R.%3B+Connors%2C+R.+W.%3B+Cummings%2C+M.+D.%3B+Galemmo%2C+R.+A.%3B+Hufnagel%2C+H.+R.%3B+Johnson%2C+D.+L.%3B+Khalil%2C+E.%3B+Leonard%2C+K.+A.%3B+Markotan%2C+T.+P.%3B+Maroney%2C+A.+C.%3B+Sechler%2C+J.+L.%3B+Travins%2C+J.+M.%3B+Tuman%2C+R.+W.PCT+Int.+Appl.+WO+2007075567%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DT.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Schadt, O.; Bladt, F.; Blaukat, A.; Dorsch, D.; Friese-Hamim, M.; Fittschen, C.; Graedler, U.; Meyring, M.; Rautenberg, W.; Stieber, F.; Wilm, C.</span><span> </span><span class="NLM_article-title">EMD 1214063, An Exquisitely Selective c-Met Kinase Inhibitor in Clinical Phase 1</span>.  <span class="NLM_conf-name">AACR 101st Annual Meeting</span>, <span class="NLM_conf-loc">Washington, DC</span>, <span class="NLM_conf-date">Apr 17–21, 2010</span>; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span> <span class="NLM_fpage">Poster 5777</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=Poster+5777&conference=AACR+101st+Annual+Meeting&author=O.+Schadt&author=F.+Bladt&author=A.+Blaukat&author=D.+Dorsch&author=M.+Friese-Hamim&author=C.+Fittschen&author=U.+Graedler&author=M.+Meyring&author=W.+Rautenberg&author=F.+Stieber&author=C.+Wilm&title=EMD+1214063%2C+An+Exquisitely+Selective+c-Met+Kinase+Inhibitor+in+Clinical+Phase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSchadt%26aufirst%3DO.%26atitle%3DEMD%25201214063%252C%2520An%2520Exquisitely%2520Selective%2520c-Met%2520Kinase%2520Inhibitor%2520in%2520Clinical%2520Phase%25201%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2010%26spage%3DPoster%25205777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Class of Exquisitely Selective Mesenchymal–Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8091</span><span class="NLM_x">–</span> <span class="NLM_lpage">8109</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300967g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8091-8109&author=J.+J.+Cuiauthor=M.+McTigueauthor=M.+Nambuauthor=M.+Tran-Dub%C3%A9author=M.+Pairishauthor=H.+Shenauthor=L.+Jiaauthor=H.+Chengauthor=J.+Hoffmanauthor=P.+Leauthor=M.+Jalaieauthor=G.+H.+Goetzauthor=K.+Ryanauthor=N.+Grodskyauthor=Y.-L.+Dengauthor=M.+Parkerauthor=S.+Timofeevskiauthor=B.+W.+Murrayauthor=S.+Yamazakiauthor=S.+Aguirreauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Discovery+of+a+Novel+Class+of+Exquisitely+Selective+Mesenchymal%E2%80%93Epithelial+Transition+Factor+%28c-MET%29+Protein+Kinase+Inhibitors+and+Identification+of+the+Clinical+Candidate+2-%284-%281-%28Quinolin-6-ylmethyl%29-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-b%5Dpyrazin-6-yl%29-1H-pyrazol-1-yl%29ethanol+%28PF-04217903%29+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%2BH.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Class%2520of%2520Exquisitely%2520Selective%2520Mesenchymal%25E2%2580%2593Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Protein%2520Kinase%2520Inhibitors%2520and%2520Identification%2520of%2520the%2520Clinical%2520Candidate%25202-%25284-%25281-%2528Quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2520%2528PF-04217903%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8091%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Bode, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M-H.J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of a Potent and Selective Triazolopyridinone Series of c-Met Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4089</span><span class="NLM_x">–</span> <span class="NLM_lpage">4093</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1016%2Fj.bmcl.2012.04.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=22595176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVyrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4089-4093&author=C.+M.+Bodeauthor=A.+A.+Boezioauthor=B.+K.+Albrechtauthor=S.+F.+Bellonauthor=L.+Berryauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=I.+Dussaultauthor=R.+T.+Lewisauthor=M-H.J.+Linauthor=K.+Rexauthor=D.+A.+Whittingtonauthor=Y.+Yangauthor=J.-C.+Harmange&title=Discovery+and+Optimization+of+a+Potent+and+Selective+Triazolopyridinone+Series+of+c-Met+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors</span></div><div class="casAuthors">Bode, Christiane M.; Boezio, Alessandro A.; Albrecht, Brian K.; Bellon, Steven F.; Berry, Loren; Broome, Martin A.; Choquette, Deborah; Dussault, Isabelle; Lewis, Richard T.; Lin, Min-Hwa Jasmine; Rex, Karen; Whittington, Douglas A.; Yang, Yajing; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4089-4093</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small mol. drug discovery.  The discovery of a structurally diverse series of quinolinylmethyltriazolopyridinones, which demonstrates nanomolar inhibition of c-Met kinase activity is reported.  This novel series of inhibitors exhibits favorable pharmacokinetics as well as potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver pharmacodynamic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2bZorS8wwhrVg90H21EOLACvtfcHk0lj7kuCZAg7S6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVyrtLo%253D&md5=0f80a577ebee0df3c3a219273c43b738</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.072%26sid%3Dliteratum%253Aachs%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DM-H.J.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Potent%2520and%2520Selective%2520Triazolopyridinone%2520Series%2520of%2520c-Met%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4089%26epage%3D4093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Cepero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sierra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casorzo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">7580</span><span class="NLM_x">–</span> <span class="NLM_lpage">7590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=7580-7590&author=V.+Ceperoauthor=J.+R.+Sierraauthor=S.+Corsoauthor=E.+Ghisoauthor=L.+Casorzoauthor=T.+Pereraauthor=P.+M.+Comoglioauthor=S.+Giordano&title=MET+and+KRAS+Gene+Amplification+Mediates+Acquired+Resistance+to+MET+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCepero%26aufirst%3DV.%26aulast%3DSierra%26aufirst%3DJ.%2BR.%26aulast%3DCorso%26aufirst%3DS.%26aulast%3DGhiso%26aufirst%3DE.%26aulast%3DCasorzo%26aufirst%3DL.%26aulast%3DPerera%26aufirst%3DT.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DMET%2520and%2520KRAS%2520Gene%2520Amplification%2520Mediates%2520Acquired%2520Resistance%2520to%2520MET%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D7580%26epage%3D7590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leggett, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. J.</span><span> </span><span class="NLM_article-title">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.-R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+Novel+and+Selective+Inhibitor+of+the+Human+c-Met+Receptor+Tyrosine+Kinase+with+Antitumor+Activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0lj7kuCZAg7S6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.-R.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520Novel%2520and%2520Selective%2520Inhibitor%2520of%2520the%2520Human%2520c-Met%2520Receptor%2520Tyrosine%2520Kinase%2520with%2520Antitumor%2520Activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabarda, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathvink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazef, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span> </span><span class="NLM_article-title">Discovery of a 5<i>H</i>-Benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4092</span><span class="NLM_x">–</span> <span class="NLM_lpage">4108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200112k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4092-4108&author=J.+D.+Katzauthor=J.+P.+Jewellauthor=D.+J.+Guerinauthor=J.+Limauthor=C.+J.+Dinsmoreauthor=S.+V.+Deshmukhauthor=B.-S.+Panauthor=C.+G.+Marshallauthor=W.+Luauthor=M.+D.+Altmanauthor=W.+K.+Dahlbergauthor=L.+Davisauthor=D.+Falconeauthor=A.+E.+Gabardaauthor=G.+Hangauthor=H.+Hatchauthor=R.+Holmesauthor=K.+Kuniiauthor=K.+J.+Lumbauthor=B.+Lutterbachauthor=R.+Mathvinkauthor=N.+Nazefauthor=S.+B.+Patelauthor=X.+Quauthor=J.+F.+Reillyauthor=K.+W.+Rickertauthor=C.+Rosensteinauthor=S.+M.+Soissonauthor=K.+B.+Spencerauthor=A.+A.+Szewczakauthor=D.+Walkerauthor=W.+Wangauthor=J.+Youngauthor=Q.+Zeng&title=Discovery+of+a+5H-Benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+Inhibitor+of+c-Met+Kinase+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm200112k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200112k%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DFalcone%26aufirst%3DD.%26aulast%3DGabarda%26aufirst%3DA.%2BE.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DR.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DLutterbach%26aufirst%3DB.%26aulast%3DMathvink%26aufirst%3DR.%26aulast%3DNazef%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DSpencer%26aufirst%3DK.%2BB.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520a%25205H-Benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-5-one%2520%2528MK-2461%2529%2520Inhibitor%2520of%2520c-Met%2520Kinase%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4092%26epage%3D4108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kawatsura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartwig, J. F.</span><span> </span><span class="NLM_article-title">Simple, Highly Active Palladium Catalysts for Ketone and Malonate Arylation: Dissecting the Importance of Chelation and Steric Hindrance</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">1473</span><span class="NLM_x">–</span> <span class="NLM_lpage">1478</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja983378u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADyaK1MXntlaisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1999&pages=1473-1478&author=M.+Kawatsuraauthor=J.+F.+Hartwig&title=Simple%2C+Highly+Active+Palladium+Catalysts+for+Ketone+and+Malonate+Arylation%3A+Dissecting+the+Importance+of+Chelation+and+Steric+Hindrance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Simple, Highly Active Palladium Catalysts for Ketone and Malonate Arylation: Dissecting the Importance of Chelation and Steric Hindrance</span></div><div class="casAuthors">Kawatsura, Motoi; Hartwig, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1473-1478</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A remarkably active catalyst system for α-arylation of ketones and malonates was developed by proposing that sterically hindered alkylphosphines would accelerate the catalytic reaction rates.  The authors initially tested the bisphosphine ligand DtBPF (1,1'-bis-(di-tert-butylphosphino)ferrocene) for this Pd-catalyzed chem.  This catalyst system led to fast reaction rates for reactions of aryl bromides with ketones, including room temp. chem. in many cases.  In some cases turnover nos. were 20,000.  The catalyst also gave mild reactions with aryl chlorides with yields that were similar to the chem. with aryl bromides.  Independent synthesis of the arylpalladium enolate complexes with isobutyrophenone enolate showed that only one P of the bisphosphine ligand DtBPF was coordinated in the enolate complex. Thus, the authors tested sterically hindered alkylphosphine ligands for the ketone and malonate arylation process and found that P(CMe3)3 gave exceptionally fast rates and high turnover nos. for these reactions.  These results demonstrate several principles for the catalytic chem. that the authors did not anticipate: Pd complexes of monophosphine ligands can activate aryl chlorides under mild conditions, and Pd enolates coordinated by certain monophosphines can undergo C-C bond-forming reductive elimination much faster than β-H elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfLvbhmM8JpbVg90H21EOLACvtfcHk0li6uyRsAd_zYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntlaisg%253D%253D&md5=d06792e673b3987a3c6143f50d883eff</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Fja983378u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja983378u%26sid%3Dliteratum%253Aachs%26aulast%3DKawatsura%26aufirst%3DM.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26atitle%3DSimple%252C%2520Highly%2520Active%2520Palladium%2520Catalysts%2520for%2520Ketone%2520and%2520Malonate%2520Arylation%253A%2520Dissecting%2520the%2520Importance%2520of%2520Chelation%2520and%2520Steric%2520Hindrance%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1999%26volume%3D121%26spage%3D1473%26epage%3D1478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fox, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chieffi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Highly Active and Selective Catalysts for the Formation of α-Aryl Ketones</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1360</span><span class="NLM_x">–</span> <span class="NLM_lpage">1370</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja993912d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotl2isg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=1360-1370&author=J.+M.+Foxauthor=X.+Huangauthor=A.+Chieffiauthor=S.+L.+Buchwald&title=Highly+Active+and+Selective+Catalysts+for+the+Formation+of+%CE%B1-Aryl+Ketones"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Highly active and selective catalysts for the formation of α-aryl ketones</span></div><div class="casAuthors">Fox, Joseph M.; Huang, Xiaohua; Chieffi, Andre; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1360-1370</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bulky, electron-rich phosphine ligands with a biphenyl backbone, when combined with Pd(OAc)2, give highly active catalysts for the α-arylation of ketones.  Thus, arylation of propiophenone with 4-chlorotoluene using 4-PhC6H4P(CMe3)2 as ligand gave 4-MeC6H4CHMeCOPh in 91% yield.  2-Methyl-2'-dicyclohexylphosphinobiphenyl I is particularly effective as a ligand in palladium-catalyzed arylations; with 0.1-1.0 mol% Pd, a large variety of aryl halides and ketones react efficiently and with high selectivity.  For two types of substrates, the ligands BINAP and Xantphos II are more effective than the biphenyl-based ligands.  K3PO4 can be used as the base in these reactions; base-sensitive functional groups are better tolerated if K3PO4 is used instead of NaO-tert-Bu or NaHMDS.  In some cases, α-aryl ketones can be produced without adding a ligand to the reaction.  Although the substrate scope of the ligand-less conditions is limited, some combinations react in high yield, and in one case, 100,000 turnovers were obtained.  The results of expts. on the Pd-catalyzed arylation of di-Et malonate, cyclic 1,3-diketones, and nitroalkanes are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY_KAycKtH27Vg90H21EOLACvtfcHk0li6uyRsAd_zYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotl2isg%253D%253D&md5=c8702155bcce7c25d03b22b5f8158191</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fja993912d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja993912d%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DJ.%2BM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DChieffi%26aufirst%3DA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DHighly%2520Active%2520and%2520Selective%2520Catalysts%2520for%2520the%2520Formation%2520of%2520%25CE%25B1-Aryl%2520Ketones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D1360%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Netherton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, G. C.</span><span> </span><span class="NLM_article-title">Air-Stable Trialkylphosphonium Salts: Simple, Practical, and Versatile Replacements for Air-Sensitive Trialkylphosphines. Applications in Stoichiometric and Catalytic Processes</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">4295</span><span class="NLM_x">–</span> <span class="NLM_lpage">4298</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol016971g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD3MXoslygur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=4295-4298&author=M.+R.+Nethertonauthor=G.+C.+Fu&title=Air-Stable+Trialkylphosphonium+Salts%3A+Simple%2C+Practical%2C+and+Versatile+Replacements+for+Air-Sensitive+Trialkylphosphines.+Applications+in+Stoichiometric+and+Catalytic+Processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Air-Stable Trialkylphosphonium Salts: Simple, Practical, and Versatile Replacements for Air-Sensitive Trialkylphosphines. Applications in Stoichiometric and Catalytic Processes</span></div><div class="casAuthors">Netherton, Matthew R.; Fu, Gregory C.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4295-4298</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trialkylphosphines furnish unusual, sometimes unique, reactivity in a range of transformations.  Unfortunately, their utility is compromised by their sensitivity to oxidn.  A simple but powerful strategy for addressing this problem is proposed: convert air-sensitive trialkylphosphines into air-stable phosphonium salts via protonation on phosphorus.  These robust salts serve as direct replacements for the corresponding phosphines (simple deprotonation under the reaction conditions by a Bronsted base liberates the trialkylphosphine) in a diverse set of applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-wMNyILHzR7Vg90H21EOLACvtfcHk0lj3HMqnqLgO7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXoslygur4%253D&md5=a875987aaccfb12fdb0de9cb5a835023</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1021%2Fol016971g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol016971g%26sid%3Dliteratum%253Aachs%26aulast%3DNetherton%26aufirst%3DM.%2BR.%26aulast%3DFu%26aufirst%3DG.%2BC.%26atitle%3DAir-Stable%2520Trialkylphosphonium%2520Salts%253A%2520Simple%252C%2520Practical%252C%2520and%2520Versatile%2520Replacements%2520for%2520Air-Sensitive%2520Trialkylphosphines.%2520Applications%2520in%2520Stoichiometric%2520and%2520Catalytic%2520Processes%26jtitle%3DOrg.%2520Lett.%26date%3D2001%26volume%3D3%26spage%3D4295%26epage%3D4298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Grimm, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katcher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northrup, A. B.</span><span> </span><span class="NLM_article-title">A New Strategy for the Synthesis of Benzylic Sulfonamides: Palladium-Catalyzed Arylation and Sulfonamide Metathesis</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">8135</span><span class="NLM_x">–</span> <span class="NLM_lpage">8138</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo701431j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=8135-8138&author=J.+B.+Grimmauthor=M.+H.+Katcherauthor=D.+J.+Witterauthor=A.+B.+Northrup&title=A+New+Strategy+for+the+Synthesis+of+Benzylic+Sulfonamides%3A+Palladium-Catalyzed+Arylation+and+Sulfonamide+Metathesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjo701431j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo701431j%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DJ.%2BB.%26aulast%3DKatcher%26aufirst%3DM.%2BH.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DNorthrup%26aufirst%3DA.%2BB.%26atitle%3DA%2520New%2520Strategy%2520for%2520the%2520Synthesis%2520of%2520Benzylic%2520Sulfonamides%253A%2520Palladium-Catalyzed%2520Arylation%2520and%2520Sulfonamide%2520Metathesis%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D8135%26epage%3D8138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goel, S.</span><span> </span><span class="NLM_article-title">Alterations of Chemotherapeutic Pharmacokinetic Profiles by Drug–Drug Interactions</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1517%2F17425250902753212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=19239394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1eksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=109-130&author=S.+Maniauthor=M.+Ghalibauthor=I.+Chaudharyauthor=S.+Goel&title=Alterations+of+Chemotherapeutic+Pharmacokinetic+Profiles+by+Drug%E2%80%93Drug+Interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions</span></div><div class="casAuthors">Mani, Sridhar; Ghalib, Mohammed; Chaudhary, Imran; Goel, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-130</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Drug interactions in oncol. are common place and largely ignored as we tolerate high thresholds of toxic' drug responses in these patients.  However, in the era of targeted' or seemingly less toxic' therapy, these interactions are more commonly flagged and contribute significantly towards poor quality of life' and medical fatalities.  Objective: This review and opinion article focuses on alteration of chemotherapeutic pharmacokinetic profiles by drug interactions in the setting of polypharmacy.  The assumption is that the drugs, with changes in their pharmacokinetics, will contribute towards changes in their pharmacodynamics.  Methods: The examples cited for such drug-drug interactions are culled from published literature with an emphasis on those interactions that have been well characterized at the mol. level.  Results: Although very few drug interaction studies have been performed on approved oncol. based drugs, it is clear that drugs whose pharmacokinetics profiles are closely related to their pharmacodynamics will indeed result in clin. important drug interactions.  Some newer mechanisms are described that involve interactions at the level of gene transcription, whereby, drug metab. is significantly altered.  However, for any given drug interaction, there does not seem to be a comprehensive model describing interactions.  Conclusions: Mechanisms based drug interactions are plentiful in oncol.; however, there is an abs. lack of a comprehensive model that would predict drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq_zoumy_GyLVg90H21EOLACvtfcHk0lj3HMqnqLgO7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1eksrc%253D&md5=3b120e4b308ef907e19b189dc9a64d56</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1517%2F17425250902753212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250902753212%26sid%3Dliteratum%253Aachs%26aulast%3DMani%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DM.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DGoel%26aufirst%3DS.%26atitle%3DAlterations%2520of%2520Chemotherapeutic%2520Pharmacokinetic%2520Profiles%2520by%2520Drug%25E2%2580%2593Drug%2520Interactions%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D109%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mcleod, H. L.</span><span> </span><span class="NLM_article-title">Clinically Relevant Drug–Drug Interactions in Oncology</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1046%2Fj.1365-2125.1998.00719.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=9663808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADyaK1cXktFaitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1998&pages=539-544&author=H.+L.+Mcleod&title=Clinically+Relevant+Drug%E2%80%93Drug+Interactions+in+Oncology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinically relevant drug-drug interactions in oncology</span></div><div class="casAuthors">Mcleod, Howard L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">539-544</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 33 refs.  Although anticancer agents are one of the most toxic classes of medication prescribed today, there is relatively little information available about clin. relevant drug-drug interactions.  Pharmacokinetic drug interactions have been described, including alterations in absorption, catabolism, and excretion.  For example, an increased bioavailability of 6-mercaptopurine has been obsd. when combined with either allopurinol or methotrexate, leading to increased toxicity in some patients.  Induction of etoposide or teniposide clearance by anticonvulsants has also been described, resulting in a lower systemic exposure and risk for lower anticancer activity.  Alterations in elimination of methotrexate has been obsd. with probenecid, presumably through competition for renal secretion.  There are also several examples of pharmacodynamic interactions.  The combination of 5-fluorouracil plus folinic acid results in more efficient inhibition of thymidylate synthase, a finding which is now utilized routinely in the treatment of colorectal cancer.  Improvements in the in vitro and early clin. testing now allow a relatively high degree of prediction of potential clin. drug interactions, prior to observations of untoward drug effects.  In conclusion, drug interactions among commonly used anticancer agents have been identified.  Their clin. significance can have more impact than many other classes of medications due to the narrow therapeutic index of antineoplastic agents and the potential for lethal side-effects.  It is only through prospective, preclin. and early clin. evaluation that the presence of clin. significant drug interactions can be identified and the information used to provide better therapy for this significant health problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0bt37gQxUMbVg90H21EOLACvtfcHk0lj3HMqnqLgO7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktFaitrs%253D&md5=d2dd35189d4b9b81b751cf9e038d020c</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.1998.00719.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.1998.00719.x%26sid%3Dliteratum%253Aachs%26aulast%3DMcleod%26aufirst%3DH.%2BL.%26atitle%3DClinically%2520Relevant%2520Drug%25E2%2580%2593Drug%2520Interactions%2520in%2520Oncology%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1998%26volume%3D45%26spage%3D539%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><div class="note"><p class="first last">and references therein</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+Comprehensive+Listing+of+Bioactivation+Pathways+of+Organic+Functional+Groups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lipOZLscTwonQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520Comprehensive%2520Listing%2520of%2520Bioactivation%2520Pathways%2520of%2520Organic%2520Functional%2520Groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">Signficantly, both <b>5a</b> and <b>5g</b> did not show significant inhibition of CYP3A4 (<10%) at the zero minute time point as potent reversible CYP3A4 inhibitors are not evaluable in this assay format.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G. K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariv, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span> </span><span class="NLM_article-title">MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1524</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1524-1533&author=B.-S.+Panauthor=G.+K.+Y.+Chanauthor=M.+Chenardauthor=A.+Chiauthor=L.+J.+Davisauthor=S.+V.+Deshmukhauthor=J.+B.+Gibbsauthor=S.+Gilauthor=G.+Hangauthor=H.+Hatchauthor=J.+P.+Jewellauthor=I.+Karivauthor=J.+D.+Katzauthor=K.+Kuniiauthor=W.+Luauthor=B.+A.+Lutterbachauthor=C.+P.+Paweletzauthor=X.+Quauthor=J.+F.+Reillyauthor=A.+A.+Szewczakauthor=Q.+Zengauthor=N.+E.+Kohlauthor=C.+J.+Dinsmore&title=MK-2461%2C+a+Novel+Multitargeted+Kinase+Inhibitor%2C+Preferentially+Inhibits+the+Activated+c-Met+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DChan%26aufirst%3DG.%2BK.%2BY.%26aulast%3DChenard%26aufirst%3DM.%26aulast%3DChi%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DL.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DGibbs%26aufirst%3DJ.%2BB.%26aulast%3DGil%26aufirst%3DS.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26atitle%3DMK-2461%252C%2520a%2520Novel%2520Multitargeted%2520Kinase%2520Inhibitor%252C%2520Preferentially%2520Inhibits%2520the%2520Activated%2520c-Met%2520Receptor%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1524%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darke, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornienko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span> </span><span class="NLM_article-title">Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">11218</span><span class="NLM_x">–</span> <span class="NLM_lpage">11225</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=11218-11225&author=K.+W.+Rickertauthor=S.+B.+Patelauthor=T.+J.+Allisonauthor=N.+J.+Byrneauthor=P.+L.+Darkeauthor=R.+E.+Fordauthor=D.+J.+Guerinauthor=D.+L.+Hallauthor=M.+Kornienkoauthor=J.+Luauthor=S.+K.+Munshiauthor=J.+C.+Reidauthor=J.+M.+Shipmanauthor=E.+F.+Stantonauthor=K.+J.+Wilsonauthor=J.+R.+Youngauthor=S.+M.+Soissonauthor=K.+J.+Lumb&title=Structural+Basis+for+Selective+Small+Molecule+Kinase+Inhibition+of+Activated+c-Met"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DAllison%26aufirst%3DT.%2BJ.%26aulast%3DByrne%26aufirst%3DN.%2BJ.%26aulast%3DDarke%26aufirst%3DP.%2BL.%26aulast%3DFord%26aufirst%3DR.%2BE.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DStanton%26aufirst%3DE.%2BF.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26atitle%3DStructural%2520Basis%2520for%2520Selective%2520Small%2520Molecule%2520Kinase%2520Inhibition%2520of%2520Activated%2520c-Met%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D11218%26epage%3D11225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Lutterbach, B.</span><div class="note"><p class="first last">manuscript in preparation</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lutterbach%2C+B.manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLutterbach%26aufirst%3DB." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="ref27_1"><span><span class="NLM_contrib-group">Szymonifka, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heck, J. V.</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2869</span><span class="NLM_x">–</span> <span class="NLM_lpage">2872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Szymonifka%2C+M.+J.%3B+Heck%2C+J.+V.Tetrahedron+Lett.+1989%2C+30%2C+2869%E2%80%932872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref27_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSzymonifka%26aufirst%3DM.%2BJ.%26aulast%3DHeck%26aufirst%3DJ.%2BV.%26jtitle%3DTetrahedron%2520Lett.%26date%3D1989%26volume%3D30%26spage%3D2869%26epage%3D2872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b','cit5c','cit5d'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g','cit6h'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':[],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['ref27_1']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 24 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Serge  Christmann-Franck</span>, <span class="hlFld-ContribAuthor ">Gerard J. P.  van Westen</span>, <span class="hlFld-ContribAuthor ">George  Papadatos</span>, <span class="hlFld-ContribAuthor ">Fanny  Beltran Escudie</span>, <span class="hlFld-ContribAuthor ">Alexander  Roberts</span>, <span class="hlFld-ContribAuthor ">John P.  Overington</span>, and <span class="hlFld-ContribAuthor ">Daniel  Domine</span>  . </span><span class="cited-content_cbyCitation_article-title">Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound–Kinase Activities: A Way toward Selective Promiscuity by Design?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (9)
                                     , 1654-1675. <a href="https://doi.org/10.1021/acs.jcim.6b00122" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00122%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DUnprecedently%252BLarge-Scale%252BKinase%252BInhibitor%252BSet%252BEnabling%252Bthe%252BAccurate%252BPrediction%252Bof%252BCompound%2525E2%252580%252593Kinase%252BActivities%25253A%252BA%252BWay%252Btoward%252BSelective%252BPromiscuity%252Bby%252BDesign%25253F%26aulast%3DChristmann-Franck%26aufirst%3DSerge%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03032016%26date%3D11082016%26date%3D26092016%26date%3D02082016%26volume%3D56%26issue%3D9%26spage%3D1654%26epage%3D1675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William  McCoull</span>, <span class="hlFld-ContribAuthor ">Peter  Barton</span>, <span class="hlFld-ContribAuthor ">Alastair J. H.  Brown</span>, <span class="hlFld-ContribAuthor ">Suzanne S.  Bowker</span>, <span class="hlFld-ContribAuthor ">Jennifer  Cameron</span>, <span class="hlFld-ContribAuthor ">David S.  Clarke</span>, <span class="hlFld-ContribAuthor ">Robert D. M.  Davies</span>, <span class="hlFld-ContribAuthor ">Alexander G.  Dossetter</span>, <span class="hlFld-ContribAuthor ">Anne  Ertan</span>, <span class="hlFld-ContribAuthor ">Mark  Fenwick</span>, <span class="hlFld-ContribAuthor ">Clive  Green</span>, <span class="hlFld-ContribAuthor ">Jane L.  Holmes</span>, <span class="hlFld-ContribAuthor ">Nathaniel  Martin</span>, <span class="hlFld-ContribAuthor ">David  Masters</span>, <span class="hlFld-ContribAuthor ">Jane E.  Moore</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Newcombe</span>, <span class="hlFld-ContribAuthor ">Claire  Newton</span>, <span class="hlFld-ContribAuthor ">Helen  Pointon</span>, <span class="hlFld-ContribAuthor ">Graeme R.  Robb</span>, <span class="hlFld-ContribAuthor ">Christopher  Sheldon</span>, <span class="hlFld-ContribAuthor ">Stephen  Stokes</span>, and <span class="hlFld-ContribAuthor ">David  Morgan</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification, Optimization, and Pharmacology of Acylurea GHS-R1a Inverse Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (14)
                                     , 6128-6140. <a href="https://doi.org/10.1021/jm500610n" title="DOI URL">https://doi.org/10.1021/jm500610n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500610n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500610n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%25252C%252BOptimization%25252C%252Band%252BPharmacology%252Bof%252BAcylurea%252BGHS-R1a%252BInverse%252BAgonists%26aulast%3DMcCoull%26aufirst%3DWilliam%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18042014%26date%3D08072014%26date%3D24072014%26date%3D26062014%26volume%3D57%26issue%3D14%26spage%3D6128%26epage%3D6140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shao-Long  Chen</span>, <span class="hlFld-ContribAuthor ">Guo-Ping  Wang</span>, <span class="hlFld-ContribAuthor ">Dan-Rong  Shi</span>, <span class="hlFld-ContribAuthor ">Shu-Hao  Yao</span>, <span class="hlFld-ContribAuthor ">Ke-Da  Chen</span>, <span class="hlFld-ContribAuthor ">Hang-Ping  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Gastroenterology</span><span> <strong>2021,</strong> <em>27 </em>
                                    (20)
                                     , 2507-2520. <a href="https://doi.org/10.3748/wjg.v27.i20.2507" title="DOI URL">https://doi.org/10.3748/wjg.v27.i20.2507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3748/wjg.v27.i20.2507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3748%2Fwjg.v27.i20.2507%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26atitle%3DRON%252Bin%252Bhepatobiliary%252Band%252Bpancreatic%252Bcancers%25253A%252BPathogenesis%252Band%252Bpotential%252Btherapeutic%252Btargets%26aulast%3DChen%26aufirst%3DShao-Long%26date%3D2021%26volume%3D27%26issue%3D20%26spage%3D2507%26epage%3D2520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guolin  Luo</span>, <span class="hlFld-ContribAuthor ">Yanxia  Ma</span>, <span class="hlFld-ContribAuthor ">Xintong  Liang</span>, <span class="hlFld-ContribAuthor ">Guoquan  Xie</span>, <span class="hlFld-ContribAuthor ">Yingqi  Luo</span>, <span class="hlFld-ContribAuthor ">Dailong  Zha</span>, <span class="hlFld-ContribAuthor ">Sheng  Wang</span>, <span class="hlFld-ContribAuthor ">Lihong  Yu</span>, <span class="hlFld-ContribAuthor ">Xuehua  Zheng</span>, <span class="hlFld-ContribAuthor ">Wenhao  Wu</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104356. <a href="https://doi.org/10.1016/j.bioorg.2020.104356" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104356</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104356%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bevaluation%252Bof%252Bnovel%252B5-methylpyrazolo%25255B1%25252C5-a%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotential%252Bc-Met%252Binhibitors%26aulast%3DLuo%26aufirst%3DGuolin%26date%3D2020%26volume%3D104%26spage%3D104356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shovan  Mondal</span>, <span class="hlFld-ContribAuthor ">Suniti  Malakar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of sulfonamide and their synthetic and therapeutic applications: Recent advances. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (48)
                                     , 131662. <a href="https://doi.org/10.1016/j.tet.2020.131662" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131662</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131662%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSynthesis%252Bof%252Bsulfonamide%252Band%252Btheir%252Bsynthetic%252Band%252Btherapeutic%252Bapplications%25253A%252BRecent%252Badvances%26aulast%3DMondal%26aufirst%3DShovan%26date%3D2020%26volume%3D76%26issue%3D48%26spage%3D131662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuting  Zhou</span>, <span class="hlFld-ContribAuthor ">Xingwei  Xu</span>, <span class="hlFld-ContribAuthor ">Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Huan  He</span>, <span class="hlFld-ContribAuthor ">Guowei  Gong</span>, <span class="hlFld-ContribAuthor ">Li  Xiong</span>, <span class="hlFld-ContribAuthor ">Baohui  Qi</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112643. <a href="https://doi.org/10.1016/j.ejmech.2020.112643" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112643%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnovel%252Bquinoline%252Banalogues%252Bbearing%252Bthiazolidinones%252Bas%252Bpotent%252Bkinase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bcolorectal%252Bcancer%26aulast%3DZhou%26aufirst%3DYuting%26date%3D2020%26volume%3D204%26spage%3D112643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maaged  Abdullah</span>, <span class="hlFld-ContribAuthor ">Lalitha  Guruprasad</span>. </span><span class="cited-content_cbyCitation_article-title">Computational fragment-based design of Wee1 kinase inhibitors with tricyclic core scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Structural Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (1)
                                     , 213-226. <a href="https://doi.org/10.1007/s11224-018-1176-3" title="DOI URL">https://doi.org/10.1007/s11224-018-1176-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11224-018-1176-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11224-018-1176-3%26sid%3Dliteratum%253Aachs%26jtitle%3DStructural%2520Chemistry%26atitle%3DComputational%252Bfragment-based%252Bdesign%252Bof%252BWee1%252Bkinase%252Binhibitors%252Bwith%252Btricyclic%252Bcore%252Bscaffolds%26aulast%3DAbdullah%26aufirst%3DMaaged%26date%3D2019%26date%3D2018%26volume%3D30%26issue%3D1%26spage%3D213%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vicki L.  Keedy</span>, <span class="hlFld-ContribAuthor ">Heinz-Josef  Lenz</span>, <span class="hlFld-ContribAuthor ">Leonard  Saltz</span>, <span class="hlFld-ContribAuthor ">Jennifer G.  Whisenant</span>, <span class="hlFld-ContribAuthor ">Jordan D.  Berlin</span>, <span class="hlFld-ContribAuthor ">Luis H.  Camacho</span>. </span><span class="cited-content_cbyCitation_article-title">First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2018,</strong> <em>36 </em>
                                    (5)
                                     , 860-868. <a href="https://doi.org/10.1007/s10637-018-0567-z" title="DOI URL">https://doi.org/10.1007/s10637-018-0567-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-018-0567-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-018-0567-z%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DFirst-in-human%252Bphase%252BI%252Bdose%252Bescalation%252Bstudy%252Bof%252BMK-8033%252Bin%252Bpatients%252Bwith%252Badvanced%252Bsolid%252Btumors%26aulast%3DKeedy%26aufirst%3DVicki%2BL.%26date%3D2018%26date%3D2018%26volume%3D36%26issue%3D5%26spage%3D860%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Palak K.  Parikh</span>, <span class="hlFld-ContribAuthor ">Manjunath D.  Ghate</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the discovery of small molecule c-Met Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1103-1138. <a href="https://doi.org/10.1016/j.ejmech.2017.08.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bdiscovery%252Bof%252Bsmall%252Bmolecule%252Bc-Met%252BKinase%252Binhibitors%26aulast%3DParikh%26aufirst%3DPalak%2BK.%26date%3D2018%26volume%3D143%26spage%3D1103%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Neil  Grodsky</span>, <span class="hlFld-ContribAuthor ">Ben  Bolaños</span>, <span class="hlFld-ContribAuthor ">Junli  Feng</span>, <span class="hlFld-ContribAuthor ">RoseAnn  Ferre</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Meirong  Xu</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>, <span class="hlFld-ContribAuthor ">Al  Stewart</span>. </span><span class="cited-content_cbyCitation_article-title">The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2017,</strong> <em>292 </em>
                                    (38)
                                     , 15705-15716. <a href="https://doi.org/10.1074/jbc.M116.771485" title="DOI URL">https://doi.org/10.1074/jbc.M116.771485</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.M116.771485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.M116.771485%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DThe%252BAxl%252Bkinase%252Bdomain%252Bin%252Bcomplex%252Bwith%252Ba%252Bmacrocyclic%252Binhibitor%252Boffers%252Bfirst%252Bstructural%252Binsights%252Binto%252Ban%252Bactive%252BTAM%252Breceptor%252Bkinase%26aulast%3DGajiwala%26aufirst%3DKetan%2BS.%26date%3D2017%26volume%3D292%26issue%3D38%26spage%3D15705%26epage%3D15716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bengen  Liu</span>, <span class="hlFld-ContribAuthor ">Dongshan  Su</span>, <span class="hlFld-ContribAuthor ">Zhonglin  Wei</span>, <span class="hlFld-ContribAuthor ">Jungang  Cao</span>, <span class="hlFld-ContribAuthor ">Dapeng  Liang</span>, <span class="hlFld-ContribAuthor ">Yingjie  Lin</span>, <span class="hlFld-ContribAuthor ">Haifeng  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Condensation of Vilsmeier Salts, Derived from Tetraalkylureas, with α-Hydroxy Amide Derivatives: One-pot Approach to Synthesize 2-Dialkylamino-2-oxazolin-4-ones. </span><span class="cited-content_cbyCitation_journal-name">Chemistry Letters</span><span> <strong>2017,</strong> <em>46 </em>
                                    (2)
                                     , 249-252. <a href="https://doi.org/10.1246/cl.161006" title="DOI URL">https://doi.org/10.1246/cl.161006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1246/cl.161006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1246%2Fcl.161006%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520Letters%26atitle%3DCondensation%252Bof%252BVilsmeier%252BSalts%25252C%252BDerived%252Bfrom%252BTetraalkylureas%25252C%252Bwith%252B%2525CE%2525B1-Hydroxy%252BAmide%252BDerivatives%25253A%252BOne-pot%252BApproach%252Bto%252BSynthesize%252B2-Dialkylamino-2-oxazolin-4-ones%26aulast%3DLiu%26aufirst%3DBengen%26date%3D2017%26volume%3D46%26issue%3D2%26spage%3D249%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Omid  Zarei</span>, <span class="hlFld-ContribAuthor ">Silvia  Benvenuti</span>, <span class="hlFld-ContribAuthor ">Fulya  Ustun-Alkan</span>, <span class="hlFld-ContribAuthor ">Maryam  Hamzeh-Mivehroud</span>, <span class="hlFld-ContribAuthor ">Siavoush  Dastmalchi</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cancer Research and Clinical Oncology</span><span> <strong>2016,</strong> <em>142 </em>
                                    (12)
                                     , 2429-2446. <a href="https://doi.org/10.1007/s00432-016-2214-4" title="DOI URL">https://doi.org/10.1007/s00432-016-2214-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00432-016-2214-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00432-016-2214-4%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cancer%2520Research%2520and%2520Clinical%2520Oncology%26atitle%3DStrategies%252Bof%252Btargeting%252Bthe%252Bextracellular%252Bdomain%252Bof%252BRON%252Btyrosine%252Bkinase%252Breceptor%252Bfor%252Bcancer%252Btherapy%252Band%252Bdrug%252Bdelivery%26aulast%3DZarei%26aufirst%3DOmid%26date%3D2016%26date%3D2016%26volume%3D142%26issue%3D12%26spage%3D2429%26epage%3D2446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang  Feng</span>, <span class="hlFld-ContribAuthor ">Hang-Ping  Yao</span>, <span class="hlFld-ContribAuthor ">Sharad  Sharma</span>, <span class="hlFld-ContribAuthor ">Yong-Qing  Zhou</span>, <span class="hlFld-ContribAuthor ">Jianwei  Zhou</span>, <span class="hlFld-ContribAuthor ">Ruiwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming-Hai  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2016,</strong> <em>35 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-016-0347-6" title="DOI URL">https://doi.org/10.1186/s13046-016-0347-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-016-0347-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-016-0347-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DBiological%252Bevaluation%252Bof%252Bantibody-maytansinoid%252Bconjugates%252Bas%252Ba%252Bstrategy%252Bof%252BRON%252Btargeted%252Bdrug%252Bdelivery%252Bfor%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DFeng%26aufirst%3DLiang%26date%3D2016%26date%3D2016%26volume%3D35%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Mereiter</span>, <span class="hlFld-ContribAuthor ">Ana  Magalhães</span>, <span class="hlFld-ContribAuthor ">Barbara  Adamczyk</span>, <span class="hlFld-ContribAuthor ">Chunsheng  Jin</span>, <span class="hlFld-ContribAuthor ">Andreia  Almeida</span>, <span class="hlFld-ContribAuthor ">Lylia  Drici</span>, <span class="hlFld-ContribAuthor ">Maria  Ibáñez-Vea</span>, <span class="hlFld-ContribAuthor ">Catarina  Gomes</span>, <span class="hlFld-ContribAuthor ">José A.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Luis P.  Afonso</span>, <span class="hlFld-ContribAuthor ">Lúcio L.  Santos</span>, <span class="hlFld-ContribAuthor ">Martin R.  Larsen</span>, <span class="hlFld-ContribAuthor ">Daniel  Kolarich</span>, <span class="hlFld-ContribAuthor ">Niclas G.  Karlsson</span>, <span class="hlFld-ContribAuthor ">Celso A.  Reis</span>. </span><span class="cited-content_cbyCitation_article-title">Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - General Subjects</span><span> <strong>2016,</strong> <em>1860 </em>
                                    (8)
                                     , 1795-1808. <a href="https://doi.org/10.1016/j.bbagen.2015.12.016" title="DOI URL">https://doi.org/10.1016/j.bbagen.2015.12.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbagen.2015.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbagen.2015.12.016%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520General%2520Subjects%26atitle%3DGlycomic%252Banalysis%252Bof%252Bgastric%252Bcarcinoma%252Bcells%252Bdiscloses%252Bglycans%252Bas%252Bmodulators%252Bof%252BRON%252Breceptor%252Btyrosine%252Bkinase%252Bactivation%252Bin%252Bcancer%26aulast%3DMereiter%26aufirst%3DStefan%26date%3D2016%26volume%3D1860%26issue%3D8%26spage%3D1795%26epage%3D1808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Shiyu  Jin</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Dong  Lu</span>, <span class="hlFld-ContribAuthor ">Limin  Zeng</span>, <span class="hlFld-ContribAuthor ">Yiming  Sun</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Youhong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>108 </em>, 322-333. <a href="https://doi.org/10.1016/j.ejmech.2015.11.042" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.11.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.11.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.11.042%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyridazinone%252Bderivatives%252Bdisplaying%252Bhighly%252Bpotent%252Band%252Bselective%252Binhibitory%252Bactivities%252Bagainst%252Bc-Met%252Btyrosine%252Bkinase%26aulast%3DLiu%26aufirst%3DYang%26date%3D2016%26volume%3D108%26spage%3D322%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iacopo  Fioroni</span>, <span class="hlFld-ContribAuthor ">Emanuela  Dell’Aquila</span>, <span class="hlFld-ContribAuthor ">Francesco  Pantano</span>, <span class="hlFld-ContribAuthor ">Salvatore  Intagliata</span>, <span class="hlFld-ContribAuthor ">Marco  Caricato</span>, <span class="hlFld-ContribAuthor ">Bruno  Vincenzi</span>, <span class="hlFld-ContribAuthor ">Roberto  Coppola</span>, <span class="hlFld-ContribAuthor ">Daniele  Santini</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Tonini</span>. </span><span class="cited-content_cbyCitation_article-title">Role of c-mesenchymal–epithelial transition pathway in gastric cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2015,</strong> <em>16 </em>
                                    (8)
                                     , 1195-1207. <a href="https://doi.org/10.1517/14656566.2015.1037739" title="DOI URL">https://doi.org/10.1517/14656566.2015.1037739</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/14656566.2015.1037739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F14656566.2015.1037739%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DRole%252Bof%252Bc-mesenchymal%2525E2%252580%252593epithelial%252Btransition%252Bpathway%252Bin%252Bgastric%252Bcancer%26aulast%3DFioroni%26aufirst%3DIacopo%26date%3D2015%26date%3D2015%26volume%3D16%26issue%3D8%26spage%3D1195%26epage%3D1207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiqiang  Xing</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Shiyu  Jin</span>, <span class="hlFld-ContribAuthor ">Zhangxing  Shi</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Lang  Wang</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Dong  Lu</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Youhong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>95 </em>, 302-312. <a href="https://doi.org/10.1016/j.ejmech.2015.03.041" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.03.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.03.041%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEnhancing%252Bthe%252Bcellular%252Banti-proliferation%252Bactivity%252Bof%252Bpyridazinones%252Bas%252Bc-met%252Binhibitors%252Busing%252Bdocking%252Banalysis%26aulast%3DXing%26aufirst%3DWeiqiang%26date%3D2015%26volume%3D95%26spage%3D302%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Tavakoli</span>, <span class="hlFld-ContribAuthor ">Jahan B.  Ghasemi</span>. </span><span class="cited-content_cbyCitation_article-title">An improved ensemble learning machine for biological activity prediction of tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemometrics</span><span> <strong>2015,</strong> <em>29 </em>
                                    (4)
                                     , 213-223. <a href="https://doi.org/10.1002/cem.2698" title="DOI URL">https://doi.org/10.1002/cem.2698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cem.2698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcem.2698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemometrics%26atitle%3DAn%252Bimproved%252Bensemble%252Blearning%252Bmachine%252Bfor%252Bbiological%252Bactivity%252Bprediction%252Bof%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DTavakoli%26aufirst%3DHossein%26date%3D2015%26date%3D2015%26volume%3D29%26issue%3D4%26spage%3D213%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sharad  Sharma</span>, <span class="hlFld-ContribAuthor ">Hang-Ping  Yao</span>, <span class="hlFld-ContribAuthor ">Yong-Qing  Zhou</span>, <span class="hlFld-ContribAuthor ">Jianwei  Zhou</span>, <span class="hlFld-ContribAuthor ">Ruiwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming-Hai  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2014,</strong> <em>8 </em>
                                    (3)
                                     , 469-482. <a href="https://doi.org/10.1016/j.molonc.2013.12.014" title="DOI URL">https://doi.org/10.1016/j.molonc.2013.12.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molonc.2013.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molonc.2013.12.014%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DPrevention%252Bof%252BBMS-777607-induced%252Bpolyploidy%25252Fsenescence%252Bby%252BmTOR%252Binhibitor%252BAZD8055%252Bsensitizes%252Bbreast%252Bcancer%252Bcells%252Bto%252Bcytotoxic%252Bchemotherapeutics%26aulast%3DSharma%26aufirst%3DSharad%26date%3D2014%26date%3D2014%26volume%3D8%26issue%3D3%26spage%3D469%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wentao  Gao</span>, <span class="hlFld-ContribAuthor ">Xueda  Xing</span>, <span class="hlFld-ContribAuthor ">Yang  Li</span>, <span class="hlFld-ContribAuthor ">Shuai  Lan</span>. </span><span class="cited-content_cbyCitation_article-title">A novel construction of quino-fused tropone skeleton: first synthesis of 12H-benzo[4,5]cyclohepta[1,2-b]quinolin-12-one derivatives. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2014,</strong> <em>70 </em>
                                    (12)
                                     , 2180-2189. <a href="https://doi.org/10.1016/j.tet.2014.01.049" title="DOI URL">https://doi.org/10.1016/j.tet.2014.01.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2014.01.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2014.01.049%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DA%252Bnovel%252Bconstruction%252Bof%252Bquino-fused%252Btropone%252Bskeleton%25253A%252Bfirst%252Bsynthesis%252Bof%252B12H-benzo%25255B4%25252C5%25255Dcyclohepta%25255B1%25252C2-b%25255Dquinolin-12-one%252Bderivatives%26aulast%3DGao%26aufirst%3DWentao%26date%3D2014%26volume%3D70%26issue%3D12%26spage%3D2180%26epage%3D2189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Panpan  Qu</span>, <span class="hlFld-ContribAuthor ">Chunlou  Sun</span>, <span class="hlFld-ContribAuthor ">Juan  Ma</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">The
              N
              -Alkylation of Sulfonamides with Alcohols in Water Catalyzed by the Water-Soluble Iridium Complex {Cp*Ir[6,6′-(OH)
              2
              bpy](H
              2
              O)}[OTf]
              2. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2014,</strong> <em>356 </em>
                                    (2-3)
                                     , 447-459. <a href="https://doi.org/10.1002/adsc.201300711" title="DOI URL">https://doi.org/10.1002/adsc.201300711</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201300711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201300711%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DThe%252BN%252B-Alkylation%252Bof%252BSulfonamides%252Bwith%252BAlcohols%252Bin%252BWater%252BCatalyzed%252Bby%252Bthe%252BWater-Soluble%252BIridium%252BComplex%252B%25257BCp%252AIr%25255B6%25252C6%2525E2%252580%2525B2-%252528OH%252529%252B2%252Bbpy%25255D%252528H%252B2%252BO%252529%25257D%25255BOTf%25255D%252B2%26aulast%3DQu%26aufirst%3DPanpan%26date%3D2014%26date%3D2014%26volume%3D356%26issue%3D2-3%26spage%3D447%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William  McCoull</span>, <span class="hlFld-ContribAuthor ">Edward J.  Hennessy</span>, <span class="hlFld-ContribAuthor ">Kevin  Blades</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Box</span>, <span class="hlFld-ContribAuthor ">Claudio  Chuaqui</span>, <span class="hlFld-ContribAuthor ">James E.  Dowling</span>, <span class="hlFld-ContribAuthor ">Christopher D.  Davies</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Ferguson</span>, <span class="hlFld-ContribAuthor ">Frederick W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Howe</span>, <span class="hlFld-ContribAuthor ">Paul D.  Kemmitt</span>, <span class="hlFld-ContribAuthor ">Gillian M.  Lamont</span>, <span class="hlFld-ContribAuthor ">Katrina  Madden</span>, <span class="hlFld-ContribAuthor ">Claire  McWhirter</span>, <span class="hlFld-ContribAuthor ">Jeffrey G.  Varnes</span>, <span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">Jason D.  Williams</span>, <span class="hlFld-ContribAuthor ">Bin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and optimisation of 7-azaindole PAK1 inhibitors with improved potency and kinase selectivity. </span><span class="cited-content_cbyCitation_journal-name">Med. Chem. Commun.</span><span> <strong>2014,</strong> <em>5 </em>
                                    (10)
                                     , 1533-1539. <a href="https://doi.org/10.1039/C4MD00280F" title="DOI URL">https://doi.org/10.1039/C4MD00280F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MD00280F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MD00280F%26sid%3Dliteratum%253Aachs%26jtitle%3DMed.%2520Chem.%2520Commun.%26atitle%3DIdentification%252Band%252Boptimisation%252Bof%252B7-azaindole%252BPAK1%252Binhibitors%252Bwith%252Bimproved%252Bpotency%252Band%252Bkinase%252Bselectivity%26aulast%3DMcCoull%26aufirst%3DWilliam%26date%3D2014%26date%3D2014%26volume%3D5%26issue%3D10%26spage%3D1533%26epage%3D1539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Wenting  Tai</span>, <span class="hlFld-ContribAuthor ">Shihe  Hu</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Sihui  Yao</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Ke</span>, <span class="hlFld-ContribAuthor ">Xiao  Xiong</span>, <span class="hlFld-ContribAuthor ">Jinxing  Xu</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-based strategy for structural optimization in combination with 3D-QSAR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2013,</strong> <em>27 </em>
                                    (10)
                                     , 897-915. <a href="https://doi.org/10.1007/s10822-013-9687-x" title="DOI URL">https://doi.org/10.1007/s10822-013-9687-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-013-9687-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-013-9687-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DFragment-based%252Bstrategy%252Bfor%252Bstructural%252Boptimization%252Bin%252Bcombination%252Bwith%252B3D-QSAR%26aulast%3DYuan%26aufirst%3DHaoliang%26date%3D2013%26date%3D2013%26volume%3D27%26issue%3D10%26spage%3D897%26epage%3D915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hang-Ping  Yao</span>, <span class="hlFld-ContribAuthor ">Yong-Qing  Zhou</span>, <span class="hlFld-ContribAuthor ">Ruiwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming-Hai  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">MSP–RON signalling in cancer: pathogenesis and therapeutic potential. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Cancer</span><span> <strong>2013,</strong> <em>13 </em>
                                    (7)
                                     , 466-481. <a href="https://doi.org/10.1038/nrc3545" title="DOI URL">https://doi.org/10.1038/nrc3545</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrc3545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrc3545%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Cancer%26atitle%3DMSP%2525E2%252580%252593RON%252Bsignalling%252Bin%252Bcancer%25253A%252Bpathogenesis%252Band%252Btherapeutic%252Bpotential%26aulast%3DYao%26aufirst%3DHang-Ping%26date%3D2013%26date%3D2013%26volume%3D13%26issue%3D7%26spage%3D466%26epage%3D481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Acetamide Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Pd<sub>2</sub>(dba)<sub>3</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF<sub>4</sub>, dimethylmalonate, K<sub>3</sub>PO<sub>4</sub>, toluene, 70 °C; (b) 6N HCl, AcOH, 110 °C; (c) SOCl<sub>2</sub>, MeOH, relux; (d) Pd<sub>2</sub>(dba)<sub>3</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF4, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, KF, DMF, 130 °C; (e) 1N NaOH, THF, rt; (f) Et<sub>3</sub>N, HATU, amine, CH<sub>2</sub>Cl<sub>2</sub>, rt; (g) LDA, MeI, THF, −78 °C; (h) LDA, <i>rac</i>-(10)-(camphorylsulfonyl)oxaziridine, THF, −78 °C.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benzylic Sulfonamide Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) for <b>8a</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, PPh<sub>3</sub>, NaH, dioxane 70 °C; for <b>8b</b>, Pd(OAc)<sub>2</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF<sub>4</sub>, NaO<i>t</i>-Bu, dioxane, 90 °C. (b) 1N NaOH, 50 °C. (c) Pd<sub>2</sub>(dba)<sub>3</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF<sub>4</sub>, 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, KF, DMF, 130 °C. (d) for <b>9a</b>, Cs<sub>2</sub>CO<sub>3</sub>, amine, dioxane, 180 °C; for <b>9b</b>, amine, NMP, 190 °C. (e) 2-aminomethylpyridine, NMP, 130–135 °C. (f) for <b>11r</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, PCy<sub>3</sub>, lithium 2-hydroxy-4,4,5,5-tetramethyl-2-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,3,2-dioxaborolan-2-uide hydrate, DMF, 100 °C; for <b>16</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, P(<i>t</i>-Bu)<sub>3</sub>·HBF<sub>4</sub>, KF, <i>tert</i>-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl]piperidine-1-carboxylate, DMF, 130 °C, then HCl, dioxane.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Sulfone <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Potassium (2-(trimethylsilyl)ethoxy)methyltrifluoroborate Pd(OAc)<sub>2</sub>, RuPhos, Cs<sub>2</sub>CO<sub>3,</sub> 10:1 dioxane/water, 100 °C; (b) BF<sub>3</sub>·OEt<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (c) MsCl, Et<sub>3</sub>N, dioxane, 0 °C; (d) NaH, 2-pyridin-2-ylethanethiol, DMF; (e) MCPBA, CH<sub>2</sub>Cl<sub>2</sub>; (f) Pd<sub>2</sub>(dba)<sub>3</sub>, X-Phos, lithium 2-hydroxy-4,4,5,5-tetramethyl-2-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1,3,2-dioxaborolan-2-uide hydrate, DMF, 150 °C.</p></p></figure><figure data-id="fig1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. c-Met ligands <b>15</b> and <b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Ribbon cartoon image of the X-ray crystal structure of <b>16</b> (green) bound to activated c-Met kinase domain (gray). Phosphotyrosines pY1234 and pY1235 (magenta) part of the activation loop are also highlighted. (B) Binding pose of <b>16</b> in the ATP binding pocket. (C) Close-up view of the interactions of <b>16</b> with c-Met. (D) Overlay of the structures of <b>15</b> (cyan)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and <b>16</b> (green) bound to activated c-Met. The yellow arrow highlights the different disposition of the pyridymethylamine fragment between the two structures. (E) Overlay of the structures of <b>17</b> (magenta)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and <b>16</b> (green) bound to activated c-Met.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/medium/jm-2012-01619u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. GTL-16 tumor xenograft PK/PD and efficacy of <b>11r</b>. (A) Inhibition by <b>11r</b> of c-Met (Y1349) phosphorylation in GTL-16 tumors. The tumor bearing mice were given a single oral dose of 10, 30, 100, or 400 mg/kg of <b>11r</b> and euthanized 1 h after dosing. The extent of c-Met (Y1349) phosphorylation in the tumors was determined by quantitative Western blotting. Shown are representative images of phospho-c-Met (Y1349) and total c-Met blots. (B) The relationship between the phospho-c-Met (Y1349) levels of all individual tumors and the corresponding host plasma total <b>11r</b> concentrations. (C) The effects of orally administered <b>11r</b> on the growth of GTL-16 tumor. Asterisks indicate statistically significant difference from vehicle-treated group based on two way repeated measures ANOVA (* <i>P</i> < 0.05, ** P = 0.011, *** <i>P</i> < 0.01).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-6/jm301619u/production/images/large/jm-2012-01619u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301619u&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="note"><p class="first last">For example, see:</p></div><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mansi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiery-Vuillemin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calcagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocquain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demarchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurina, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivot, X.</span><span> </span><span class="NLM_article-title">Safety profile of new Anticancer Drugs</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1517%2F14740330903530663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=20175699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVCgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=301-317&author=L.+Mansiauthor=A.+Thiery-Vuilleminauthor=T.+Nguyenauthor=F.+Bazanauthor=F.+Calcagnoauthor=J.+Rocquainauthor=M.+Demarchiauthor=C.+Villanuevaauthor=T.+Maurinaauthor=X.+Pivot&title=Safety+profile+of+new+Anticancer+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of new anticancer drugs</span></div><div class="casAuthors">Mansi, Laura; Thiery-Vuillemin, Antoine; Nguyen, Thierry; Bazan, Fernando; Calcagno, Fabien; Rocquain, Julien; Demarchi, Martin; Villanueva, Cristian; Maurina, Tristan; Pivot, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-317</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The development of targeted anticancer therapies stems from advances in mol. biol.  New agents range from antibodies that form complexes with antigens on the surface of the cancer cell to small mols. that have been engineered to block key enzymic reactions.  The interaction of the antibody or drug with its target inhibits key pathways involved in cell proliferation or metastasis, or activates pathways leading to cell death.  Such pathways constitute ideal pharmacol. targets.  Clin. benefits from these novel therapeutic strategies are striking for patients with metastatic diseases.  Areas covered: This review analyses the main toxicities among most common targeted therapies that have been approved by the FDA or European Medicines Agency for their clin. utilization in solid tumors treatment.  What the reader will gain: Here, the main toxicity and safety data among new anticancer targeted therapies are described.  Data are organized through the pathways targeted by the drugs.  Take home message: The emergence of new targeted anticancer therapies promises more efficient and less toxic therapies.  Generally, they are well tolerated, toxicities are commonly mild to moderate and can be handled rapidly.  However, if most of these adverse events are manageable, life threatening and fatal complications can still occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiiiFyqEsHs7Vg90H21EOLACvtfcHk0lipkStfAoztjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVCgtr8%253D&md5=dc68a83909ddc594ec9359fc15123e68</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1517%2F14740330903530663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740330903530663%26sid%3Dliteratum%253Aachs%26aulast%3DMansi%26aufirst%3DL.%26aulast%3DThiery-Vuillemin%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DBazan%26aufirst%3DF.%26aulast%3DCalcagno%26aufirst%3DF.%26aulast%3DRocquain%26aufirst%3DJ.%26aulast%3DDemarchi%26aufirst%3DM.%26aulast%3DVillanueva%26aufirst%3DC.%26aulast%3DMaurina%26aufirst%3DT.%26aulast%3DPivot%26aufirst%3DX.%26atitle%3DSafety%2520profile%2520of%2520new%2520Anticancer%2520Drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2010%26volume%3D9%26spage%3D301%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mellor, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentin, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R.R A.</span><span> </span><span class="NLM_article-title">Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1093%2Ftoxsci%2Fkfq378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=21177772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1eksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2011&pages=14-32&author=H.+R.+Mellorauthor=A.+R.+Bellauthor=J.-P.+Valentinauthor=R.R+A.+Roberts&title=Cardiotoxicity+Associated+with+Targeting+Kinase+Pathways+in+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer</span></div><div class="casAuthors">Mellor, Howard R.; Bell, Alex R.; Valentin, Jean-Pierre; Roberts, Ruth R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-32</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Cardiotoxicity, also referred to as drug-induced cardiac injury, is an issue assocd. with the use of some small-mol. kinase inhibitors and antibody-based therapies targeting signaling pathways in cancer.  Although these drugs have had a major impact on cancer patient survival, data have implicated kinase-targeting agents such as sunitinib, imatinib, trastuzumab, and sorafenib in adversely affecting cardiac function in a subset of treated individuals.  In many cases, adverse cardiac events in the clinic were not anticipated based on preclin. safety evaluation of the mol.  To support the development of efficacious and safe kinase inhibitors for the treatment of cancer and other indications, new preclin. approaches and screens are required to predict clin. cardiotoxicity.  Lab. investigations into the underlying mol. mechanisms of heart toxicity induced by these mols. have identified potentially common themes including mitochondrial perturbation and modulation of adenosine monophosphate-activated protein kinase activity.  Studies characterizing cardiac-specific kinase knockout mouse models have developed our understanding of the homeostatic role of some of these signaling mediators in the heart.  Therefore, when considering kinases as potential future targets or when examg. secondary pharmacol. interactions of novel kinase inhibitors, these models may help to inform us of the potential adverse cardiac effects in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQ3BHazaLTrVg90H21EOLACvtfcHk0lim9NGRRty14g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1eksL8%253D&md5=eb48e8a0b89ef96d7e48255c51ff8728</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfq378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfq378%26sid%3Dliteratum%253Aachs%26aulast%3DMellor%26aufirst%3DH.%2BR.%26aulast%3DBell%26aufirst%3DA.%2BR.%26aulast%3DValentin%26aufirst%3DJ.-P.%26aulast%3DRoberts%26aufirst%3DR.R%2BA.%26atitle%3DCardiotoxicity%2520Associated%2520with%2520Targeting%2520Kinase%2520Pathways%2520in%2520Cancer%26jtitle%3DToxicol.%2520Sci.%26date%3D2011%26volume%3D120%26spage%3D14%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Force, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaja, K. L.</span><span> </span><span class="NLM_article-title">Cardiotoxicity of Kinase Inhibitors: The Prediction and Translation of Preclinical Models to Clinical Outcomes</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=111-126&author=T.+Forceauthor=K.+L.+Kolaja&title=Cardiotoxicity+of+Kinase+Inhibitors%3A+The+Prediction+and+Translation+of+Preclinical+Models+to+Clinical+Outcomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForce%26aufirst%3DT.%26aulast%3DKolaja%26aufirst%3DK.%2BL.%26atitle%3DCardiotoxicity%2520of%2520Kinase%2520Inhibitors%253A%2520The%2520Prediction%2520and%2520Translation%2520of%2520Preclinical%2520Models%2520to%2520Clinical%2520Outcomes%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D111%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2681</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+the+%E2%80%9CGatekeeper+Door%E2%80%9D%3A+Exploiting+the+Active+Kinase+Conformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520the%2520%25E2%2580%259CGatekeeper%2520Door%25E2%2580%259D%253A%2520Exploiting%2520the%2520Active%2520Kinase%2520Conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2681%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-1509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wisserauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0lim9NGRRty14g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWisser%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D1509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="note"><p class="first last">For the discovery and characterization of Nilotinib, see:</p></div><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">AMN107: Tightening the Grip of Imatinib</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=117-119&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=M.+W.+N.+Deiningerauthor=B.+J.+Druker&title=AMN107%3A+Tightening+the+Grip+of+Imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DAMN107%253A%2520Tightening%2520the%2520Grip%2520of%2520Imatinib%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D117%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a Selective Inhibitor of Native and Mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Brueggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+Selective+Inhibitor+of+Native+and+Mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lh39rL_m_x77g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Native%2520and%2520Mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="note"><p class="first last">For general references on c-Met and Ron, see</p></div><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Birchmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Met, Metastasis, Motility and More</span> <span class="citation_source-journal">Nature Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1038%2Fnrm1261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=14685170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFeju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=915-925&author=C.+Birchmeierauthor=W.+Birchmeierauthor=E.+Gherardiauthor=G.+F.+Vande+Woude&title=Met%2C+Metastasis%2C+Motility+and+More"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Met, metastasis, motility and more</span></div><div class="casAuthors">Birchmeier, Carmen; Birhcmeier, Walter; Gherardi, Ermanno; Vande Woude, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-925</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatocyte growth factor. scatter factor and its receptor, the tyrosine kinase Met, arose late in evolution and are unique to vertebrates.  In spite of this, Met uses mols. such as Gab1 - homologues of which are present in Caenorhabditis elegans and Drosophila melanogaster - for downstream signalling. Pivotal roles for Met in development and cancer have been established: Met controls cell migration and growth in embryogenesis; it also controls growth, invasion and metastasis in cancer cells; and activating Met mutations predispose to human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_-6XRpZ-sLVg90H21EOLACvtfcHk0lh39rL_m_x77g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFeju7s%253D&md5=ff5a02c73415784480c628fe65299a81</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1038%2Fnrm1261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1261%26sid%3Dliteratum%253Aachs%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DMet%252C%2520Metastasis%252C%2520Motility%2520and%2520More%26jtitle%3DNature%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D915%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Benvenuti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">The MET Receptor Tyrosine Kinase in Invasion and Metastasis</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">213</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1002%2Fjcp.21183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=17607709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=316-325&author=S.+Benvenutiauthor=P.+M.+Comoglio&title=The+MET+Receptor+Tyrosine+Kinase+in+Invasion+and+Metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">The MET receptor tyrosine kinase in invasion and metastasis</span></div><div class="casAuthors">Benvenuti, Silvia; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-325</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Various cytokines and sol. growth factors upon interaction with their membrane receptors are responsible for inducing cellular proliferation, differentiation, movement, and protection from anoikis (a planned suicide activated by normal cells in absence of attachment to neighboring cells or extracellular matrix (EMC)).  Among those sol. factors a major position is exerted by hepatocyte growth factor (HGF) together with its receptor MET and macrophage-stimulating protein (MSP) in cooperation with its receptor RON.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1QrqNHPoSM7Vg90H21EOLACvtfcHk0li3ZtDhALKOIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7rM&md5=8994572071201c78fd2df1b504ab1a4e</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21183%26sid%3Dliteratum%253Aachs%26aulast%3DBenvenuti%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DThe%2520MET%2520Receptor%2520Tyrosine%2520Kinase%2520in%2520Invasion%2520and%2520Metastasis%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D316%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ponzetto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maina, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dalla Zonca, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panayotou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">A Multifunctional Docking Site Mediates Signaling and Transformation by the Hepatocyte Growth Factor/Scatter Factor Receptor Family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1994&pages=261-271&author=C.+Ponzettoauthor=A.+Bardelliauthor=Z.+Zhenauthor=F.+Mainaauthor=P.+dalla+Zoncaauthor=S.+Giordanoauthor=A.+Grazianiauthor=G.+Panayotouauthor=P.+M.+Comoglio&title=A+Multifunctional+Docking+Site+Mediates+Signaling+and+Transformation+by+the+Hepatocyte+Growth+Factor%2FScatter+Factor+Receptor+Family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPonzetto%26aufirst%3DC.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DZ.%26aulast%3DMaina%26aufirst%3DF.%26aulast%3Ddalla%2BZonca%26aufirst%3DP.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DGraziani%26aufirst%3DA.%26aulast%3DPanayotou%26aufirst%3DG.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DA%2520Multifunctional%2520Docking%2520Site%2520Mediates%2520Signaling%2520and%2520Transformation%2520by%2520the%2520Hepatocyte%2520Growth%2520Factor%252FScatter%2520Factor%2520Receptor%2520Family%26jtitle%3DCell%26date%3D1994%26volume%3D77%26spage%3D261%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Accornero, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavone, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baratta, M.</span><span> </span><span class="NLM_article-title">The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2699</span><span class="NLM_x">–</span> <span class="NLM_lpage">2712</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.2174%2F092986710791859261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=20586722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaju7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2699-2712&author=P.+Accorneroauthor=L.+M.+Pavoneauthor=M.+Baratta&title=The+Scatter+Factor+Signaling+Pathways+as+Therapeutic+Associated+Target+in+Cancer+Treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">The scatter factor signaling pathways as therapeutic associated target in cancer treatment</span></div><div class="casAuthors">Accornero, P.; Pavone, L. M.; Baratta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2699-2712</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTKs) are key regulators of crit. cellular processes such as proliferation, differentiation, neo-vascularization, and tissue repair.  In addn. to their importance in the regulation of normal physiol., aberrant expression of certain RTKs has also been assocd. to the development and progression of many types of cancer.  C-Met and RON are two RTKs with closely related sequences, structural homol., and similar functional properties.  Both these receptors, once activated by their resp. ligands, the Hepatocyte Growth Factor/Scatter Factor (HGF/SF1) and the Macrophage Stimulating Protein/Scatter Factor 2 (MSP/SF2), can induce cell migration, invasion and proliferation.  Soon after its discovery in the mid-1980s, c-Met attracted a great interest because of its role in modulating cell motility.  Moreover, the causal role for c-Met activating mutations in human cancer propelled an intensive drug discovery effort throughout academic institutions and pharmaceutical companies.  While c-Met is now a well-accepted target for anticancer drug design, less is known about the role of RON in cancer and less has been done to target this receptor.  In this review we will discuss the biol. relevance of c-Met and RON, their deregulation in human cancers and the progress, so far, in identifying c-Met and RON signaling inhibitors.  Finally, we will focus on the development of therapeutic strategies and drug efficacy studies based on interfering the scatter factor signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Hgvw__jLh7Vg90H21EOLACvtfcHk0li3ZtDhALKOIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaju7bO&md5=fa07abb77ab1a86234c9ebee9d377cf3</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.2174%2F092986710791859261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791859261%26sid%3Dliteratum%253Aachs%26aulast%3DAccornero%26aufirst%3DP.%26aulast%3DPavone%26aufirst%3DL.%2BM.%26aulast%3DBaratta%26aufirst%3DM.%26atitle%3DThe%2520Scatter%2520Factor%2520Signaling%2520Pathways%2520as%2520Therapeutic%2520Associated%2520Target%2520in%2520Cancer%2520Treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D2699%26epage%3D2712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="note"><p class="first last">For examples of Met mutations or overexpression in human cancer, see</p></div><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gonzatti-Haces, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oroszlan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Characterization of the TPR-MET Oncogene p65 and the MET Protooncogene p140 Protein–Tyrosine Kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=21-25&author=M.+Gonzatti-Hacesauthor=A.+Sethauthor=M.+Parkauthor=T.+Copelandauthor=S.+Oroszlanauthor=G.+F.+Vande+Woude&title=Characterization+of+the+TPR-MET+Oncogene+p65+and+the+MET+Protooncogene+p140+Protein%E2%80%93Tyrosine+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGonzatti-Haces%26aufirst%3DM.%26aulast%3DSeth%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DCopeland%26aufirst%3DT.%26aulast%3DOroszlan%26aufirst%3DS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DCharacterization%2520of%2520the%2520TPR-MET%2520Oncogene%2520p65%2520and%2520the%2520MET%2520Protooncogene%2520p140%2520Protein%25E2%2580%2593Tyrosine%2520Kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1988%26volume%3D85%26spage%3D21%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schmidt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duh, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choyke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubensky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allikmets, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chidambaram, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergerheim, U. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltis, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamarron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernues, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lips, C. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, L.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geil, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orcutt, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stackhouse, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slife, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brauch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niehans, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storkel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerman, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linehan, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zbar, B.</span><span> </span><span class="NLM_article-title">Germline and Somatic Mutations in the Tyrosine Kinase Domain of the MET Proto-oncogene in Papillary Renal Carcinomas</span> <span class="citation_source-journal">Nature Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1038%2Fng0597-68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=9140397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADyaK2sXivFKhsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=68-73&author=L.+Schmidtauthor=F.+M.+Duhauthor=F.+Chenauthor=T.+Kishidaauthor=G.+Glennauthor=P.+Choykeauthor=S.+W.+Schererauthor=Z.+Zhuangauthor=I.+Lubenskyauthor=M.+Deanauthor=R.+Allikmetsauthor=A.+Chidambaramauthor=U.+R.+Bergerheimauthor=J.+T.+Feltisauthor=C.+Casadevallauthor=A.+Zamarronauthor=M.+Bernuesauthor=S.+Richardauthor=C.+J.+M.+Lipsauthor=M.+M.+Waltherauthor=L.-C.+Tsuiauthor=L.+Geilauthor=M.+L.+Orcuttauthor=T.+Stackhouseauthor=J.+Lipanauthor=L.+Slifeauthor=H.+Brauchauthor=J.+Deckerauthor=G.+Niehansauthor=M.+D.+Hughsonauthor=H.+Mochauthor=S.+Storkelauthor=M.+I.+Lermanauthor=W.+M.+Linehanauthor=B.+Zbar&title=Germline+and+Somatic+Mutations+in+the+Tyrosine+Kinase+Domain+of+the+MET+Proto-oncogene+in+Papillary+Renal+Carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas</span></div><div class="casAuthors">Schmidt, Laura; Duh, Fuh-Mei; Chen, Fan; Kishida, Takeshi; Glenn, Gladys; Choyke, Peter; Scherer, Stephen W.; Zhuang, Zhenping; Lubensky, Irina; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumors.  The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance.  HPRC is histol. and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8).  Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome.  Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of both copies of the VHL gene by mutation, and/or by hypermethylation.  We found that the HPRC gene was located at chromosome 7q31.1-34 in a 27-centimorgan (cM) interval between D7S496 and D7S1837.  We identified missense mutations located in the tyrosine kinase domain of the MET gene in the germline of affected members of HPRC families and in a subset of sporadic papillary renal carcinomas.  Three mutations in the MET gene are located in codons that are homologous to those in c-kit and RET, proto-oncogenes that are targets of naturally-occurring mutations.  The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm-x_dqJPR-7Vg90H21EOLACvtfcHk0li8smK5VtroRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFKhsbw%253D&md5=7209dbbaa538b418defad117830df3c9</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1038%2Fng0597-68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0597-68%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DL.%26aulast%3DDuh%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DKishida%26aufirst%3DT.%26aulast%3DGlenn%26aufirst%3DG.%26aulast%3DChoyke%26aufirst%3DP.%26aulast%3DScherer%26aufirst%3DS.%2BW.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DLubensky%26aufirst%3DI.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DChidambaram%26aufirst%3DA.%26aulast%3DBergerheim%26aufirst%3DU.%2BR.%26aulast%3DFeltis%26aufirst%3DJ.%2BT.%26aulast%3DCasadevall%26aufirst%3DC.%26aulast%3DZamarron%26aufirst%3DA.%26aulast%3DBernues%26aufirst%3DM.%26aulast%3DRichard%26aufirst%3DS.%26aulast%3DLips%26aufirst%3DC.%2BJ.%2BM.%26aulast%3DWalther%26aufirst%3DM.%2BM.%26aulast%3DTsui%26aufirst%3DL.-C.%26aulast%3DGeil%26aufirst%3DL.%26aulast%3DOrcutt%26aufirst%3DM.%2BL.%26aulast%3DStackhouse%26aufirst%3DT.%26aulast%3DLipan%26aufirst%3DJ.%26aulast%3DSlife%26aufirst%3DL.%26aulast%3DBrauch%26aufirst%3DH.%26aulast%3DDecker%26aufirst%3DJ.%26aulast%3DNiehans%26aufirst%3DG.%26aulast%3DHughson%26aufirst%3DM.%2BD.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DStorkel%26aufirst%3DS.%26aulast%3DLerman%26aufirst%3DM.%2BI.%26aulast%3DLinehan%26aufirst%3DW.%2BM.%26aulast%3DZbar%26aufirst%3DB.%26atitle%3DGermline%2520and%2520Somatic%2520Mutations%2520in%2520the%2520Tyrosine%2520Kinase%2520Domain%2520of%2520the%2520MET%2520Proto-oncogene%2520in%2520Papillary%2520Renal%2520Carcinomas%26jtitle%3DNature%2520Genet.%26date%3D1997%26volume%3D16%26spage%3D68%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jeffers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiscella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anver, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koochekpour, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">The Mutationally Activated Met Receptor Mediates Motility and Metastasis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">14422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=1441-14422&author=M.+Jeffersauthor=M.+Fiscellaauthor=C.+P.+Webbauthor=M.+Anverauthor=S.+Koochekpourauthor=G.+F.+Vande+Woude&title=The+Mutationally+Activated+Met+Receptor+Mediates+Motility+and+Metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DFiscella%26aufirst%3DM.%26aulast%3DWebb%26aufirst%3DC.%2BP.%26aulast%3DAnver%26aufirst%3DM.%26aulast%3DKoochekpour%26aufirst%3DS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DThe%2520Mutationally%2520Activated%2520Met%2520Receptor%2520Mediates%2520Motility%2520and%2520Metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D1441%26epage%3D14422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Bean, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitale, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motoi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szoke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broderick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdarl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pass, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerald, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">MET Amplification Occurs With or Without T790M Mutations in EGFR Mutant Lung Tumors with Acquired Resistance to Gefitinib or Erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">20932</span><span class="NLM_x">–</span> <span class="NLM_lpage">20937</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=20932-20937&author=J.+Beanauthor=C.+Brennanauthor=J.-Y.+Shihauthor=G.+Rielyauthor=A.+Vialeauthor=L.+Wangauthor=D.+Chitaleauthor=N.+Motoiauthor=J.+Szokeauthor=S.+Broderickauthor=M.+Balakauthor=W.-C.+Changauthor=C.-J.+Yuauthor=A.+Gazdarlauthor=H.+Passauthor=V.+Ruschauthor=W.+Geraldauthor=S.-F.+Huangauthor=P.-C.+Yangauthor=V.+Millerauthor=M.+Ladanyiauthor=C.-H.+Yangauthor=W.+Pao&title=MET+Amplification+Occurs+With+or+Without+T790M+Mutations+in+EGFR+Mutant+Lung+Tumors+with+Acquired+Resistance+to+Gefitinib+or+Erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBean%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DShih%26aufirst%3DJ.-Y.%26aulast%3DRiely%26aufirst%3DG.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChitale%26aufirst%3DD.%26aulast%3DMotoi%26aufirst%3DN.%26aulast%3DSzoke%26aufirst%3DJ.%26aulast%3DBroderick%26aufirst%3DS.%26aulast%3DBalak%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DW.-C.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DGazdarl%26aufirst%3DA.%26aulast%3DPass%26aufirst%3DH.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DGerald%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DS.-F.%26aulast%3DYang%26aufirst%3DP.-C.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DMET%2520Amplification%2520Occurs%2520With%2520or%2520Without%2520T790M%2520Mutations%2520in%2520EGFR%2520Mutant%2520Lung%2520Tumors%2520with%2520Acquired%2520Resistance%2520to%2520Gefitinib%2520or%2520Erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D20932%26epage%3D20937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For examples of Ron mutations or overexpression in human cancer, see</p></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtz, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiang, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. H.</span><span> </span><span class="NLM_article-title">Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">261</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1006%2Fexcr.2000.5012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=11082293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotVyntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=2000&pages=229-238&author=Y.+Q.+Chenauthor=Y.+Q.+Zhouauthor=D.+Angeloniauthor=A.+L.+Kurtzauthor=X.+Z.+Qiangauthor=M.+H.+Wang&title=Overexpression+and+Activation+of+the+RON+Receptor+Tyrosine+Kinase+in+a+Panel+of+Human+Colorectal+Carcinoma+Cell+Lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines</span></div><div class="casAuthors">Chen, Yi-Qing; Zhou, Yong-Qing; Angeloni, Debora; Kurtz, Avrom L.; Qiang, Xiao-Zhi; Wang, Ming-Hai</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">RON is a receptor tyrosine kinase belonging to the MET proto-oncogene family.  The purposes of this study are to det. the expression and activation of RON in a panel of human colon carcinoma cell lines.  Western blotting showed that RON is barely detectable in normal and SV-40-transformed colon epithelial cells, but highly expressed and constitutively activated in several colon carcinoma cell lines including Colo201, HT-29, HCT116, and SW837.  Moreover, a novel RON variant with a mol. mass of 160 kDa (RONΔ160) was identified from HT-29 cells.  The cDNA encoding RONΔ160 has an in-frame deletion of 109 amino acids in the extracellular domain of the RON β chain, which is caused by splicing out of two exons in the RON mRNA.  No mutations were found in the kinase domain of the RON gene in five carcinoma cell lines screened.  By expressing RON in colon epithelial cells, the authors found that RON activation increases cell motile-invasive activities and protects cells against apoptotic death.  These data suggest that RON expression and activation are deregulated in colon carcinoma cell lines.  By abnormal activation of RON, this receptor and its variant may regulate motile-invasive phenotypes of certain colon carcinoma cells in vivo.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR0_6X3BvVi7Vg90H21EOLACvtfcHk0liILs-sH9jw5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotVyntrg%253D&md5=7d0ad2a749fb3cc647452dfafce89a03</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1006%2Fexcr.2000.5012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexcr.2000.5012%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DZhou%26aufirst%3DY.%2BQ.%26aulast%3DAngeloni%26aufirst%3DD.%26aulast%3DKurtz%26aufirst%3DA.%2BL.%26aulast%3DQiang%26aufirst%3DX.%2BZ.%26aulast%3DWang%26aufirst%3DM.%2BH.%26atitle%3DOverexpression%2520and%2520Activation%2520of%2520the%2520RON%2520Receptor%2520Tyrosine%2520Kinase%2520in%2520a%2520Panel%2520of%2520Human%2520Colorectal%2520Carcinoma%2520Cell%2520Lines%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2000%26volume%3D261%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zhou, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. H.</span><span> </span><span class="NLM_article-title">Altered Expression of the RON Receptor Tyrosine Kinase in Primary Human Colorectal Adenocarcinomas: Generation of Different Splicing RON Variants and their Oncogenic Potential</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=186-197&author=Y.+Q.+Zhouauthor=C.+Heauthor=Y.+Q.+Chenauthor=D.+Wangauthor=M.+H.+Wang&title=Altered+Expression+of+the+RON+Receptor+Tyrosine+Kinase+in+Primary+Human+Colorectal+Adenocarcinomas%3A+Generation+of+Different+Splicing+RON+Variants+and+their+Oncogenic+Potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%2BQ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DM.%2BH.%26atitle%3DAltered%2520Expression%2520of%2520the%2520RON%2520Receptor%2520Tyrosine%2520Kinase%2520in%2520Primary%2520Human%2520Colorectal%2520Adenocarcinomas%253A%2520Generation%2520of%2520Different%2520Splicing%2520RON%2520Variants%2520and%2520their%2520Oncogenic%2520Potential%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D186%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Bardella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggiora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patane, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranzani, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span> </span><span class="NLM_article-title">Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell–Cell Adhesion through E-Cadherin Transcriptional Repression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">5154</span><span class="NLM_x">–</span> <span class="NLM_lpage">5161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=5154-5161&author=C.+Bardellaauthor=B.+Costaauthor=P.+Maggioraauthor=S.+Pataneauthor=M.+Oliveroauthor=G.+N.+Ranzaniauthor=B.+M.+Deauthor=P.+M.+Comoglioauthor=M.+F.+Di+Renzo&title=Truncated+RON+Tyrosine+Kinase+Drives+Tumor+Cell+Progression+and+Abrogates+Cell%E2%80%93Cell+Adhesion+through+E-Cadherin+Transcriptional+Repression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBardella%26aufirst%3DC.%26aulast%3DCosta%26aufirst%3DB.%26aulast%3DMaggiora%26aufirst%3DP.%26aulast%3DPatane%26aufirst%3DS.%26aulast%3DOlivero%26aufirst%3DM.%26aulast%3DRanzani%26aufirst%3DG.%2BN.%26aulast%3DDe%26aufirst%3DB.%2BM.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26atitle%3DTruncated%2520RON%2520Tyrosine%2520Kinase%2520Drives%2520Tumor%2520Cell%2520Progression%2520and%2520Abrogates%2520Cell%25E2%2580%2593Cell%2520Adhesion%2520through%2520E-Cadherin%2520Transcriptional%2520Repression%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D5154%26epage%3D5161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Zinser, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toney, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathrose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thobe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kader, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peace, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, S. E.</span><span> </span><span class="NLM_article-title">Mammary-Specific Ron Receptor Overexpression Induces Highly Metastatic Mammary Tumors Associated with Beta-Catenin Activation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11967</span><span class="NLM_x">–</span> <span class="NLM_lpage">11974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11967-11974&author=G.+M.+Zinserauthor=M.+A.+Leonisauthor=K.+Toneyauthor=P.+Pathroseauthor=M.+Thobeauthor=S.+A.+Kaderauthor=B.+E.+Peaceauthor=S.+R.+Beaumanauthor=M.+H.+Collinsauthor=S.+E.+Waltz&title=Mammary-Specific+Ron+Receptor+Overexpression+Induces+Highly+Metastatic+Mammary+Tumors+Associated+with+Beta-Catenin+Activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZinser%26aufirst%3DG.%2BM.%26aulast%3DLeonis%26aufirst%3DM.%2BA.%26aulast%3DToney%26aufirst%3DK.%26aulast%3DPathrose%26aufirst%3DP.%26aulast%3DThobe%26aufirst%3DM.%26aulast%3DKader%26aufirst%3DS.%2BA.%26aulast%3DPeace%26aufirst%3DB.%2BE.%26aulast%3DBeauman%26aufirst%3DS.%2BR.%26aulast%3DCollins%26aufirst%3DM.%2BH.%26aulast%3DWaltz%26aufirst%3DS.%2BE.%26atitle%3DMammary-Specific%2520Ron%2520Receptor%2520Overexpression%2520Induces%2520Highly%2520Metastatic%2520Mammary%2520Tumors%2520Associated%2520with%2520Beta-Catenin%2520Activation%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11967%26epage%3D11974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Follenzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gual, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Cross-Talk Between the Proto-Oncogenes Met and Ron</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3049</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3041-3049&author=A.+Follenziauthor=S.+Bakovicauthor=P.+Gualauthor=M.+C.+Stellaauthor=P.+Longatiauthor=P.+M.+Comoglio&title=Cross-Talk+Between+the+Proto-Oncogenes+Met+and+Ron"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFollenzi%26aufirst%3DA.%26aulast%3DBakovic%26aufirst%3DS.%26aulast%3DGual%26aufirst%3DP.%26aulast%3DStella%26aufirst%3DM.%2BC.%26aulast%3DLongati%26aufirst%3DP.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DCross-Talk%2520Between%2520the%2520Proto-Oncogenes%2520Met%2520and%2520Ron%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D3041%26epage%3D3049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lee, W.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.-R.</span><span> </span><span class="NLM_article-title">Prognostic Significance of Co-Expression of RON and MET Receptors in Node-Negative Breast Cancer Patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2222</span><span class="NLM_x">–</span> <span class="NLM_lpage">2228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1158%2F1078-0432.CCR-04-1761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=15788670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFajurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=2222-2228&author=W.-Y.+Leeauthor=H.+H.+W.+Chenauthor=N.-H.+Chowauthor=W.-C.+Suauthor=P.-W.+Linauthor=H.-R.+Guo&title=Prognostic+Significance+of+Co-Expression+of+RON+and+MET+Receptors+in+Node-Negative+Breast+Cancer+Patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients</span></div><div class="casAuthors">Lee, Wen-Ying; Chen, Helen H. W.; Chow, Nan-Haw; Su, Wu-Chou; Lin, Pin-Wen; Guo, How-Ran</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2222-2228</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">RON and MET belong to a subfamily of tyrosine kinase receptors.  They both can induce invasive growth, including migration, cell dissocn., and matrix invasion.  Crosslinking expts. show that RON and MET form a noncovalent complex on the cell surface and cooperate in intracellular signaling.  We wanted to examine the clin. significance of RON and MET expression patterns in node-neg. breast cancer.  We studied the protein expressions of RON and MET in five breast cancer cell lines and a homogeneous cohort of 103 T1-2N0M0 breast carcinoma patients, including 52 patients with distant metastases and 51 patients with no evidence of disease after at least a 10-yr follow-up.  Both HCC1937 and MDA-MB-231 cancer cell lines co-overexpressed RON and MET.  The MCF-7 cell line did not express RON or MET.  In multiple logistic regression anal., RON expression (odds ratio, 2.6; P = 0.05) and MET expression (odds ratio, 4.7; P = 0.009) were independent predictors of distant relapse.  RON+/MET+ and RON-/MET+ tumors resulted in a large risk increase for 10-yr disease-free survival after adjusting for tumor size, histol. grade, estrogen receptor, bcl-2, HER-2/neu, and p53 status by multivariate Cox anal. (risk ratio, 5.3; P = 0.001 and risk ratio, 3.76; P = 0.005).  The 10-yr disease-free survival was 79.3% in patients with RON-/MET- tumors, was only 11.8% in patients with RON+/MET+ tumors, and was 43.9% and 55.6% in patients with RON-/MET+ and RON+/MET- tumors.  Co-expression of RON and MET seems to signify an aggressive phenotype in node-neg. breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZp05sUF36GLVg90H21EOLACvtfcHk0lgCwACMLTbODw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFajurk%253D&md5=214da143124696d658d77bcdb2a6c0af</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1761%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.-Y.%26aulast%3DChen%26aufirst%3DH.%2BH.%2BW.%26aulast%3DChow%26aufirst%3DN.-H.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DLin%26aufirst%3DP.-W.%26aulast%3DGuo%26aufirst%3DH.-R.%26atitle%3DPrognostic%2520Significance%2520of%2520Co-Expression%2520of%2520RON%2520and%2520MET%2520Receptors%2520in%2520Node-Negative%2520Breast%2520Cancer%2520Patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D2222%26epage%3D2228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cheng, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. H-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzai, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, N.-H.</span><span> </span><span class="NLM_article-title">Co-Expression of RON and MET is a Prognostic Indicator for Patients with Transitional-Cell Carcinoma of the Bladder</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">1906</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1038%2Fsj.bjc.6602593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=15870710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkt1Sgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=1906-1914&author=H.-L.+Chengauthor=H.-S.+Liuauthor=Y.-J.+Linauthor=H.+H-W.+Chenauthor=P.-Y.+Hsuauthor=T.-Y.+Changauthor=C.-L.+Hoauthor=T.-S.+Tzaiauthor=N.-H.+Chow&title=Co-Expression+of+RON+and+MET+is+a+Prognostic+Indicator+for+Patients+with+Transitional-Cell+Carcinoma+of+the+Bladder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder</span></div><div class="casAuthors">Cheng, H-L.; Liu, H-S.; Lin, Y-J.; Chen, H. H-W.; Hsu, P-Y.; Chang, T-Y.; Ho, C-L.; Tzai, T-S.; Chow, N-H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1906-1914</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Recepteur d'Origine Nantais (RON) is a distinct receptor tyrosine kinase in the c-met proto-oncogene family.  We examd. the mutational and expression patterns of RON in eight human uroepithelial cell lines.  Biol. effects of RON overexpression on cancer cells were investigated in vitro, and the prognostic significance of RON and/or c-met protein (MET) expression was analyzed in a bladder cancer cohort (n=183).  There was no evidence of mutation in the kinase domain of RON.  Overexpression of RON using an inducible Tet-off system induced increased cell proliferation, motility, and antiapoptosis.  Immunohistochem. anal. showed that RON was overexpressed in 60 cases (32.8%) of primary tumors, with 14 (23.3%) showing a high level of expression.  Recepteur d'Origine Nantais expression was pos. assocd. with histol. grading, larger size, nonpapillary contour, and tumor stage (all P<0.01).  In addn., MET was overexpressed in 82 cases (44.8%).  Co-expressed RON and MET was significantly assocd. with decreased overall survival (P=0.005) or metastasis-free survival (P=0.01) in 35 cases (19.1%).  Recepteur d'Origine Nantais-assocd. signalling may play an important role in the progression of human bladder cancer.  Evaluation of RON and MET expression status may identify a subset of bladder-cancer patients who require more intensive treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy3Jc9r7lea7Vg90H21EOLACvtfcHk0lgCwACMLTbODw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkt1Sgsrs%253D&md5=2da682ab6fe899da8b0b959e6c86d0e4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602593%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.-L.%26aulast%3DLiu%26aufirst%3DH.-S.%26aulast%3DLin%26aufirst%3DY.-J.%26aulast%3DChen%26aufirst%3DH.%2BH-W.%26aulast%3DHsu%26aufirst%3DP.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DHo%26aufirst%3DC.-L.%26aulast%3DTzai%26aufirst%3DT.-S.%26aulast%3DChow%26aufirst%3DN.-H.%26atitle%3DCo-Expression%2520of%2520RON%2520and%2520MET%2520is%2520a%2520Prognostic%2520Indicator%2520for%2520Patients%2520with%2520Transitional-Cell%2520Carcinoma%2520of%2520the%2520Bladder%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D1906%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.-P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+Orally+Available+Small-Molecule+Inhibitor+of+c-Met%2C+PF-2341066%2C+Exhibits+Cytoreductive+Antitumor+Efficacy+through+Antiproliferative+and+Antiangiogenic+Mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0ljBCUWSlGBscA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520Orally%2520Available%2520Small-Molecule%2520Inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520Exhibits%2520Cytoreductive%2520Antitumor%2520Efficacy%2520through%2520Antiproliferative%2520and%2520Antiangiogenic%2520Mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.-A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+Tumor+Cell+Growth%2C+Invasion%2C+and+Metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+Novel+Inhibitor+of+HGF+and+VEGF+Receptor+Tyrosine+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.-A.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520Tumor%2520Cell%2520Growth%252C%2520Invasion%252C%2520and%2520Metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520Novel%2520Inhibitor%2520of%2520HGF%2520and%2520VEGF%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">See also a recent report of a more selective type II inhibitor:</p></div><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Angelo, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span> </span><span class="NLM_article-title">Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1858</span><span class="NLM_x">–</span> <span class="NLM_lpage">1867</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1858-1867&author=L.+Liuauthor=M.+H.+Normanauthor=M.+Leeauthor=N.+Xiauthor=A.+Siegmundauthor=A.+A.+Boezioauthor=S.+Bookerauthor=D.+Choquetteauthor=N.+D.+D%E2%80%99Angeloauthor=J.+Germainauthor=K.+Yangauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+F.+Bellonauthor=D.+A.+Whittingtonauthor=J.-C.+Harmangeauthor=C.+Dominguezauthor=T.-S.+Kimauthor=I.+Dussault&title=Structure-Based+Design+of+Novel+Class+II+c-Met+Inhibitors%3A+1.+Identification+of+Pyrazolone-Based+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBooker%26aufirst%3DS.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DT.-S.%26aulast%3DDussault%26aufirst%3DI.%26atitle%3DStructure-Based%2520Design%2520of%2520Novel%2520Class%2520II%2520c-Met%2520Inhibitors%253A%25201.%2520Identification%2520of%2520Pyrazolone-Based%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1858%26epage%3D1867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Lu, T.; Alexander, R.; Connors, R. W.; Cummings, M. D.; Galemmo, R. A.; Hufnagel, H. R.; Johnson, D. L.; Khalil, E.; Leonard, K. A.; Markotan, T. P.; Maroney, A. C.; Sechler, J. L.; Travins, J. M.; Tuman, R. W.</span>PCT Int. Appl. WO 2007075567,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lu%2C+T.%3B+Alexander%2C+R.%3B+Connors%2C+R.+W.%3B+Cummings%2C+M.+D.%3B+Galemmo%2C+R.+A.%3B+Hufnagel%2C+H.+R.%3B+Johnson%2C+D.+L.%3B+Khalil%2C+E.%3B+Leonard%2C+K.+A.%3B+Markotan%2C+T.+P.%3B+Maroney%2C+A.+C.%3B+Sechler%2C+J.+L.%3B+Travins%2C+J.+M.%3B+Tuman%2C+R.+W.PCT+Int.+Appl.+WO+2007075567%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DT.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Schadt, O.; Bladt, F.; Blaukat, A.; Dorsch, D.; Friese-Hamim, M.; Fittschen, C.; Graedler, U.; Meyring, M.; Rautenberg, W.; Stieber, F.; Wilm, C.</span><span> </span><span class="NLM_article-title">EMD 1214063, An Exquisitely Selective c-Met Kinase Inhibitor in Clinical Phase 1</span>.  <span class="NLM_conf-name">AACR 101st Annual Meeting</span>, <span class="NLM_conf-loc">Washington, DC</span>, <span class="NLM_conf-date">Apr 17–21, 2010</span>; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span> <span class="NLM_fpage">Poster 5777</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=Poster+5777&conference=AACR+101st+Annual+Meeting&author=O.+Schadt&author=F.+Bladt&author=A.+Blaukat&author=D.+Dorsch&author=M.+Friese-Hamim&author=C.+Fittschen&author=U.+Graedler&author=M.+Meyring&author=W.+Rautenberg&author=F.+Stieber&author=C.+Wilm&title=EMD+1214063%2C+An+Exquisitely+Selective+c-Met+Kinase+Inhibitor+in+Clinical+Phase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSchadt%26aufirst%3DO.%26atitle%3DEMD%25201214063%252C%2520An%2520Exquisitely%2520Selective%2520c-Met%2520Kinase%2520Inhibitor%2520in%2520Clinical%2520Phase%25201%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2010%26spage%3DPoster%25205777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Class of Exquisitely Selective Mesenchymal–Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8091</span><span class="NLM_x">–</span> <span class="NLM_lpage">8109</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300967g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8091-8109&author=J.+J.+Cuiauthor=M.+McTigueauthor=M.+Nambuauthor=M.+Tran-Dub%C3%A9author=M.+Pairishauthor=H.+Shenauthor=L.+Jiaauthor=H.+Chengauthor=J.+Hoffmanauthor=P.+Leauthor=M.+Jalaieauthor=G.+H.+Goetzauthor=K.+Ryanauthor=N.+Grodskyauthor=Y.-L.+Dengauthor=M.+Parkerauthor=S.+Timofeevskiauthor=B.+W.+Murrayauthor=S.+Yamazakiauthor=S.+Aguirreauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Discovery+of+a+Novel+Class+of+Exquisitely+Selective+Mesenchymal%E2%80%93Epithelial+Transition+Factor+%28c-MET%29+Protein+Kinase+Inhibitors+and+Identification+of+the+Clinical+Candidate+2-%284-%281-%28Quinolin-6-ylmethyl%29-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-b%5Dpyrazin-6-yl%29-1H-pyrazol-1-yl%29ethanol+%28PF-04217903%29+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%2BH.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Class%2520of%2520Exquisitely%2520Selective%2520Mesenchymal%25E2%2580%2593Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Protein%2520Kinase%2520Inhibitors%2520and%2520Identification%2520of%2520the%2520Clinical%2520Candidate%25202-%25284-%25281-%2528Quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2520%2528PF-04217903%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8091%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Bode, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M-H.J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of a Potent and Selective Triazolopyridinone Series of c-Met Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4089</span><span class="NLM_x">–</span> <span class="NLM_lpage">4093</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1016%2Fj.bmcl.2012.04.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=22595176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVyrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4089-4093&author=C.+M.+Bodeauthor=A.+A.+Boezioauthor=B.+K.+Albrechtauthor=S.+F.+Bellonauthor=L.+Berryauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=I.+Dussaultauthor=R.+T.+Lewisauthor=M-H.J.+Linauthor=K.+Rexauthor=D.+A.+Whittingtonauthor=Y.+Yangauthor=J.-C.+Harmange&title=Discovery+and+Optimization+of+a+Potent+and+Selective+Triazolopyridinone+Series+of+c-Met+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors</span></div><div class="casAuthors">Bode, Christiane M.; Boezio, Alessandro A.; Albrecht, Brian K.; Bellon, Steven F.; Berry, Loren; Broome, Martin A.; Choquette, Deborah; Dussault, Isabelle; Lewis, Richard T.; Lin, Min-Hwa Jasmine; Rex, Karen; Whittington, Douglas A.; Yang, Yajing; Harmange, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4089-4093</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small mol. drug discovery.  The discovery of a structurally diverse series of quinolinylmethyltriazolopyridinones, which demonstrates nanomolar inhibition of c-Met kinase activity is reported.  This novel series of inhibitors exhibits favorable pharmacokinetics as well as potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver pharmacodynamic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2bZorS8wwhrVg90H21EOLACvtfcHk0lgRf-2Oz9R_hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVyrtLo%253D&md5=0f80a577ebee0df3c3a219273c43b738</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.072%26sid%3Dliteratum%253Aachs%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DM-H.J.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520a%2520Potent%2520and%2520Selective%2520Triazolopyridinone%2520Series%2520of%2520c-Met%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4089%26epage%3D4093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Cepero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sierra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casorzo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">7580</span><span class="NLM_x">–</span> <span class="NLM_lpage">7590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=7580-7590&author=V.+Ceperoauthor=J.+R.+Sierraauthor=S.+Corsoauthor=E.+Ghisoauthor=L.+Casorzoauthor=T.+Pereraauthor=P.+M.+Comoglioauthor=S.+Giordano&title=MET+and+KRAS+Gene+Amplification+Mediates+Acquired+Resistance+to+MET+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCepero%26aufirst%3DV.%26aulast%3DSierra%26aufirst%3DJ.%2BR.%26aulast%3DCorso%26aufirst%3DS.%26aulast%3DGhiso%26aufirst%3DE.%26aulast%3DCasorzo%26aufirst%3DL.%26aulast%3DPerera%26aufirst%3DT.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DMET%2520and%2520KRAS%2520Gene%2520Amplification%2520Mediates%2520Acquired%2520Resistance%2520to%2520MET%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D7580%26epage%3D7590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leggett, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. J.</span><span> </span><span class="NLM_article-title">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.-R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+Novel+and+Selective+Inhibitor+of+the+Human+c-Met+Receptor+Tyrosine+Kinase+with+Antitumor+Activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0liamO6biRU2Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.-R.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520Novel%2520and%2520Selective%2520Inhibitor%2520of%2520the%2520Human%2520c-Met%2520Receptor%2520Tyrosine%2520Kinase%2520with%2520Antitumor%2520Activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabarda, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathvink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazef, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span> </span><span class="NLM_article-title">Discovery of a 5<i>H</i>-Benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4092</span><span class="NLM_x">–</span> <span class="NLM_lpage">4108</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200112k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4092-4108&author=J.+D.+Katzauthor=J.+P.+Jewellauthor=D.+J.+Guerinauthor=J.+Limauthor=C.+J.+Dinsmoreauthor=S.+V.+Deshmukhauthor=B.-S.+Panauthor=C.+G.+Marshallauthor=W.+Luauthor=M.+D.+Altmanauthor=W.+K.+Dahlbergauthor=L.+Davisauthor=D.+Falconeauthor=A.+E.+Gabardaauthor=G.+Hangauthor=H.+Hatchauthor=R.+Holmesauthor=K.+Kuniiauthor=K.+J.+Lumbauthor=B.+Lutterbachauthor=R.+Mathvinkauthor=N.+Nazefauthor=S.+B.+Patelauthor=X.+Quauthor=J.+F.+Reillyauthor=K.+W.+Rickertauthor=C.+Rosensteinauthor=S.+M.+Soissonauthor=K.+B.+Spencerauthor=A.+A.+Szewczakauthor=D.+Walkerauthor=W.+Wangauthor=J.+Youngauthor=Q.+Zeng&title=Discovery+of+a+5H-Benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+Inhibitor+of+c-Met+Kinase+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm200112k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200112k%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DFalcone%26aufirst%3DD.%26aulast%3DGabarda%26aufirst%3DA.%2BE.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DR.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DLutterbach%26aufirst%3DB.%26aulast%3DMathvink%26aufirst%3DR.%26aulast%3DNazef%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DSpencer%26aufirst%3DK.%2BB.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520a%25205H-Benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-5-one%2520%2528MK-2461%2529%2520Inhibitor%2520of%2520c-Met%2520Kinase%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4092%26epage%3D4108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kawatsura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartwig, J. F.</span><span> </span><span class="NLM_article-title">Simple, Highly Active Palladium Catalysts for Ketone and Malonate Arylation: Dissecting the Importance of Chelation and Steric Hindrance</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">1473</span><span class="NLM_x">–</span> <span class="NLM_lpage">1478</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja983378u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADyaK1MXntlaisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1999&pages=1473-1478&author=M.+Kawatsuraauthor=J.+F.+Hartwig&title=Simple%2C+Highly+Active+Palladium+Catalysts+for+Ketone+and+Malonate+Arylation%3A+Dissecting+the+Importance+of+Chelation+and+Steric+Hindrance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Simple, Highly Active Palladium Catalysts for Ketone and Malonate Arylation: Dissecting the Importance of Chelation and Steric Hindrance</span></div><div class="casAuthors">Kawatsura, Motoi; Hartwig, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1473-1478</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A remarkably active catalyst system for α-arylation of ketones and malonates was developed by proposing that sterically hindered alkylphosphines would accelerate the catalytic reaction rates.  The authors initially tested the bisphosphine ligand DtBPF (1,1'-bis-(di-tert-butylphosphino)ferrocene) for this Pd-catalyzed chem.  This catalyst system led to fast reaction rates for reactions of aryl bromides with ketones, including room temp. chem. in many cases.  In some cases turnover nos. were 20,000.  The catalyst also gave mild reactions with aryl chlorides with yields that were similar to the chem. with aryl bromides.  Independent synthesis of the arylpalladium enolate complexes with isobutyrophenone enolate showed that only one P of the bisphosphine ligand DtBPF was coordinated in the enolate complex. Thus, the authors tested sterically hindered alkylphosphine ligands for the ketone and malonate arylation process and found that P(CMe3)3 gave exceptionally fast rates and high turnover nos. for these reactions.  These results demonstrate several principles for the catalytic chem. that the authors did not anticipate: Pd complexes of monophosphine ligands can activate aryl chlorides under mild conditions, and Pd enolates coordinated by certain monophosphines can undergo C-C bond-forming reductive elimination much faster than β-H elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfLvbhmM8JpbVg90H21EOLACvtfcHk0lhTA07-aGJ3UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntlaisg%253D%253D&md5=d06792e673b3987a3c6143f50d883eff</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1021%2Fja983378u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja983378u%26sid%3Dliteratum%253Aachs%26aulast%3DKawatsura%26aufirst%3DM.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26atitle%3DSimple%252C%2520Highly%2520Active%2520Palladium%2520Catalysts%2520for%2520Ketone%2520and%2520Malonate%2520Arylation%253A%2520Dissecting%2520the%2520Importance%2520of%2520Chelation%2520and%2520Steric%2520Hindrance%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1999%26volume%3D121%26spage%3D1473%26epage%3D1478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fox, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chieffi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Highly Active and Selective Catalysts for the Formation of α-Aryl Ketones</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1360</span><span class="NLM_x">–</span> <span class="NLM_lpage">1370</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja993912d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotl2isg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=1360-1370&author=J.+M.+Foxauthor=X.+Huangauthor=A.+Chieffiauthor=S.+L.+Buchwald&title=Highly+Active+and+Selective+Catalysts+for+the+Formation+of+%CE%B1-Aryl+Ketones"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Highly active and selective catalysts for the formation of α-aryl ketones</span></div><div class="casAuthors">Fox, Joseph M.; Huang, Xiaohua; Chieffi, Andre; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1360-1370</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bulky, electron-rich phosphine ligands with a biphenyl backbone, when combined with Pd(OAc)2, give highly active catalysts for the α-arylation of ketones.  Thus, arylation of propiophenone with 4-chlorotoluene using 4-PhC6H4P(CMe3)2 as ligand gave 4-MeC6H4CHMeCOPh in 91% yield.  2-Methyl-2'-dicyclohexylphosphinobiphenyl I is particularly effective as a ligand in palladium-catalyzed arylations; with 0.1-1.0 mol% Pd, a large variety of aryl halides and ketones react efficiently and with high selectivity.  For two types of substrates, the ligands BINAP and Xantphos II are more effective than the biphenyl-based ligands.  K3PO4 can be used as the base in these reactions; base-sensitive functional groups are better tolerated if K3PO4 is used instead of NaO-tert-Bu or NaHMDS.  In some cases, α-aryl ketones can be produced without adding a ligand to the reaction.  Although the substrate scope of the ligand-less conditions is limited, some combinations react in high yield, and in one case, 100,000 turnovers were obtained.  The results of expts. on the Pd-catalyzed arylation of di-Et malonate, cyclic 1,3-diketones, and nitroalkanes are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY_KAycKtH27Vg90H21EOLACvtfcHk0lgnee9us0vYwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotl2isg%253D%253D&md5=c8702155bcce7c25d03b22b5f8158191</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fja993912d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja993912d%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DJ.%2BM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DChieffi%26aufirst%3DA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DHighly%2520Active%2520and%2520Selective%2520Catalysts%2520for%2520the%2520Formation%2520of%2520%25CE%25B1-Aryl%2520Ketones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D1360%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Netherton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, G. C.</span><span> </span><span class="NLM_article-title">Air-Stable Trialkylphosphonium Salts: Simple, Practical, and Versatile Replacements for Air-Sensitive Trialkylphosphines. Applications in Stoichiometric and Catalytic Processes</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">4295</span><span class="NLM_x">–</span> <span class="NLM_lpage">4298</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol016971g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD3MXoslygur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=4295-4298&author=M.+R.+Nethertonauthor=G.+C.+Fu&title=Air-Stable+Trialkylphosphonium+Salts%3A+Simple%2C+Practical%2C+and+Versatile+Replacements+for+Air-Sensitive+Trialkylphosphines.+Applications+in+Stoichiometric+and+Catalytic+Processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Air-Stable Trialkylphosphonium Salts: Simple, Practical, and Versatile Replacements for Air-Sensitive Trialkylphosphines. Applications in Stoichiometric and Catalytic Processes</span></div><div class="casAuthors">Netherton, Matthew R.; Fu, Gregory C.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4295-4298</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trialkylphosphines furnish unusual, sometimes unique, reactivity in a range of transformations.  Unfortunately, their utility is compromised by their sensitivity to oxidn.  A simple but powerful strategy for addressing this problem is proposed: convert air-sensitive trialkylphosphines into air-stable phosphonium salts via protonation on phosphorus.  These robust salts serve as direct replacements for the corresponding phosphines (simple deprotonation under the reaction conditions by a Bronsted base liberates the trialkylphosphine) in a diverse set of applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-wMNyILHzR7Vg90H21EOLACvtfcHk0lgnee9us0vYwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXoslygur4%253D&md5=a875987aaccfb12fdb0de9cb5a835023</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1021%2Fol016971g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol016971g%26sid%3Dliteratum%253Aachs%26aulast%3DNetherton%26aufirst%3DM.%2BR.%26aulast%3DFu%26aufirst%3DG.%2BC.%26atitle%3DAir-Stable%2520Trialkylphosphonium%2520Salts%253A%2520Simple%252C%2520Practical%252C%2520and%2520Versatile%2520Replacements%2520for%2520Air-Sensitive%2520Trialkylphosphines.%2520Applications%2520in%2520Stoichiometric%2520and%2520Catalytic%2520Processes%26jtitle%3DOrg.%2520Lett.%26date%3D2001%26volume%3D3%26spage%3D4295%26epage%3D4298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Grimm, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katcher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witter, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northrup, A. B.</span><span> </span><span class="NLM_article-title">A New Strategy for the Synthesis of Benzylic Sulfonamides: Palladium-Catalyzed Arylation and Sulfonamide Metathesis</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">8135</span><span class="NLM_x">–</span> <span class="NLM_lpage">8138</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo701431j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=8135-8138&author=J.+B.+Grimmauthor=M.+H.+Katcherauthor=D.+J.+Witterauthor=A.+B.+Northrup&title=A+New+Strategy+for+the+Synthesis+of+Benzylic+Sulfonamides%3A+Palladium-Catalyzed+Arylation+and+Sulfonamide+Metathesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjo701431j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo701431j%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DJ.%2BB.%26aulast%3DKatcher%26aufirst%3DM.%2BH.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DNorthrup%26aufirst%3DA.%2BB.%26atitle%3DA%2520New%2520Strategy%2520for%2520the%2520Synthesis%2520of%2520Benzylic%2520Sulfonamides%253A%2520Palladium-Catalyzed%2520Arylation%2520and%2520Sulfonamide%2520Metathesis%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D8135%26epage%3D8138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goel, S.</span><span> </span><span class="NLM_article-title">Alterations of Chemotherapeutic Pharmacokinetic Profiles by Drug–Drug Interactions</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1517%2F17425250902753212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=19239394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1eksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=109-130&author=S.+Maniauthor=M.+Ghalibauthor=I.+Chaudharyauthor=S.+Goel&title=Alterations+of+Chemotherapeutic+Pharmacokinetic+Profiles+by+Drug%E2%80%93Drug+Interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions</span></div><div class="casAuthors">Mani, Sridhar; Ghalib, Mohammed; Chaudhary, Imran; Goel, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-130</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Drug interactions in oncol. are common place and largely ignored as we tolerate high thresholds of toxic' drug responses in these patients.  However, in the era of targeted' or seemingly less toxic' therapy, these interactions are more commonly flagged and contribute significantly towards poor quality of life' and medical fatalities.  Objective: This review and opinion article focuses on alteration of chemotherapeutic pharmacokinetic profiles by drug interactions in the setting of polypharmacy.  The assumption is that the drugs, with changes in their pharmacokinetics, will contribute towards changes in their pharmacodynamics.  Methods: The examples cited for such drug-drug interactions are culled from published literature with an emphasis on those interactions that have been well characterized at the mol. level.  Results: Although very few drug interaction studies have been performed on approved oncol. based drugs, it is clear that drugs whose pharmacokinetics profiles are closely related to their pharmacodynamics will indeed result in clin. important drug interactions.  Some newer mechanisms are described that involve interactions at the level of gene transcription, whereby, drug metab. is significantly altered.  However, for any given drug interaction, there does not seem to be a comprehensive model describing interactions.  Conclusions: Mechanisms based drug interactions are plentiful in oncol.; however, there is an abs. lack of a comprehensive model that would predict drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq_zoumy_GyLVg90H21EOLACvtfcHk0lgnee9us0vYwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1eksrc%253D&md5=3b120e4b308ef907e19b189dc9a64d56</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1517%2F17425250902753212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250902753212%26sid%3Dliteratum%253Aachs%26aulast%3DMani%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DM.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DGoel%26aufirst%3DS.%26atitle%3DAlterations%2520of%2520Chemotherapeutic%2520Pharmacokinetic%2520Profiles%2520by%2520Drug%25E2%2580%2593Drug%2520Interactions%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D109%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mcleod, H. L.</span><span> </span><span class="NLM_article-title">Clinically Relevant Drug–Drug Interactions in Oncology</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.1046%2Fj.1365-2125.1998.00719.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=9663808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADyaK1cXktFaitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1998&pages=539-544&author=H.+L.+Mcleod&title=Clinically+Relevant+Drug%E2%80%93Drug+Interactions+in+Oncology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinically relevant drug-drug interactions in oncology</span></div><div class="casAuthors">Mcleod, Howard L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">539-544</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 33 refs.  Although anticancer agents are one of the most toxic classes of medication prescribed today, there is relatively little information available about clin. relevant drug-drug interactions.  Pharmacokinetic drug interactions have been described, including alterations in absorption, catabolism, and excretion.  For example, an increased bioavailability of 6-mercaptopurine has been obsd. when combined with either allopurinol or methotrexate, leading to increased toxicity in some patients.  Induction of etoposide or teniposide clearance by anticonvulsants has also been described, resulting in a lower systemic exposure and risk for lower anticancer activity.  Alterations in elimination of methotrexate has been obsd. with probenecid, presumably through competition for renal secretion.  There are also several examples of pharmacodynamic interactions.  The combination of 5-fluorouracil plus folinic acid results in more efficient inhibition of thymidylate synthase, a finding which is now utilized routinely in the treatment of colorectal cancer.  Improvements in the in vitro and early clin. testing now allow a relatively high degree of prediction of potential clin. drug interactions, prior to observations of untoward drug effects.  In conclusion, drug interactions among commonly used anticancer agents have been identified.  Their clin. significance can have more impact than many other classes of medications due to the narrow therapeutic index of antineoplastic agents and the potential for lethal side-effects.  It is only through prospective, preclin. and early clin. evaluation that the presence of clin. significant drug interactions can be identified and the information used to provide better therapy for this significant health problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0bt37gQxUMbVg90H21EOLACvtfcHk0lhZSUgIpdYM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktFaitrs%253D&md5=d2dd35189d4b9b81b751cf9e038d020c</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.1998.00719.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.1998.00719.x%26sid%3Dliteratum%253Aachs%26aulast%3DMcleod%26aufirst%3DH.%2BL.%26atitle%3DClinically%2520Relevant%2520Drug%25E2%2580%2593Drug%2520Interactions%2520in%2520Oncology%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1998%26volume%3D45%26spage%3D539%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><div class="note"><p class="first last">and references therein</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301619u&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm301619u&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm301619u&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+Comprehensive+Listing+of+Bioactivation+Pathways+of+Organic+Functional+Groups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lhZSUgIpdYM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520Comprehensive%2520Listing%2520of%2520Bioactivation%2520Pathways%2520of%2520Organic%2520Functional%2520Groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">Signficantly, both <b>5a</b> and <b>5g</b> did not show significant inhibition of CYP3A4 (<10%) at the zero minute time point as potent reversible CYP3A4 inhibitors are not evaluable in this assay format.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G. K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariv, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span> </span><span class="NLM_article-title">MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1524</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1524-1533&author=B.-S.+Panauthor=G.+K.+Y.+Chanauthor=M.+Chenardauthor=A.+Chiauthor=L.+J.+Davisauthor=S.+V.+Deshmukhauthor=J.+B.+Gibbsauthor=S.+Gilauthor=G.+Hangauthor=H.+Hatchauthor=J.+P.+Jewellauthor=I.+Karivauthor=J.+D.+Katzauthor=K.+Kuniiauthor=W.+Luauthor=B.+A.+Lutterbachauthor=C.+P.+Paweletzauthor=X.+Quauthor=J.+F.+Reillyauthor=A.+A.+Szewczakauthor=Q.+Zengauthor=N.+E.+Kohlauthor=C.+J.+Dinsmore&title=MK-2461%2C+a+Novel+Multitargeted+Kinase+Inhibitor%2C+Preferentially+Inhibits+the+Activated+c-Met+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DChan%26aufirst%3DG.%2BK.%2BY.%26aulast%3DChenard%26aufirst%3DM.%26aulast%3DChi%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DL.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DGibbs%26aufirst%3DJ.%2BB.%26aulast%3DGil%26aufirst%3DS.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26atitle%3DMK-2461%252C%2520a%2520Novel%2520Multitargeted%2520Kinase%2520Inhibitor%252C%2520Preferentially%2520Inhibits%2520the%2520Activated%2520c-Met%2520Receptor%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1524%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darke, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornienko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span> </span><span class="NLM_article-title">Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">11218</span><span class="NLM_x">–</span> <span class="NLM_lpage">11225</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=11218-11225&author=K.+W.+Rickertauthor=S.+B.+Patelauthor=T.+J.+Allisonauthor=N.+J.+Byrneauthor=P.+L.+Darkeauthor=R.+E.+Fordauthor=D.+J.+Guerinauthor=D.+L.+Hallauthor=M.+Kornienkoauthor=J.+Luauthor=S.+K.+Munshiauthor=J.+C.+Reidauthor=J.+M.+Shipmanauthor=E.+F.+Stantonauthor=K.+J.+Wilsonauthor=J.+R.+Youngauthor=S.+M.+Soissonauthor=K.+J.+Lumb&title=Structural+Basis+for+Selective+Small+Molecule+Kinase+Inhibition+of+Activated+c-Met"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DAllison%26aufirst%3DT.%2BJ.%26aulast%3DByrne%26aufirst%3DN.%2BJ.%26aulast%3DDarke%26aufirst%3DP.%2BL.%26aulast%3DFord%26aufirst%3DR.%2BE.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DStanton%26aufirst%3DE.%2BF.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26atitle%3DStructural%2520Basis%2520for%2520Selective%2520Small%2520Molecule%2520Kinase%2520Inhibition%2520of%2520Activated%2520c-Met%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D11218%26epage%3D11225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Lutterbach, B.</span><div class="note"><p class="first last">manuscript in preparation</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lutterbach%2C+B.manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLutterbach%26aufirst%3DB." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-ref27_1"><span><span class="NLM_contrib-group">Szymonifka, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heck, J. V.</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2869</span><span class="NLM_x">–</span> <span class="NLM_lpage">2872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Szymonifka%2C+M.+J.%3B+Heck%2C+J.+V.Tetrahedron+Lett.+1989%2C+30%2C+2869%E2%80%932872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref27_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSzymonifka%26aufirst%3DM.%2BJ.%26aulast%3DHeck%26aufirst%3DJ.%2BV.%26jtitle%3DTetrahedron%2520Lett.%26date%3D1989%26volume%3D30%26spage%3D2869%26epage%3D2872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W','PDB','1R1W'); return false;">PDB: 1R1W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IWD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IWD','PDB','4IWD'); return false;">PDB: 4IWD</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i53"><a href="/doi/suppl/10.1021/jm301619u">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_65246"></div></div></div></div></div><hr /></hr><p class="last">Kinase selectivity profiles of compounds <b>5g</b>, <b>11a</b>, <b>11r</b>, <b>11u</b>, <b>11w</b>, <b>12</b>–<b>16</b>, X-ray statistics for <b>16</b>, time course of exposure in the GTL-16 xenograft efficacy and PK/PD experiments, and characterization data for <b>5b</b>–<b>d</b>, <b>11a</b>–<b>f</b>, <b>11i</b>–<b>m</b>, <b>11p</b>–<b>q</b>, <b>11s</b>, <b>11u</b>–<b>w</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301619u/suppl_file/jm301619u_si_001.pdf">jm301619u_si_001.pdf (600.77 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IWD">4IWD</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301619u&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-6%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm301619u%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301619u" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994a21cc7d3c16","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
